BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cosnes J, Cattan S, Blain A, Beaugerie L, Carbonnel F, Parc R, Gendre JP. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis. 2002;8:244-250. [PMID: 12131607 DOI: 10.1097/00054725-200207000-00002] [Cited by in Crossref: 892] [Cited by in F6Publishing: 720] [Article Influence: 46.9] [Reference Citation Analysis]
Number Citing Articles
1 Sorrentino D. Role of biologics and other therapies in stricturing Crohn's disease: what have we learnt so far? Digestion. 2008;77:38-47. [PMID: 18285676 DOI: 10.1159/000117306] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
2 Hotta Y, Uchiyama K, Takagi T, Kashiwagi S, Nakano T, Mukai R, Toyokawa Y, Yasuda T, Ueda T, Suyama Y, Murakami T, Tanaka M, Majima A, Doi T, Hirai Y, Mizushima K, Morita M, Higashimura Y, Inoue K, Fukui A, Okayama T, Katada K, Kamada K, Handa O, Ishikawa T, Naito Y, Itoh Y. Transforming growth factor β1-induced collagen production in myofibroblasts is mediated by reactive oxygen species derived from NADPH oxidase 4. Biochem Biophys Res Commun 2018;506:557-62. [PMID: 30361098 DOI: 10.1016/j.bbrc.2018.10.116] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
3 Bruining DH, Oliva S, Fleisher MR, Fischer M, Fletcher JG; BLINK study group. Panenteric capsule endoscopy versus ileocolonoscopy plus magnetic resonance enterography in Crohn's disease: a multicentre, prospective study.BMJ Open Gastroenterol. 2020;7. [PMID: 32499275 DOI: 10.1136/bmjgast-2019-000365] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
4 Siegel CA, Horton H, Siegel LS, Thompson KD, Mackenzie T, Stewart SK, Rice PW, Stempak JM, Dezfoli S, Haritunians T, Levy A, Baek M, Milgrom R, Dulai PS, Targan SR, Silverberg MS, Dubinsky MC, McGovern DP. A validated web-based tool to display individualised Crohn's disease predicted outcomes based on clinical, serologic and genetic variables. Aliment Pharmacol Ther 2016;43:262-71. [PMID: 26567467 DOI: 10.1111/apt.13460] [Cited by in Crossref: 63] [Cited by in F6Publishing: 47] [Article Influence: 10.5] [Reference Citation Analysis]
5 van der Valk ME, Mangen MJ, Leenders M, Dijkstra G, van Bodegraven AA, Fidder HH, de Jong DJ, Pierik M, van der Woude CJ, Romberg-Camps MJ. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study. Gut. 2014;63:72-79. [PMID: 23135759 DOI: 10.1136/gutjnl-2012-303376] [Cited by in Crossref: 311] [Cited by in F6Publishing: 257] [Article Influence: 34.6] [Reference Citation Analysis]
6 Malgras B, Pautrat K, Dray X, Pasquier P, Valleur P, Pocard M, Soyer P. Multidisciplinary Management of Gastrointestinal Fibrotic Stenosis in Crohn’s Disease. Dig Dis Sci 2015;60:1152-68. [DOI: 10.1007/s10620-014-3421-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.9] [Reference Citation Analysis]
7 Eglinton T, Reilly M, Chang C, Barclay M, Frizelle F, Gearry R. Ileal disease is associated with surgery for perianal disease in a population-based Crohn's disease cohort. Br J Surg 2010;97:1103-9. [PMID: 20632279 DOI: 10.1002/bjs.7031] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
8 Fumery M, Pariente B, Sarter H, Savoye G, Spyckerelle C, Djeddi D, Mouterde O, Bouguen G, Ley D, Peneau A, Dupas J, Turck D, Gower-rousseau C. Long-term outcome of pediatric-onset Crohn’s disease: A population-based cohort study. Digestive and Liver Disease 2019;51:496-502. [DOI: 10.1016/j.dld.2018.11.033] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 8.5] [Reference Citation Analysis]
9 Ramos A, Calvet X, Sicilia B, Vergara M, Figuerola A, Motos J, Sastre A, Villoria A, Gomollón F. IBD-related work disability in the community: Prevalence, severity and predictive factors. A cross-sectional study. United European Gastroenterol J 2015;3:335-42. [PMID: 26279841 DOI: 10.1177/2050640615577532] [Cited by in Crossref: 25] [Cited by in F6Publishing: 15] [Article Influence: 4.2] [Reference Citation Analysis]
10 Bajaj JS, Saeian K, Varma RR, Franco J, Knox JF, Podoll J, Emmons J, Levy M, Binion DG. Increased rates of early adverse reaction to azathioprine in patients with Crohn's disease compared to autoimmune hepatitis: a tertiary referral center experience. Am J Gastroenterol. 2005;100:1121-1125. [PMID: 15842588 DOI: 10.1111/j.1572-0241.2005.41598.x] [Cited by in Crossref: 47] [Cited by in F6Publishing: 37] [Article Influence: 2.9] [Reference Citation Analysis]
11 Diefenbach KA, Breuer CK. Pediatric inflammatory bowel disease. World J Gastroenterol 2006;12:3204-12. [PMID: 16718840 DOI: 10.3748/wjg.v12.i20.3204] [Cited by in CrossRef: 67] [Cited by in F6Publishing: 52] [Article Influence: 4.5] [Reference Citation Analysis]
12 Magarotto A, Orlando S, Coletta M, Conte D, Fraquelli M, Caprioli F. Evolving roles of cross-sectional imaging in Crohn's disease. Digestive and Liver Disease 2016;48:975-83. [DOI: 10.1016/j.dld.2016.05.017] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
13 Devlin SM, Panaccione R. Evolving inflammatory bowel disease treatment paradigms: top-down versus step-up. Gastroenterol Clin North Am. 2009;38:577-594. [PMID: 19913203 DOI: 10.1016/j.gtc.2009.07.007] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
14 Moran GW, Dubeau MF, Kaplan GG, Panaccione R, Ghosh S. Novel concepts in inflammatory bowel disease. British Medical Bulletin 2014;109:55-72. [DOI: 10.1093/bmb/ldt039] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
15 Shen B, Kochhar G, Navaneethan U, Farraye FA, Schwartz DA, Iacucci M, Bernstein CN, Dryden G, Cross R, Bruining DH, Kobayashi T, Lukas M, Shergill A, Bortlik M, Lan N, Lukas M, Tang SJ, Kotze PG, Kiran RP, Dulai PS, El-Hachem S, Coelho-Prabhu N, Thakkar S, Mao R, Chen G, Zhang S, Suárez BG, Lama YG, Silverberg MS, Sandborn WJ. Practical guidelines on endoscopic treatment for Crohn's disease strictures: a consensus statement from the Global Interventional Inflammatory Bowel Disease Group. Lancet Gastroenterol Hepatol 2020;5:393-405. [PMID: 31954438 DOI: 10.1016/S2468-1253(19)30366-8] [Cited by in Crossref: 20] [Cited by in F6Publishing: 3] [Article Influence: 20.0] [Reference Citation Analysis]
16 Bardhan KD, Simmonds N, Royston C, Dhar A, Edwards CM. A United Kingdom inflammatory bowel disease database: making the effort worthwhile. J Crohns Colitis. 2010;4:405-412. [PMID: 21122536 DOI: 10.1016/j.crohns.2010.01.003] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 2.2] [Reference Citation Analysis]
17 Connelly TM. Predictors of recurrence of Crohn’s disease after ileocolectomy: A review. WJG 2014;20:14393. [DOI: 10.3748/wjg.v20.i39.14393] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
18 Lee YS, Baek SH, Kim MJ, Lee YM, Lee Y, Choe YH. Efficacy of early infliximab treatment for pediatric Crohn's disease: A three-year follow-up. Pediatr Gastroenterol Hepatol Nutr. 2012;15:243-249. [PMID: 24010094 DOI: 10.5223/pghn.2012.15.4.243] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
19 Armuzzi A, De Pascalis B, Fedeli P, De Vincentis F, Gasbarrini A. Infliximab in Crohn's disease: early and long-term treatment. Digestive and Liver Disease 2008;40:S271-9. [DOI: 10.1016/s1590-8658(08)60537-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
20 Truffi M, Sorrentino L, Monieri M, Fociani P, Mazzucchelli S, Bonzini M, Zerbi P, Sampietro GM, Di Sabatino A, Corsi F. Inhibition of Fibroblast Activation Protein Restores a Balanced Extracellular Matrix and Reduces Fibrosis in Crohn’s Disease Strictures Ex Vivo. Inflammatory Bowel Diseases 2018;24:332-45. [DOI: 10.1093/ibd/izx008] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
21 Nunes T, Etchevers MJ, Domènech E, García-sánchez V, Ber Y, Peñalva M, Merino O, Nos P, Garcia-planella E, Casbas AG, Esteve M, Taxonera Samsó C, Montoro Huguet M, Gisbert JP, Martín Arranz MD, García-sepulcre MF, de Acosta MB, Beltrán B, Alcaide Suárez N, Saro Gismera C, Cabriada JL, Cañas-ventura A, Gomollón F, Panés J; Tobacco-Eneida Study Group of GETECCU. Smoking does influence disease behaviour and impacts the need for therapy in Crohn′s disease in the biologic era. Aliment Pharmacol Ther 2013;38:752-60. [DOI: 10.1111/apt.12440] [Cited by in Crossref: 53] [Cited by in F6Publishing: 48] [Article Influence: 6.6] [Reference Citation Analysis]
22 Cheung M, Khan S, Akerman M, Hung CK, Vennard K, Hristis N, Sultan K. Clinical markers of Crohn’s disease severity and their association with opiate use. J Clin Med Res. 2015;7:33-36. [PMID: 25368699 DOI: 10.14740/jocmr1969w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
23 van der Woude CJ, Hommes DW. Are we ready for top-down therapy for inflammatory bowel diseases: pro. Expert Review of Gastroenterology & Hepatology 2014;1:243-8. [DOI: 10.1586/17474124.1.2.243] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
24 Dias CC, Portela F, Fernandes S, Ministro P, Lago P, Rosa I, Correia L, Magro F. The timing of early therapeutic strategies has a significant impact on Crohn’s disease prognosis. Digestive and Liver Disease 2018;50:462-8. [DOI: 10.1016/j.dld.2018.01.135] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
25 Bokemeyer B. CED-Behandlung in Deutschland: Betrachtungen zur sinnvollen Vernetzung. Gastroenterologe 2007;2:447-55. [DOI: 10.1007/s11377-007-0113-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
26 Hyams JS, Markowitz JF. Can we alter the natural history of Crohn disease in children? J Pediatr Gastroenterol Nutr 2005;40:262-72. [PMID: 15735477 DOI: 10.1097/01.mpg.0000154660.62359.fe] [Cited by in Crossref: 27] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
27 Ananthakrishnan AN, Sakuraba A, Barnes EL, Pekow J, Raffals L, Long MD, Sandler RS. The benefit of combination therapy depends on disease phenotype and duration in Crohn's disease. Aliment Pharmacol Ther 2017;46:162-8. [PMID: 28470787 DOI: 10.1111/apt.14125] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
28 Pernat Drobež C, Repnik K, Gorenjak M, Ferkolj I, Weersma RK, Potočnik U. DNA polymorphisms predict time to progression from uncomplicated to complicated Crohn's disease. Eur J Gastroenterol Hepatol 2018;30:447-55. [PMID: 29293112 DOI: 10.1097/MEG.0000000000001055] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
29 Civitelli F, Nuti F, Oliva S, Messina L, La Torre G, Viola F, Cucchiara S, Aloi M. Looking Beyond Mucosal Healing: Effect of Biologic Therapy on Transmural Healing in Pediatric Crohn's Disease. Inflamm Bowel Dis 2016;22:2418-24. [PMID: 27598739 DOI: 10.1097/MIB.0000000000000897] [Cited by in Crossref: 23] [Cited by in F6Publishing: 7] [Article Influence: 7.7] [Reference Citation Analysis]
30 Mahid SS, Minor KS, Stevens PL, Galandiuk S. The role of smoking in Crohn's disease as defined by clinical variables. Dig Dis Sci 2007;52:2897-903. [PMID: 17401688 DOI: 10.1007/s10620-006-9624-0] [Cited by in Crossref: 47] [Cited by in F6Publishing: 50] [Article Influence: 3.4] [Reference Citation Analysis]
31 Chhaya V, Pollok RCG, Cecil E, Subramanian V, Curcin V, Majeed A, Saxena S. Impact of early thiopurines on surgery in 2770 children and young people diagnosed with inflammatory bowel disease: a national population-based study. Aliment Pharmacol Ther 2015;42:990-9. [DOI: 10.1111/apt.13361] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
32 Sandborn WJ, Colombel JF, Panés J, Castillo M, Robinson AM, Zhou Q, Yang M, Thakkar R. Exploring the use of adalimumab for patients with moderate Crohn's disease: subanalyses from induction and maintenance trials.J Crohns Colitis. 2013;7:958-967. [PMID: 23517933 DOI: 10.1016/j.crohns.2013.02.016] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
33 Zankel E, Rogler G, Andus T, Reng CM, Schölmerich J, Timmer A. Crohn's disease patient characteristics in a tertiary referral center: comparison with patients from a population-based cohort. Eur J Gastroenterol Hepatol. 2005;17:395-401. [PMID: 15756091 DOI: 10.1097/00042737-200504000-00002] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 2.1] [Reference Citation Analysis]
34 Jensen MD, Kjeldsen J, Rafaelsen SR, Nathan T. Diagnostic accuracies of MR enterography and CT enterography in symptomatic Crohn’s disease. Scand J Gastroenterol. 2011;46:1449-1457. [PMID: 21905974 DOI: 10.3109/00365521.2011.613947] [Cited by in Crossref: 60] [Cited by in F6Publishing: 51] [Article Influence: 6.0] [Reference Citation Analysis]
35 Chen M, Shen B. Comparable short- and long-term outcomes of colonoscopic balloon dilation of Crohn's Disease and benign non-Crohn's Disease strictures. Inflamm Bowel Dis 2014;20:1739-46. [PMID: 25153504 DOI: 10.1097/MIB.0000000000000145] [Cited by in Crossref: 25] [Cited by in F6Publishing: 8] [Article Influence: 4.2] [Reference Citation Analysis]
36 Shen B. IBD: Step-up vs top-down therapy for Crohn's disease: medicine vs surgery. Nat Rev Gastroenterol Hepatol 2017;14:693-5. [PMID: 29018276 DOI: 10.1038/nrgastro.2017.139] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
37 Vernier-Massouille G, Balde M, Salleron J, Turck D, Dupas JL, Mouterde O, Merle V, Salomez JL, Branche J, Marti R, Lerebours E, Cortot A, Gower-Rousseau C, Colombel JF. Natural history of pediatric Crohn's disease: a population-based cohort study. Gastroenterology. 2008;135:1106-1113. [PMID: 18692056 DOI: 10.1053/j.gastro.2008.06.079] [Cited by in Crossref: 390] [Cited by in F6Publishing: 317] [Article Influence: 30.0] [Reference Citation Analysis]
38 Maccioni F, Staltari I, Pino AR, Tiberti A. Value of T2-weighted magnetic resonance imaging in the assessment of wall inflammation and fibrosis in Crohn’s disease. Abdom Imaging. 2012;37:944-957. [PMID: 22639331 DOI: 10.1007/s00261-012-9853-y] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.4] [Reference Citation Analysis]
39 Park SJ, Kim WH, Cheon JH. Clinical characteristics and treatment of inflammatory bowel disease: a comparison of Eastern and Western perspectives. World J Gastroenterol 2014;20:11525-37. [PMID: 25206259 DOI: 10.3748/wjg.v20.i33.11525] [Cited by in CrossRef: 65] [Cited by in F6Publishing: 57] [Article Influence: 10.8] [Reference Citation Analysis]
40 Nishida Y, Hosomi S, Yamagami H, Yukawa T, Nagami Y, Tanaka F, Kamata N, Tanigawa T, Shiba M, Watanabe T, Tominaga K, Fujiwara Y, Arakawa T. Analysis of the Risk Factors of Surgery after Endoscopic Balloon Dilation for Small Intestinal Strictures in Crohn's Disease Using Double-balloon Endoscopy. Intern Med 2017;56:2245-52. [PMID: 28794359 DOI: 10.2169/internalmedicine.8224-16] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
41 Park JJ, Cheon JH, Hong SP, Kim TI, Kim WH. Outcome predictors for thiopurine maintenance therapy in patients with Crohn’s disease. Dig Dis Sci. 2012;57:133-141. [PMID: 22057283 DOI: 10.1007/s10620-011-1955-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
42 Rieder F, Fiocchi C, Rogler G. Mechanisms, Management, and Treatment of Fibrosis in Patients With Inflammatory Bowel Diseases. Gastroenterology. 2017;152:340-350.e6. [PMID: 27720839 DOI: 10.1053/j.gastro.2016.09.047] [Cited by in Crossref: 163] [Cited by in F6Publishing: 133] [Article Influence: 32.6] [Reference Citation Analysis]
43 Bennett A, Evers Carlini L, Duley C, Garrett A, Annis K, Wagnon J, Dalal R, Scoville E, Beaulieu D, Schwartz D, Horst S. A Single Center Experience With Long-Term Ustekinumab Use and Reinduction in Patients With Refractory Crohn Disease. Crohns Colitis 360 2020;2:otaa013. [PMID: 32201860 DOI: 10.1093/crocol/otaa013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
44 Rubin DT, Hanauer SB, Lichtenstein GR, Mcgovern DPB, Regueiro MD, Snapper S, Targan S. Refining Treatment Paradigms in Inflammatory Bowel Disease: Assessing the Options for Individualized Therapy. Am J Gastroenterol Suppl 2016;3:4-7. [DOI: 10.1038/ajgsup.2016.15] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
45 Lichtenstein GR, Hanauer SB, Kane SV, Present DH. Crohn’s Is Not a 6-Week Disease: Lifelong Management of Mild to Moderate Crohn’s Disease. Inflammatory Bowel Diseases 2004;10:S2-S10. [DOI: 10.1097/00054725-200407002-00002] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
46 Knobler R, Berlin G, Calzavara-Pinton P, Greinix H, Jaksch P, Laroche L, Ludvigsson J, Quaglino P, Reinisch W, Scarisbrick J, Schwarz T, Wolf P, Arenberger P, Assaf C, Bagot M, Barr M, Bohbot A, Bruckner-Tuderman L, Dreno B, Enk A, French L, Gniadecki R, Gollnick H, Hertl M, Jantschitsch C, Jung A, Just U, Klemke CD, Lippert U, Luger T, Papadavid E, Pehamberger H, Ranki A, Stadler R, Sterry W, Wolf IH, Worm M, Zic J, Zouboulis CC, Hillen U. Guidelines on the use of extracorporeal photopheresis. J Eur Acad Dermatol Venereol 2014;28 Suppl 1:1-37. [PMID: 24354653 DOI: 10.1111/jdv.12311] [Cited by in Crossref: 117] [Cited by in F6Publishing: 79] [Article Influence: 16.7] [Reference Citation Analysis]
47 Colombel J. The CARD15 (also known as NOD2) gene in Crohn's disease: Are there implications for current clinical practice? Clinical Gastroenterology and Hepatology 2003;1:5-9. [DOI: 10.1053/jcgh.2003.50002] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 0.8] [Reference Citation Analysis]
48 Boyapati R, Ong SY, Ye B, Kruavit A, Lee N, Vaughan R, Nandurkar S, Gibson P, Garg M. One fifth of hospitalizations for peptic ulcer-related bleeding are potentially preventable. World J Gastroenterol. 2014;20:10504-10511. [PMID: 25132768 DOI: 10.3748/wjg.v20.i30.10504] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
49 Loras Alastruey C, Andújar Murcia X, Esteve Comas M. The role of stents in the treatment of Crohn's disease strictures. Endosc Int Open. 2016;4:E301-E308. [PMID: 27014743 DOI: 10.1055/s-0042-101786] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
50 Treton X, Stefanescu C, Attar A, Alves A, Zappa M, Bouhnik Y. Sténose iléale. Gastroentérologie Clinique et Biologique 2007;31:387-92. [DOI: 10.1016/s0399-8320(07)89397-3] [Cited by in Crossref: 6] [Article Influence: 0.4] [Reference Citation Analysis]
51 Krishnareddy S, Swaminath A. When combination therapy isn't working: emerging therapies for the management of inflammatory bowel disease. World J Gastroenterol 2014;20:1139-46. [PMID: 24574790 DOI: 10.3748/wjg.v20.i5.1139] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
52 Fiorino G, Lytras T, Younge L, Fidalgo C, Coenen S, Chaparro M, Allocca M, Arnott I, Bossuyt P, Burisch J, Campmans-kuijpers M, de Ridder L, Dignass A, Drohan C, Feakins R, Gilardi D, Grosek J, Groß E, Hart A, Jäghult S, Katsanos K, Lönnfors S, Panis Y, Perovic M, Pierik M, Rimola J, Tulchinsky H, Gisbert JP. Quality of Care Standards in Inflammatory Bowel Diseases: a European Crohn’s and Colitis Organisation [ECCO] Position Paper. Journal of Crohn's and Colitis 2020;14:1037-48. [DOI: 10.1093/ecco-jcc/jjaa023] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 20.0] [Reference Citation Analysis]
53 Navaneethan U. Endoscopic Stricturotomy for Refractory Anal Strictures in Crohn’s Disease. Inflammatory Bowel Diseases 2020;26:e99-e100. [DOI: 10.1093/ibd/izaa147] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
54 Panés J, O'Connor M, Peyrin-Biroulet L, Irving P, Petersson J, Colombel JF. Improving quality of care in inflammatory bowel disease: what changes can be made today? J Crohns Colitis 2014;8:919-26. [PMID: 24713174 DOI: 10.1016/j.crohns.2014.02.022] [Cited by in Crossref: 46] [Cited by in F6Publishing: 36] [Article Influence: 6.6] [Reference Citation Analysis]
55 Huang C, Kugathasan S. Markers that differentiate early from late IBD. Dig Dis 2012;30:380-2. [PMID: 22796800 DOI: 10.1159/000338130] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
56 Kilcoyne A, Kaplan JL, Gee MS. Inflammatory bowel disease imaging: Current practice and future directions. World J Gastroenterol. 2016;22:917-932. [PMID: 26811637 DOI: 10.3748/wjg.v22.i3.917] [Cited by in CrossRef: 50] [Cited by in F6Publishing: 32] [Article Influence: 12.5] [Reference Citation Analysis]
57 Chow DK, Sung JJ, Wu JC, Tsoi KK, Leong RW, Chan FK. Upper gastrointestinal tract phenotype of Crohn's disease is associated with early surgery and further hospitalization. Inflamm Bowel Dis. 2009;15:551-557. [PMID: 19067420 DOI: 10.1002/ibd.20804] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 3.8] [Reference Citation Analysis]
58 Fletcher JG, Fidler JL, Bruining DH, Huprich JE. New concepts in intestinal imaging for inflammatory bowel diseases. Gastroenterology 2011;140:1795-806. [PMID: 21530746 DOI: 10.1053/j.gastro.2011.02.013] [Cited by in Crossref: 91] [Cited by in F6Publishing: 62] [Article Influence: 9.1] [Reference Citation Analysis]
59 Van Assche G, Vermeire S, Rutgeerts P. Optimizing treatment of inflammatory bowel diseases with biologic agents. Curr Gastroenterol Rep 2008;10:591-6. [DOI: 10.1007/s11894-008-0107-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
60 Ferrante M, D’haens G, Rutgeerts P, Vermeire S, Van Assche G. Optimizing biologic therapies for inflammatory bowel disease (ulcerative colitis and crohn’s disease). Curr Gastroenterol Rep 2009;11:504-8. [DOI: 10.1007/s11894-009-0076-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
61 af Björkesten C, Nieminen U, Turunen U, Arkkila P, Sipponen T, Färkkilä M. Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohn's disease. Scandinavian Journal of Gastroenterology 2012;47:528-37. [DOI: 10.3109/00365521.2012.660542] [Cited by in Crossref: 109] [Cited by in F6Publishing: 102] [Article Influence: 12.1] [Reference Citation Analysis]
62 Rutgeerts P. How to Guide Therapeutic Decisions in a Patient-Tailored Approach to Treatment of IBD? Dig Dis 2012;30:396-9. [DOI: 10.1159/000338137] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
63 Wauters L, Smets F, De Greef E, Bontems P, Hoffman I, Hauser B, Alliet P, Arts W, Peeters H, Van Biervliet S, Paquot I, Van de Vijver E, De Vos M, Bossuyt P, Rahier JF, Dewit O, Moreels T, Franchimont D, Muls V, Fontaine F, Louis E, Coche JC, Baert F, Paul J, Vermeire S, Veereman G. Long-term Outcomes with Anti-TNF Therapy and Accelerated Step-up in the Prospective Pediatric Belgian Crohn's Disease Registry (BELCRO). Inflamm Bowel Dis 2017;23:1584-91. [PMID: 28696956 DOI: 10.1097/MIB.0000000000001193] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
64 Li G, Ren J, Hu Q, Deng Y, Chen G, Guo K, Li R, Li Y, Wu L, Wang G, Gu G, Li J. Oral pirfenidone protects against fibrosis by inhibiting fibroblast proliferation and TGF-β signaling in a murine colitis model. Biochemical Pharmacology 2016;117:57-67. [DOI: 10.1016/j.bcp.2016.08.002] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 4.2] [Reference Citation Analysis]
65 Deepak P, Ludwig DR, Fidler JL, Guglielmo FF, Bruining DH. Medical and Endoscopic Management of Crohn Disease. Top Magn Reson Imaging 2021;30:43-61. [PMID: 33528211 DOI: 10.1097/RMR.0000000000000267] [Reference Citation Analysis]
66 Swoger JM, Loftus EV, Tremaine WJ, Faubion WA, Pardi DS, Kane SV, Hanson KA, Harmsen WS, Zinsmeister AR, Sandborn WJ. Adalimumab for Crohn's disease in clinical practice at Mayo clinic: the first 118 patients. Inflamm Bowel Dis. 2010;16:1912-1921. [PMID: 20848486 DOI: 10.1002/ibd.21272] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 3.8] [Reference Citation Analysis]
67 Irwin J, Ferguson E, Simms LA, Hanigan K, Carbonnel F, Radford-Smith G. A rolling phenotype in Crohn's disease. PLoS One 2017;12:e0174954. [PMID: 28384331 DOI: 10.1371/journal.pone.0174954] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
68 Beigel F, Deml M, Schnitzler F, Breiteneicher S, Göke B, Ochsenkühn T, Brand S. Rate and predictors of mucosal healing in patients with inflammatory bowel disease treated with anti-TNF-alpha antibodies. PLoS One 2014;9:e99293. [PMID: 24932476 DOI: 10.1371/journal.pone.0099293] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
69 Tozer PJ, Whelan K, Phillips RK, Hart AL. Etiology of perianal Crohn's disease: role of genetic, microbiological, and immunological factors. Inflamm Bowel Dis 2009;15:1591-8. [PMID: 19637358 DOI: 10.1002/ibd.21026] [Cited by in Crossref: 33] [Cited by in F6Publishing: 26] [Article Influence: 2.8] [Reference Citation Analysis]
70 Ong MS, Grand RJ, Mandl KD. Trends in Pharmacologic Interventions for Preventing Recurrence of Crohn's Disease After Ileocolonic Surgery. Inflamm Bowel Dis 2016;22:2432-41. [PMID: 27631599 DOI: 10.1097/MIB.0000000000000898] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
71 Hallé E, Azahaf M, Duveau N, Lambin T, Nachury M, Branche J, Gérard R, Lauriot Dit Prevost C, Wils P, Desreumaux P, Ernst O, Pariente B. Radiological Response Is Associated with Better Outcomes and Should Be Considered a Therapeutic Target in Crohn’s Disease. Dig Dis Sci 2020;65:2664-74. [DOI: 10.1007/s10620-019-05979-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
72 Hirten RP, Shah S, Sachar DB, Colombel JF. The Management of Intestinal Penetrating Crohn's Disease. Inflamm Bowel Dis 2018;24:752-65. [PMID: 29528400 DOI: 10.1093/ibd/izx108] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 6.5] [Reference Citation Analysis]
73 Feagan BG, Sandborn WJ, Hass S, Niecko T, White J. Health-related quality of life during natalizumab maintenance therapy for Crohn's disease. Am J Gastroenterol 2007;102:2737-46. [PMID: 18042106 DOI: 10.1111/j.1572-0241.2007.01508.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 2.5] [Reference Citation Analysis]
74 Loras C, Pérez-roldan F, Gornals JB, Barrio J, Igea F, González-huix F, González-carro P, Pérez-miranda M, Espinós JC, Fernández-bañares F, Esteve M. Endoscopic treatment with self-expanding metal stents for Crohn's disease strictures. Aliment Pharmacol Ther 2012;36:833-9. [DOI: 10.1111/apt.12039] [Cited by in Crossref: 58] [Cited by in F6Publishing: 49] [Article Influence: 6.4] [Reference Citation Analysis]
75 Park MS, Kim DH, Kim DH, Park SJ, Hong SP, Kim TI, Kim WH, Cheon JH. Leukopenia predicts remission in patients with inflammatory bowel disease and Behcet's disease on thiopurine maintenance. Dig Dis Sci 2015;60:195-204. [PMID: 25239495 DOI: 10.1007/s10620-014-3355-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
76 Ward MG, Kariyawasam VC, Mogan SB, Patel KV, Pantelidou M, Sobczyńska-Malefora A, Porté F, Griffin N, Anderson SH, Sanderson JD, Harrington DJ, Irving PM. Prevalence and Risk Factors for Functional Vitamin B12 Deficiency in Patients with Crohn's Disease. Inflamm Bowel Dis 2015;21:2839-47. [PMID: 26296064 DOI: 10.1097/MIB.0000000000000559] [Cited by in Crossref: 27] [Cited by in F6Publishing: 8] [Article Influence: 5.4] [Reference Citation Analysis]
77 Ballengee CR, Stidham RW, Liu C, Kim MO, Prince J, Mondal K, Baldassano R, Dubinsky M, Markowitz J, Leleiko N, Hyams J, Denson L, Kugathasan S. Association Between Plasma Level of Collagen Type III Alpha 1 Chain and Development of Strictures in Pediatric Patients With Crohn's Disease. Clin Gastroenterol Hepatol 2019;17:1799-806. [PMID: 30213581 DOI: 10.1016/j.cgh.2018.09.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
78 Sorrentino D. Preclinical and Undiagnosed Crohnʼs Disease: The Submerged Iceberg. Inflammatory Bowel Diseases 2016;22:476-86. [DOI: 10.1097/mib.0000000000000612] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 2.2] [Reference Citation Analysis]
79 Kopylov U, Eliakim R. The Lemann Index—A Glance Through the Window of Opportunity? ECCOJC. [DOI: 10.1093/ecco-jcc/jjw195] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
80 Lakatos PL, Papp M, Rieder F. Serologic antiglycan antibodies in inflammatory bowel disease. Am J Gastroenterol. 2011;106:406-412. [PMID: 21245832 DOI: 10.1038/ajg.2010.505] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 2.8] [Reference Citation Analysis]
81 Lashner BA, Brzezinski A. Crohn's Disease. GI/Liver Secrets. Elsevier; 2010. pp. 297-303. [DOI: 10.1016/b978-0-323-06397-5.00042-3] [Cited by in Crossref: 5] [Article Influence: 0.5] [Reference Citation Analysis]
82 Jenkinson PW, Plevris N, Siakavellas S, Lyons M, Arnott ID, Wilson D, Watson AJM, Jones GR, Lees CW. Temporal Trends in Surgical Resection Rates and Biologic Prescribing in Crohn's Disease: A Population-based Cohort Study. J Crohns Colitis 2020;14:1241-7. [PMID: 32840295 DOI: 10.1093/ecco-jcc/jjaa044] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
83 Cullen G, Vaughn B, Ahmed A, Peppercorn MA, Smith MP, Moss AC, Cheifetz AS. Abdominal phlegmons in Crohn's disease: outcomes following antitumor necrosis factor therapy. Inflamm Bowel Dis 2012;18:691-6. [PMID: 21648022 DOI: 10.1002/ibd.21783] [Cited by in Crossref: 27] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
84 Wang X, Zhou F, Zhao J, Zhou R, Huang M, Li J, Wang W, Xu S, Xia B. Elevated risk of opportunistic viral infection in patients with Crohn’s disease during biological therapies: a meta analysis of randomized controlled trials. Eur J Clin Pharmacol 2013;69:1891-9. [DOI: 10.1007/s00228-013-1559-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
85 Angelberger S, Vogelsang H, Novacek G, Miehsler W, Dejaco C, Gangl A, Reinisch W. Public awareness of Crohn's disease and ulcerative colitis: A national survey. J Crohns Colitis 2009;3:157-61. [PMID: 21172264 DOI: 10.1016/j.crohns.2009.01.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
86 Papa A, Lopetuso LR, Minordi LM, Di Veronica A, Neri M, Rapaccini G, Gasbarrini A, Papa V. A modern multidisciplinary approach to the treatment of enterocutaneous fistulas in Crohn's disease patients. Expert Rev Gastroenterol Hepatol 2020;14:857-65. [PMID: 32673498 DOI: 10.1080/17474124.2020.1797484] [Reference Citation Analysis]
87 Corte C, Saxena P, Tattersall S, Selinger C, Leong RW. When to use biological agents in inflammatory bowel disease. J Gastroenterol Hepatol 2012;27:1141-9. [PMID: 22188169 DOI: 10.1111/j.1440-1746.2011.07056.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
88 Murthy SK, Begum J, Benchimol EI, Bernstein CN, Kaplan GG, McCurdy JD, Singh H, Targownik L, Taljaard M. Introduction of anti-TNF therapy has not yielded expected declines in hospitalisation and intestinal resection rates in inflammatory bowel diseases: a population-based interrupted time series study. Gut. 2019;. [PMID: 31196874 DOI: 10.1136/gutjnl-2019-318440] [Cited by in Crossref: 55] [Cited by in F6Publishing: 43] [Article Influence: 27.5] [Reference Citation Analysis]
89 Chen M, Shen B. Endoscopic Therapy in Crohn's Disease: Principle, Preparation, and Technique. Inflamm Bowel Dis. 2015;21:2222-2240. [PMID: 26284298 DOI: 10.1097/mib.0000000000000433] [Cited by in Crossref: 43] [Cited by in F6Publishing: 9] [Article Influence: 8.6] [Reference Citation Analysis]
90 Tontini GE, Vecchi M, Pastorelli L, Neurath MF, Neumann H. Differential diagnosis in inflammatory bowel disease colitis: state of the art and future perspectives. World J Gastroenterol. 2015;21:21-46. [PMID: 25574078 DOI: 10.3748/wjg.v21.i1.21] [Cited by in CrossRef: 87] [Cited by in F6Publishing: 71] [Article Influence: 14.5] [Reference Citation Analysis]
91 Lovasz BD, Golovics PA, Vegh Z, Lakatos PL. New trends in inflammatory bowel disease epidemiology and disease course in Eastern Europe. Dig Liver Dis. 2013;45:269-276. [PMID: 23010518 DOI: 10.1016/j.dld.2012.08.020] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
92 Moss AC. Prevention of postoperative recurrence of Crohn’s disease: what does the evidence support? Inflamm Bowel Dis. 2013;19:856-859. [PMID: 23446339 DOI: 10.1097/mib.0b013e3182802c21] [Cited by in Crossref: 19] [Cited by in F6Publishing: 5] [Article Influence: 2.4] [Reference Citation Analysis]
93 Blonski W, Buchner AM, Lichtenstein GR. Clinical predictors of aggressive/disabling disease: ulcerative colitis and crohn disease. Gastroenterol Clin North Am. 2012;41:443-462. [PMID: 22500528 DOI: 10.1016/j.gtc.2012.01.008] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.2] [Reference Citation Analysis]
94 Markowitz J, Markowitz JE, Bousvaros A, Crandall W, Faubion W, Kirschner BS, Perrault J, Rosh J, Winter H. Workshop report: prevention of postoperative recurrence in Crohn's disease. J Pediatr Gastroenterol Nutr 2005;41:145-51. [PMID: 16056092 DOI: 10.1097/01.mpg.0000172746.86973.ef] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
95 Henriksen M, Jahnsen J, Lygren I, Vatn MH, Moum B; IBSEN Study Group. Are there any differences in phenotype or disease course between familial and sporadic cases of inflammatory bowel disease? Am J Gastroenterol. 2007;102:1955-1963. [PMID: 17573793 DOI: 10.1111/j.1572-0241.2007.01368.x] [Cited by in Crossref: 54] [Cited by in F6Publishing: 46] [Article Influence: 3.9] [Reference Citation Analysis]
96 Anton Decker G, Pasha SF, Leighton JA. Utility of Double Balloon Enteroscopy for the Diagnosis and Management of Crohn’s Disease. Techniques in Gastrointestinal Endoscopy 2008;10:83-6. [DOI: 10.1016/j.tgie.2007.12.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
97 Atreya R, Siegmund B. Location is important: differentiation between ileal and colonic Crohn's disease. Nat Rev Gastroenterol Hepatol 2021;18:544-58. [PMID: 33712743 DOI: 10.1038/s41575-021-00424-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
98 Migaleddu V, Quaia E, Scanu D, Carla S, Bertolotto M, Campisi G, Sirigu D, Virgilio G. Inflammatory activity in Crohn's disease: CE-US. Abdom Imaging 2011;36:142-8. [PMID: 20464392 DOI: 10.1007/s00261-010-9622-8] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
99 Knobler R, Arenberger P, Arun A, Assaf C, Bagot M, Berlin G, Bohbot A, Calzavara-Pinton P, Child F, Cho A, French LE, Gennery AR, Gniadecki R, Gollnick HPM, Guenova E, Jaksch P, Jantschitsch C, Klemke C, Ludvigsson J, Papadavid E, Scarisbrick J, Schwarz T, Stadler R, Wolf P, Zic J, Zouboulis C, Zuckermann A, Greinix H. European dermatology forum: Updated guidelines on the use of extracorporeal photopheresis 2020 - Part 2. J Eur Acad Dermatol Venereol 2021;35:27-49. [PMID: 32964529 DOI: 10.1111/jdv.16889] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
100 Sandborn WJ. The Future of Inflammatory Bowel Disease Therapy: Where Do We Go from Here? Dig Dis 2012;30:140-4. [DOI: 10.1159/000342742] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 3.0] [Reference Citation Analysis]
101 Hutter S, van Haaften WT, Hünerwadel A, Baebler K, Herfarth N, Raselli T, Mamie C, Misselwitz B, Rogler G, Weder B, Dijkstra G, Meier CF, de Vallière C, Weber A, Imenez Silva PH, Wagner CA, Frey-Wagner I, Ruiz PA, Hausmann M. Intestinal Activation of pH-Sensing Receptor OGR1 [GPR68] Contributes to Fibrogenesis. J Crohns Colitis 2018;12:1348-58. [PMID: 30165600 DOI: 10.1093/ecco-jcc/jjy118] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
102 Yablecovitch D, Kopylov U, Lahat A, Amitai MM, Klang E, Ben-Ami Shor D, Neuman S, Levhar N, Fudim E, Avidan B, Laish I, Selinger L, Zingboim-Orbach N, Picard O, Yavzori M, Eliakim R, Ben-Horin S. Serum MMP-9: a novel biomarker for prediction of clinical relapse in patients with quiescent Crohn's disease, a post hoc analysis. Therap Adv Gastroenterol 2019;12:1756284819881590. [PMID: 31636712 DOI: 10.1177/1756284819881590] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
103 Kim GH, Kim KJ, Kim GA, Yang JE, Park HJ, Ye BD, Myung SJ, Yang SK. A New Technique Using Ultra-slim Endoscopy for High-Grade Crohn's Stricture. J Korean Soc Coloproctol 2012;28:271-4. [PMID: 23185708 DOI: 10.3393/jksc.2012.28.5.271] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
104 Naves JE, Domènech E. Amiloidosis sistémica en la enfermedad inflamatoria intestinal. Gastroenterología y Hepatología 2012;35:259-65. [DOI: 10.1016/j.gastrohep.2011.11.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
105 Fiorino G, Bonifacio C, Malesci A, Balzarini L, Danese S. MRI in Crohn’s disease--current and future clinical applications. Nat Rev Gastroenterol Hepatol. 2012;9:23-31. [PMID: 22105109 DOI: 10.1038/nrgastro.2011.2142] [Reference Citation Analysis]
106 Kabakchiev B, Halder S, Silverberg MS. The future of molecular approaches to inflammatory bowel disease. Mol Diagn Ther 2009;13:217-23. [PMID: 19712002 DOI: 10.1007/BF03256328] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
107 Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011;140:1785-1794. [PMID: 21530745 DOI: 10.1053/j.gastro.2011.01.055] [Cited by in Crossref: 1157] [Cited by in F6Publishing: 953] [Article Influence: 115.7] [Reference Citation Analysis]
108 Chhaya V, Saxena S, Cecil E, Chatu S, Subramanian V, Curcin V, Majeed A, Pollok RC. The impact of timing and duration of thiopurine treatment on colectomy in ulcerative colitis: a national population-based study of incident cases between 1989-2009. Aliment Pharmacol Ther. 2015;41:87-98. [PMID: 25382737 DOI: 10.1111/apt.13017] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.9] [Reference Citation Analysis]
109 Rieder F, de Bruyn JR, Pham BT, Katsanos K, Annese V, Higgins PD, Magro F, Dotan I. Results of the 4th scientific workshop of the ECCO (Group II): markers of intestinal fibrosis in inflammatory bowel disease. J Crohns Colitis. 2014;8:1166-1178. [PMID: 24726695 DOI: 10.1016/j.crohns.2014.03.009] [Cited by in Crossref: 45] [Cited by in F6Publishing: 38] [Article Influence: 6.4] [Reference Citation Analysis]
110 Chowers Y. Taking Crohn's disease personally. Rambam Maimonides Med J 2013;4:e0011. [PMID: 23908861 DOI: 10.5041/RMMJ.10111] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
111 Sato Y, Matsui T, Yano Y, Tsurumi K, Okado Y, Matsushima Y, Koga A, Takahashi H, Ninomiya K, Ono Y, Takatsu N, Beppu T, Nagahama T, Hisabe T, Takaki Y, Hirai F, Yao K, Higashi D, Futami K, Washio M. Long-term course of Crohn's disease in Japan: Incidence of complications, cumulative rate of initial surgery, and risk factors at diagnosis for initial surgery. J Gastroenterol Hepatol. 2015;30:1713-1719. [PMID: 26094852 DOI: 10.1111/jgh.13013] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 4.4] [Reference Citation Analysis]
112 Colombel JF, Rutgeerts P, Reinisch W, Esser D, Wang Y, Lang Y, Marano CW, Strauss R, Oddens BJ, Feagan BG, Hanauer SB, Lichtenstein GR, Present D, Sands BE, Sandborn WJ. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology. 2011;141:1194-1201. [PMID: 21723220 DOI: 10.1053/j.gastro.2011.06.054] [Cited by in Crossref: 582] [Cited by in F6Publishing: 481] [Article Influence: 58.2] [Reference Citation Analysis]
113 Li Y, Chen B, Gao X, Hu N, Huang M, Ran Z, Liu Z, Zhong J, Zou D, Wu X, Ren J, Sheng J, Zheng P, Wang H, Chen M, Chen J, Xi P, Lu J, Handel M, Liu Y, Fan H, Qian J. Current diagnosis and management of Crohn's disease in China: results from a multicenter prospective disease registry. BMC Gastroenterol. 2019;19:145. [PMID: 31420025 DOI: 10.1186/s12876-019-1057-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
114 Sjöberg D, Holmström T, Larsson M, Nielsen AL, Holmquist L, Ekbom A, Rönnblom A. Incidence and clinical course of Crohn’s disease during the first year - results from the IBD Cohort of the Uppsala Region (ICURE) of Sweden 2005-2009. J Crohns Colitis. 2014;8:215-222. [PMID: 24035547 DOI: 10.1016/j.crohns.2013.08.009] [Cited by in Crossref: 73] [Cited by in F6Publishing: 65] [Article Influence: 9.1] [Reference Citation Analysis]
115 Molina-Infante J, Schoepfer AM, Lucendo AJ, Dellon ES. Eosinophilic esophagitis: What can we learn from Crohn's disease? United European Gastroenterol J 2017;5:762-72. [PMID: 29026590 DOI: 10.1177/2050640616672953] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
116 Sorrentino D, Nguyen VQ, Chitnavis MV. Capturing the Biologic Onset of Inflammatory Bowel Diseases: Impact on Translational and Clinical Science. Cells 2019;8:E548. [PMID: 31174359 DOI: 10.3390/cells8060548] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
117 Gilletta C, Lewin M, Bourrier A, Nion-Larmurier I, Rajca S, Beaugerie L, Sokol H, Pariente B, Seksik P, Cosnes J. Changes in the Lémann Index Values During the First Years of Crohn's Disease. Clin Gastroenterol Hepatol 2015;13:1633-40.e3. [PMID: 25766650 DOI: 10.1016/j.cgh.2015.02.041] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 5.8] [Reference Citation Analysis]
118 Ananthakrishnan AN, Xavier RJ. How does genotype influence disease phenotype in inflammatory bowel disease? Inflamm Bowel Dis 2013;19:2021-30. [PMID: 23644824 DOI: 10.1097/MIB.0b013e318281f5c5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
119 Verstockt B, Cleynen I. Genetic Influences on the Development of Fibrosis in Crohn's Disease. Front Med (Lausanne) 2016;3:24. [PMID: 27303667 DOI: 10.3389/fmed.2016.00024] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
120 Gutiérrez A, Zapater P, Juanola O, Sempere L, García M, Laveda R, Martínez A, Scharl M, González-navajas JM, Such J, Wiest R, Rogler G, Francés R. Gut Bacterial DNA Translocation is an Independent Risk Factor of Flare at Short Term in Patients With Crohn’s Disease. American Journal of Gastroenterology 2016;111:529-40. [DOI: 10.1038/ajg.2016.8] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 5.2] [Reference Citation Analysis]
121 Safroneeva E, Vavricka SR, Fournier N, Pittet V, Peyrin-biroulet L, Straumann A, Rogler G, Schoepfer AM; the Swiss IBD Cohort Study Group. Impact of the early use of immunomodulators or TNF antagonists on bowel damage and surgery in Crohn's disease. Aliment Pharmacol Ther 2015;42:977-89. [DOI: 10.1111/apt.13363] [Cited by in Crossref: 64] [Cited by in F6Publishing: 43] [Article Influence: 10.7] [Reference Citation Analysis]
122 Wickramasinghe D, Adegbola S, Sahnan K, Morar P, Carvello M, Di Candido F, Maroli A, Spinelli A, Warusavitarne J. A scoring system to predict a prolonged length of stay after surgery for Crohn's disease. Colorectal Dis 2021;23:1205-12. [PMID: 33539619 DOI: 10.1111/codi.15567] [Reference Citation Analysis]
123 Fu YT, Hong T, Round A, Bressler B. Impact of medical therapy on patients with Crohn's disease requiring surgical resection. World J Gastroenterol 2014;20:11808-14. [PMID: 25206286 DOI: 10.3748/wjg.v20.i33.11808] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
124 Baars JE, Zelinkova Z, Mensink PBF, Markus T, Looman CWN, Kuipers EJ, Van Der Woude CJ. High therapy adherence but substantial limitations to daily activities amongst members of the Dutch inflammatory bowel disease patients' organization: a patient empowerment study. Alimentary Pharmacology & Therapeutics 2009;30:864-72. [DOI: 10.1111/j.1365-2036.2009.04103.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
125 Bruining DH, Loftus EV, Ehman EC, Siddiki HA, Nguyen DL, Fidler JL, Huprich JE, Mandrekar JN, Harmsen WS, Sandborn WJ, Fletcher JG. Computed tomography enterography detects intestinal wall changes and effects of treatment in patients with Crohn's disease. Clin Gastroenterol Hepatol. 2011;9:679-683.e1. [PMID: 21621641 DOI: 10.1016/j.cgh.2011.04.025] [Cited by in Crossref: 56] [Cited by in F6Publishing: 39] [Article Influence: 5.6] [Reference Citation Analysis]
126 Hibi T, Sakuraba A, Watanabe M, Motoya S, Ito H, Motegi K, Kinouchi Y, Takazoe M, Suzuki Y, Matsumoto T, Kawakami K, Matsumoto T, Hirata I, Tanaka S, Ashida T, Matsui T. Retrieval of serum infliximab level by shortening the maintenance infusion interval is correlated with clinical efficacy in Crohn's disease. Inflamm Bowel Dis 2012;18:1480-7. [PMID: 21987418 DOI: 10.1002/ibd.21886] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 3.9] [Reference Citation Analysis]
127 Carlsen A, Omdal R, Karlsen L, Kvaløy JT, Aabakken L, Steinsbø Ø, Bolstad N, Warren D, Lundin KEA, Grimstad T. Determination of lower cut-off levels of adalimumab associated with biochemical remission in Crohn's disease. JGH Open 2020;4:410-6. [PMID: 32514446 DOI: 10.1002/jgh3.12266] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
128 Dassopoulos T, Frangakis C, Cruz-Correa M, Talor MV, Burek CL, Datta L, Nouvet F, Bayless TM, Brant SR. Antibodies to saccharomyces cerevisiae in Crohn's disease: higher titers are associated with a greater frequency of mutant NOD2/CARD15 alleles and with a higher probability of complicated disease. Inflamm Bowel Dis 2007;13:143-51. [PMID: 17206688 DOI: 10.1002/ibd.20031] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 1.9] [Reference Citation Analysis]
129 Rutgeerts P, Vermeire S, Van Assche G. Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target? Gut 2007;56:453-5. [PMID: 17369375 DOI: 10.1136/gut.2005.088732] [Cited by in Crossref: 196] [Cited by in F6Publishing: 164] [Article Influence: 14.0] [Reference Citation Analysis]
130 Dorn SD, Abad JF, Panagopoulos G, Korelitz BI. Clinical characteristics of familial versus sporadic Crohn‘s disease using the Vienna Classification. Inflamm Bowel Dis. 2004;10:201-206. [PMID: 15290912 DOI: 10.1097/00054725-200405000-00004] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 1.5] [Reference Citation Analysis]
131 Zhulina Y, Udumyan R, Henriksson I, Tysk C, Montgomery S, Halfvarson J. Temporal trends in non-stricturing and non-penetrating behaviour at diagnosis of Crohn's disease in Örebro, Sweden: a population-based retrospective study. J Crohns Colitis 2014;8:1653-60. [PMID: 25113899 DOI: 10.1016/j.crohns.2014.07.006] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
132 Cravo M, Ferreira P, Sousa P, Moura-Santos P, Velho S, Tavares L, Deus JR, Ministro P, da Silva JP, Correia L, Velosa J, Maio R, Brito M. Clinical and genetic factors predicting response to therapy in patients with Crohn's disease. United European Gastroenterol J 2014;2:47-56. [PMID: 24918007 DOI: 10.1177/2050640613519626] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
133 Zhong YK, Lu BL, Huang SY, Chen YJ, Li ZP, Rimola J, Li XH. Cross-sectional imaging for assessing intestinal fibrosis in Crohn's disease. J Dig Dis 2020;21:342-50. [PMID: 32418328 DOI: 10.1111/1751-2980.12881] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
134 Rosh JR, Lerer T, Markowitz J, Goli SR, Mamula P, Noe JD, Pfefferkorn MD, Kelleher KT, Griffiths AM, Kugathasan S, Keljo D, Oliva-hemker M, Crandall W, Carvalho RS, Mack DR, Hyams JS. Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in Pediatric Crohnʼs Disease: . American Journal of Gastroenterology 2009;104:3042-9. [DOI: 10.1038/ajg.2009.493] [Cited by in Crossref: 82] [Cited by in F6Publishing: 63] [Article Influence: 6.8] [Reference Citation Analysis]
135 Thia KT, Sandborn WJ, Harmsen WS, Zinsmeister AR, Loftus EV Jr. Risk factors associated with progression to intestinal complications of Crohn's disease in a population-based cohort. Gastroenterology. 2010;139:1147-1155. [PMID: 20637205 DOI: 10.1053/j.gastro.2010.06.070] [Cited by in Crossref: 388] [Cited by in F6Publishing: 322] [Article Influence: 35.3] [Reference Citation Analysis]
136 Aarnio MT, Mecklin J, Voutilainen M. The Role of Surgery in Crohn's Disease: A Retrospective Analysis from a Single Hospital. Scand J Surg 2010;99:208-12. [DOI: 10.1177/145749691009900405] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
137 Kim B, Cheon JH, Moon HJ, Park YR, Ye BD, Yang SK, Seo GS, Jang BI, Kim YS, Kim JS, Han DS, Kim YH, Kim WH. Crohn's disease prognosis and early immunomodulator therapy: Results from the CONNECT study. J Gastroenterol Hepatol 2016;31:126-32. [PMID: 26406334 DOI: 10.1111/jgh.13169] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
138 Connell W, Andrews JM, Brown S, Sparrow M. Practical guidelines for treating inflammatory bowel disease safely with anti-tumour necrosis factor therapy in Australia: Safety of anti TNF treatment in IBD. Internal Medicine Journal 2010;40:139-49. [DOI: 10.1111/j.1445-5994.2009.02122.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
139 Chinem ESS, Esberard BC, Moreira ADL, Barbassa TG, da Cunha GM, Carneiro AJV, de Souza HS, Carvalho ATP. Changes in the Management of Patients with Crohn's Disease Based on Magnetic Resonance Enterography Patterns. Gastroenterol Res Pract. 2019;2019:3467316. [PMID: 31933630 DOI: 10.1155/2019/3467316] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
140 Hansen T, Targownik LE. Ustekinumab for the treatment of Crohn’s disease. Expert Review of Gastroenterology & Hepatology 2016;10:989-94. [DOI: 10.1080/17474124.2016.1215912] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
141 Benchimol EI, Manuel DG, Mojaverian N, Mack DR, Nguyen GC, To T, Guttmann A. Health Services Utilization, Specialist Care, and Time to Diagnosis with Inflammatory Bowel Disease in Immigrants to Ontario, Canada: A Population-Based Cohort Study. Inflamm Bowel Dis 2016;22:2482-90. [PMID: 27556836 DOI: 10.1097/MIB.0000000000000905] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 4.3] [Reference Citation Analysis]
142 Lazarev M, Ullman T, Schraut WH, Kip KE, Saul M, Regueiro M. Small bowel resection rates in Crohn’s disease and the indication for surgery over time: experience from a large tertiary care center. Inflamm Bowel Dis. 2010;16:830-835. [PMID: 19798731 DOI: 10.1002/ibd.21118] [Cited by in Crossref: 64] [Cited by in F6Publishing: 61] [Article Influence: 5.8] [Reference Citation Analysis]
143 Odes S, Vardi H, Friger M, Wolters F, Hoie O, Moum B, Bernklev T, Yona H, Russel M, Munkholm P. Effect of phenotype on health care costs in Crohn’s disease: A European study using the Montreal classification. J Crohns Colitis. 2007;1:87-96. [PMID: 21172190 DOI: 10.1016/j.crohns.2007.08.004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
144 Stidham RW, Higgins PD. Value of mucosal assessment and biomarkers in inflammatory bowel disease. Expert Rev Gastroenterol Hepatol. 2010;4:285-291. [PMID: 20528116 DOI: 10.1586/egh.10.22] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
145 Sprakes MB, Hamlin PJ, Warren L, Greer D, Ford AC. Adalimumab as second line anti-tumour necrosis factor alpha therapy for Crohn's disease: A single centre experience. Journal of Crohn's and Colitis 2011;5:324-31. [DOI: 10.1016/j.crohns.2011.02.007] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
146 Freeman HJ. Application of the Montreal classification for Crohn’s disease to a single clinician database of 1015 patients. Can J Gastroenterol. 2007;21:363-366. [PMID: 17571169 DOI: 10.1155/2007/951526] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 2.3] [Reference Citation Analysis]
147 Park JJ, Yang SK, Ye BD, Kim JW, Park DI, Yoon H, Im JP, Lee KM, Yoon SN, Lee H; IBD Study Group of the Korean Association for the Study of Intestinal Diseases. Second Korean guidelines for the management of Crohn's disease. Intest Res 2017;15:38-67. [PMID: 28239314 DOI: 10.5217/ir.2017.15.1.38] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 7.3] [Reference Citation Analysis]
148 Cosnes J, Nion-Larmurier I, Beaugerie L, Afchain P, Tiret E, Gendre JP. Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut. 2005;54:237-241. [PMID: 15647188 DOI: 10.1136/gut.2004.04294] [Reference Citation Analysis]
149 Kopylov U, Seidman E. Predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel disease. Therap Adv Gastroenterol 2016;9:513-26. [PMID: 27366220 DOI: 10.1177/1756283X16638833] [Cited by in Crossref: 33] [Cited by in F6Publishing: 13] [Article Influence: 6.6] [Reference Citation Analysis]
150 Prideaux L, Kamm MA, De Cruz PP, Chan FK, Ng SC. Inflammatory bowel disease in Asia: a systematic review. J Gastroenterol Hepatol 2012;27:1266-80. [PMID: 22497584 DOI: 10.1111/j.1440-1746.2012.07150.x] [Cited by in Crossref: 195] [Cited by in F6Publishing: 181] [Article Influence: 21.7] [Reference Citation Analysis]
151 Simon EG, Samuel S, Ghosh S, Moran GW. Ustekinumab: a novel therapeutic option in Crohn's disease. Expert Opin Biol Ther 2016;16:1065-74. [PMID: 27341173 DOI: 10.1080/14712598.2016.1205582] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
152 Shih DQ, Zheng L, Zhang X, Zhang H, Kanazawa Y, Ichikawa R, Wallace KL, Chen J, Pothoulakis C, Koon HW, Targan SR. Inhibition of a novel fibrogenic factor Tl1a reverses established colonic fibrosis. Mucosal Immunol 2014;7:1492-503. [PMID: 24850426 DOI: 10.1038/mi.2014.37] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 6.3] [Reference Citation Analysis]
153 Pigneur B, Seksik P, Viola S, Viala J, Beaugerie L, Girardet JP, Ruemmele FM, Cosnes J. Natural history of Crohn's disease: comparison between childhood- and adult-onset disease. Inflamm Bowel Dis. 2010;16:953-961. [PMID: 19834970 DOI: 10.1002/ibd.21152] [Cited by in Crossref: 158] [Cited by in F6Publishing: 128] [Article Influence: 14.4] [Reference Citation Analysis]
154 Dreesen E, Gils A. Pharmacodynamic Monitoring of Biological Therapies in Chronic Inflammatory Diseases. Ther Drug Monit 2019;41:131-41. [PMID: 30883507 DOI: 10.1097/FTD.0000000000000571] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
155 Drobne D, Bossuyt P, Breynaert C, Cattaert T, Vande Casteele N, Compernolle G, Jürgens M, Ferrante M, Ballet V, Wollants WJ. Withdrawal of immunomodulators after co-treatment does not reduce trough level of infliximab in patients with Crohn's disease. Clin Gastroenterol Hepatol. 2015;13:514-521.e4. [PMID: 25066841 DOI: 10.1016/j.cgh.2014.07.027] [Cited by in Crossref: 83] [Cited by in F6Publishing: 67] [Article Influence: 11.9] [Reference Citation Analysis]
156 Kim NH, Jung YS, Moon CM, Lee SY, Kim ER, Kim YH, Lee CK, Lee SH, Kim JH, Huh KC, Yoon SM, Song HJ, Boo SJ, Jang HJ, Kim YS, Lee KM, Shin JE, Park DI. Long-term clinical outcomes of korean patient with Crohn's disease following early use of infliximab. Intest Res 2014;12:281-6. [PMID: 25374493 DOI: 10.5217/ir.2014.12.4.281] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
157 Marehbian J, Arrighi HM, Hass S, Tian H, Sandborn WJ. Adverse Events Associated With Common Therapy Regimens for Moderate-to-Severe Crohn's Disease. Am J Gastroenterol 2009;104:2524-33. [DOI: 10.1038/ajg.2009.322] [Cited by in Crossref: 136] [Cited by in F6Publishing: 115] [Article Influence: 11.3] [Reference Citation Analysis]
158 Zabana Y, Garcia-planella E, van Domselaar M, Mañosa M, Gordillo J, López-sanromán A, Cabré E, Domènech E. Predictors of favourable outcome in inflammatory Crohn's disease. A retrospective observational study. Gastroenterología y Hepatología 2013;36:616-23. [DOI: 10.1016/j.gastrohep.2013.07.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
159 Lichtenstein GR, Hanauer SB, Sandborn WJ; Practice Parameters Committee of American College of Gastroenterology. Management of Crohn's disease in adults. Am J Gastroenterol. 2009;104:465-83; quiz 464, 484. [PMID: 19174807 DOI: 10.1038/ajg.2008.168] [Cited by in Crossref: 606] [Cited by in F6Publishing: 481] [Article Influence: 50.5] [Reference Citation Analysis]
160 Church PC, Turner D, Feldman BM, Walters TD, Greer ML, Amitai MM, Griffiths AM; ImageKids Study Group. Systematic review with meta-analysis: magnetic resonance enterography signs for the detection of inflammation and intestinal damage in Crohn's disease. Aliment Pharmacol Ther 2015;41:153-66. [PMID: 25403954 DOI: 10.1111/apt.13024] [Cited by in Crossref: 46] [Cited by in F6Publishing: 35] [Article Influence: 6.6] [Reference Citation Analysis]
161 Iacucci M, Ghosh S. Looking beyond symptom relief: evolution of mucosal healing in inflammatory bowel disease. Therap Adv Gastroenterol. 2011;4:129-143. [PMID: 21694814 DOI: 10.1177/1756283x11398930] [Cited by in Crossref: 31] [Cited by in F6Publishing: 14] [Article Influence: 3.1] [Reference Citation Analysis]
162 Torres J, Bonovas S, Doherty G, Kucharzik T, Gisbert JP, Raine T, Adamina M, Armuzzi A, Bachmann O, Bager P, Biancone L, Bokemeyer B, Bossuyt P, Burisch J, Collins P, El-hussuna A, Ellul P, Frei-lanter C, Furfaro F, Gingert C, Gionchetti P, Gomollon F, González-lorenzo M, Gordon H, Hlavaty T, Juillerat P, Katsanos K, Kopylov U, Krustins E, Lytras T, Maaser C, Magro F, Kenneth Marshall J, Myrelid P, Pellino G, Rosa I, Sabino J, Savarino E, Spinelli A, Stassen L, Uzzan M, Vavricka S, Verstockt B, Warusavitarne J, Zmora O, Fiorino G. ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment. Journal of Crohn's and Colitis 2020;14:4-22. [DOI: 10.1093/ecco-jcc/jjz180] [Cited by in Crossref: 184] [Cited by in F6Publishing: 123] [Article Influence: 92.0] [Reference Citation Analysis]
163 Li C, Kuemmerle JF. Mechanisms that mediate the development of fibrosis in patients with Crohn’s disease. Inflamm Bowel Dis. 2014;20:1250-1258. [PMID: 24831560 DOI: 10.1097/mib.0000000000000043] [Cited by in Crossref: 66] [Cited by in F6Publishing: 25] [Article Influence: 11.0] [Reference Citation Analysis]
164 Bettenworth D, Rieder F. Reversibility of Stricturing Crohn's Disease-Fact or Fiction? Inflamm Bowel Dis 2016;22:241-7. [PMID: 26588089 DOI: 10.1097/MIB.0000000000000598] [Cited by in Crossref: 26] [Cited by in F6Publishing: 14] [Article Influence: 5.2] [Reference Citation Analysis]
165 Jiang Y, Rim DS, Rodgers B, Ahlawat S. Sarcoidosis is associated with lower risks of penetrating disease and colectomy in hospitalized patients with inflammatory bowel disease. JGH Open 2020;4:1199-206. [PMID: 33319056 DOI: 10.1002/jgh3.12423] [Reference Citation Analysis]
166 Colombel JF, Louis E, Peyrin-Biroulet L, Sandborn WJ, Panaccione R. Deep remission: a new concept? Dig Dis. 2012;30 Suppl 3:107-111. [PMID: 23295700 DOI: 10.1159/000342732] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.4] [Reference Citation Analysis]
167 Krygier DS, Ko HH, Bressler B. How to manage difficult Crohn's disease: optimum delivery of anti-TNFs. Expert Rev Gastroenterol Hepatol 2009;3:407-15. [PMID: 19673627 DOI: 10.1586/egh.09.25] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
168 O'Donnell S, Borowski K, Espin-Garcia O, Milgrom R, Kabakchiev B, Stempak J, Panikkath D, Eksteen B, Xu W, Steinhart AH, Kaplan GG, McGovern DPB, Silverberg MS. The Unsolved Link of Genetic Markers and Crohn's Disease Progression: A North American Cohort Experience. Inflamm Bowel Dis 2019;25:1541-9. [PMID: 30801121 DOI: 10.1093/ibd/izz016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
169 Tharian B, George N, Navaneethan U. Endoscopy in the Diagnosis and Management of Complications of Inflammatory Bowel Disease: . Inflammatory Bowel Diseases 2016;22:1184-97. [DOI: 10.1097/mib.0000000000000626] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 2.4] [Reference Citation Analysis]
170 Bayart P, Duveau N, Nachury M, Zerbib P, Gerard R, Branche J, Maunoury V, Wils P, Boruchowicz A, Boualit M, Laberenne J, Manolache O, Desreumaux P, de Chambrun GP, Pariente B. Ileal or Anastomotic Location of Lesions Does Not Impact Rate of Postoperative Recurrence in Crohn’s Disease Patients Classified i2 on the Rutgeerts Score. Dig Dis Sci 2016;61:2986-92. [DOI: 10.1007/s10620-016-4215-1] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 4.2] [Reference Citation Analysis]
171 Ha CY, Kumar N, Raptis CA, Narra VR, Ciorba MA. Magnetic resonance enterography: safe and effective imaging for stricturing Crohn’s disease. Dig Dis Sci. 2011;56:2906-2913. [PMID: 21688128 DOI: 10.1007/s10620-011-1781-0] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
172 Sorrentino D, Fogel S, Van den Bogaerde J. Surgery for Crohn’s disease and anti-TNF agents: the changing scenario. Expert Rev Gastroenterol Hepatol. 2013;7:689-700. [PMID: 24161133 DOI: 10.1586/17474124.2013.842895] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
173 Giuffrida P, Pinzani M, Corazza GR, Di Sabatino A. Biomarkers of intestinal fibrosis - one step towards clinical trials for stricturing inflammatory bowel disease. United European Gastroenterol J 2016;4:523-30. [PMID: 27536362 DOI: 10.1177/2050640616640160] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 6.4] [Reference Citation Analysis]
174 Fiorino G, Bonifacio C, Allocca M, Danese S. Impact of therapies on bowel damage in Crohn's disease. United European Gastroenterol J 2020;8:410-7. [PMID: 32213030 DOI: 10.1177/2050640620908696] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
175 Kierkus J, Dadalski M, Szymanska E, Oracz G, Wegner A, Gorczewska M, Szymanska S, Woynarowski M, Ryzko J. The impact of infliximab induction therapy on mucosal healing and clinical remission in Polish pediatric patients with moderate-to-severe Crohn’s disease: . European Journal of Gastroenterology & Hepatology 2012;24:495-500. [DOI: 10.1097/meg.0b013e32835159f2] [Cited by in Crossref: 36] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
176 Pariente B, Cosnes J, Danese S, Sandborn WJ, Lewin M, Fletcher JG, Chowers Y, D'Haens G, Feagan BG, Hibi T, Hommes DW, Irvine EJ, Kamm MA, Loftus EV Jr, Louis E, Michetti P, Munkholm P, Oresland T, Panés J, Peyrin-Biroulet L, Reinisch W, Sands BE, Schoelmerich J, Schreiber S, Tilg H, Travis S, van Assche G, Vecchi M, Mary JY, Colombel JF, Lémann M. Development of the Crohn's disease digestive damage score, the Lémann score. Inflamm Bowel Dis 2011;17:1415-22. [PMID: 21560202 DOI: 10.1002/ibd.21506] [Cited by in Crossref: 360] [Cited by in F6Publishing: 287] [Article Influence: 32.7] [Reference Citation Analysis]
177 Ferrante M, Henckaerts L, Joossens M, Pierik M, Joossens S, Dotan N, Norman GL, Altstock RT, Van Steen K, Rutgeerts P, Van Assche G, Vermeire S. New serological markers in inflammatory bowel disease are associated with complicated disease behaviour. Gut 2007;56:1394-403. [PMID: 17456509 DOI: 10.1136/gut.2006.108043] [Cited by in Crossref: 217] [Cited by in F6Publishing: 186] [Article Influence: 15.5] [Reference Citation Analysis]
178 Lovasz BD, Lakatos L, Horvath A, Szita I, Pandur T, Mandel M, Vegh Z, Golovics PA, Mester G, Balogh M, Molnar C, Komaromi E, Kiss LS, Lakatos PL. Evolution of disease phenotype in adult and pediatric onset Crohn's disease in a population-based cohort. World J Gastroenterol. 2013;19:2217-2226. [PMID: 23599648 DOI: 10.3748/wjg.v19.i14.2217] [Cited by in CrossRef: 44] [Cited by in F6Publishing: 35] [Article Influence: 5.5] [Reference Citation Analysis]
179 Hommes D, Colombel JF, Emery P, Greco M, Sandborn WJ. Changing Crohn’s disease management: need for new goals and indices to prevent disability and improve quality of life. J Crohns Colitis. 2012;6 Suppl 2:S224-S234. [PMID: 22463929 DOI: 10.1016/s1873-9946(12)60502-9] [Cited by in Crossref: 54] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
180 Weng E, Valencia DN, Krudy ZA, Ali M. Intraperitoneal and Extraperitoneal Colonic Perforation Following Diagnostic and Therapeutic Colonoscopy with Crohn's-related Stricture Dilation. Cureus 2020;12:e7162. [PMID: 32257705 DOI: 10.7759/cureus.7162] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
181 Hirai F, Ishihara H, Yada S, Esaki M, Ohwan T, Nozaki R, Ashizuka S, Inatsu H, Ohi H, Aoyagi K, Mizuta Y, Matsumoto T, Matsui T. Effectiveness of concomitant enteral nutrition therapy and infliximab for maintenance treatment of Crohn's disease in adults. Dig Dis Sci 2013;58:1329-34. [PMID: 22926500 DOI: 10.1007/s10620-012-2374-2] [Cited by in Crossref: 47] [Cited by in F6Publishing: 36] [Article Influence: 5.2] [Reference Citation Analysis]
182 Zhu C, Ma X, Xue L, Xu J, Li Q, Wang Y, Zhang J. Small intestine contrast ultrasonography for the detection and assessment of Crohn disease: A meta-analysis. Medicine (Baltimore) 2016;95:e4235. [PMID: 27495028 DOI: 10.1097/MD.0000000000004235] [Cited by in Crossref: 11] [Cited by in F6Publishing: 1] [Article Influence: 2.8] [Reference Citation Analysis]
183 Molendijk I, Peeters KC, Baeten CI, Veenendaal RA, van der Meulen-de Jong AE. Improving the outcome of fistulising Crohn's disease. Best Practice & Research Clinical Gastroenterology 2014;28:505-18. [DOI: 10.1016/j.bpg.2014.04.011] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
184 Ananthakrishnan AN, Korzenik JR, Hur C. Can mucosal healing be a cost-effective endpoint for biologic therapy in Crohn's disease? A decision analysis. Inflamm Bowel Dis. 2013;19:37-44. [PMID: 22416019 DOI: 10.1002/ibd.22951] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 4.1] [Reference Citation Analysis]
185 Harper JW, Welch MP, Sinanan MN, Wahbeh GT, Lee SD. Co-morbid diabetes in patients with Crohn’s disease predicts a greater need for surgical intervention: Co-morbid diabetes in patients with Crohn’s disease. Alimentary Pharmacology & Therapeutics 2012;35:126-32. [DOI: 10.1111/j.1365-2036.2011.04915.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
186 Freeman HJ. Age-dependent phenotypic clinical expression of Crohn’s disease. J Clin Gastroenterol. 2005;39:774-777. [PMID: 16145338 DOI: 10.1097/01.mcg.0000177243.51967.ca] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.1] [Reference Citation Analysis]
187 Mak JWY, Tang W, Yip TCF, Ran ZH, Wei SC, Ahuja V, Kumar S, Leung WK, Hilmi I, Limsrivilai J, Aniwan S, Lam BCY, Chan KH, Ng KM, Leung CM, Li MKK, Lo FH, Sze ASF, Tsang SWC, Hui AJ, Hartono JL, Ng SC. Stopping anti-tumour necrosis factor therapy in patients with perianal Crohn's disease. Aliment Pharmacol Ther. 2019;50:1195-1203. [PMID: 31638274 DOI: 10.1111/apt.15547] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
188 Loly C, Belaiche J, Louis E. Predictors of severe Crohn's disease. Scand J Gastroenterol. 2008;43:948-954. [PMID: 19086165 DOI: 10.1080/00365520801957149] [Cited by in Crossref: 194] [Cited by in F6Publishing: 171] [Article Influence: 16.2] [Reference Citation Analysis]
189 Freeman HJ. Long-term natural history of Crohn's disease. World J Gastroenterol. 2009;15:1315-1318. [PMID: 19294760 DOI: 10.3748/wjg.15.1315] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
190 Soucy G, Wang HH, Farraye FA, Schmidt JF, Farris AB, Lauwers GY, Cerda SR, Dendrinos KG, Odze RD. Clinical and pathological analysis of colonic Crohn’s disease, including a subgroup with ulcerative colitis-like features. Mod Pathol. 2012;25:295-307. [PMID: 21841769 DOI: 10.1038/modpathol.2011.120] [Cited by in Crossref: 33] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
191 Lahat A, Chowers Y. The patient with recurrent (sub) obstruction due to Crohn's disease. Best Practice & Research Clinical Gastroenterology 2007;21:427-44. [DOI: 10.1016/j.bpg.2007.02.001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
192 Lenze F, Wessling J, Bremer J, Ullerich H, Spieker T, Weckesser M, Gonschorrek S, Kannengiesser K, Rijcken E, Heidemann J. Detection and differentiation of inflammatory versus fibromatous Crohn’s disease strictures: prospective comparison of 18F-FDG-PET/CT, MR-enteroclysis, and transabdominal ultrasound versus endoscopic/histologic evaluation. Inflamm Bowel Dis. 2012;18:2252-2260. [PMID: 22359277 DOI: 10.1002/ibd.22930] [Cited by in Crossref: 60] [Cited by in F6Publishing: 50] [Article Influence: 6.7] [Reference Citation Analysis]
193 Curciarello R, Docena GH, MacDonald TT. The Role of Cytokines in the Fibrotic Responses in Crohn's Disease. Front Med (Lausanne) 2017;4:126. [PMID: 28824915 DOI: 10.3389/fmed.2017.00126] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
194 de Bie CI, Paerregaard A, Kolacek S, Ruemmele FM, Koletzko S, Fell JM, Escher JC, EUROKIDS Porto IBD Working Group of ESPGHAN. Disease phenotype at diagnosis in pediatric Crohn's disease: 5-year analyses of the EUROKIDS Registry. Inflamm Bowel Dis. 2013;19:378-385. [PMID: 22573581 DOI: 10.1002/ibd.23008] [Cited by in Crossref: 100] [Cited by in F6Publishing: 80] [Article Influence: 12.5] [Reference Citation Analysis]
195 Shergill AK, Terdiman JP. Controversies in the treatment of Crohn's disease: the case for an accelerated step-up treatment approach. World J Gastroenterol 2008;14:2670-7. [PMID: 18461652 DOI: 10.3748/wjg.14.2670] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
196 Osterman MT, Sandborn WJ, Colombel JF, Robinson AM, Lau W, Huang B, Pollack PF, Thakkar RB, Lewis JD. Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn's disease. Gastroenterology. 2014;146:941-949. [PMID: 24361468 DOI: 10.1053/j.gastro.2013.12.025] [Cited by in Crossref: 125] [Cited by in F6Publishing: 105] [Article Influence: 15.6] [Reference Citation Analysis]
197 Oefferlbauer-Ernst A, Miehsler W, Eckmüllner O, Travis S, Waldhoer T, Dejaco C, Gangl A, Vogelsang H, Reinisch W. Impact of interobserver disagreement on phenotype-genotype associations in Crohn's disease. Inflamm Bowel Dis. 2007;13:156-163. [PMID: 17206717 DOI: 10.1002/ibd.20016] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
198 Bettenworth D, Gustavsson A, Atreja A, Lopez R, Tysk C, van Assche G, Rieder F. A Pooled Analysis of Efficacy, Safety, and Long-term Outcome of Endoscopic Balloon Dilation Therapy for Patients with Stricturing Crohnʼs Disease: . Inflammatory Bowel Diseases 2017;23:133-42. [DOI: 10.1097/mib.0000000000000988] [Cited by in Crossref: 91] [Cited by in F6Publishing: 31] [Article Influence: 22.8] [Reference Citation Analysis]
199 Sandborn WJ, Feagan BG. The efficacy of azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in patients with Crohn's disease remains uncertain. Gastroenterology 2004;127:990-3. [PMID: 15362055 DOI: 10.1053/j.gastro.2004.07.037] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 2.5] [Reference Citation Analysis]
200 Bhattacharya A, Rao BB, Koutroubakis IE, Click B, Vargas EJ, Regueiro M, Schwartz M, Swoger JM, Babichenko D, Hartmann D, Rivers CR, Barrie A, Hashash JG, Dunn MA, Binion DG. Silent Crohn's Disease Predicts Increased Bowel Damage During Multiyear Follow-up: The Consequences of Under-reporting Active Inflammation. Inflamm Bowel Dis. 2016;22:2665-2671. [PMID: 27753691 DOI: 10.1097/mib.0000000000000935] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
201 Henriksen M, Jahnsen J, Lygren I, Aadland E, Schulz T, Vatn MH, Moum B, The Ibsen Study Group. Clinical course in Crohn's disease: Results of a five-year population-based follow-up study (the IBSEN study). Scandinavian Journal of Gastroenterology 2009;42:602-10. [DOI: 10.1080/00365520601076124] [Cited by in Crossref: 138] [Cited by in F6Publishing: 103] [Article Influence: 11.5] [Reference Citation Analysis]
202 Corrêa FF, Sdepanian VL. BODY IRON STATUS INDICATORS AND INFLAMMATION INDICATORS DURING INFLAMMATORY BOWEL DISEASE THERAPY IN CHILDREN AND ADOLESCENTES. Arq Gastroenterol 2021;58:48-54. [PMID: 33909796 DOI: 10.1590/S0004-2803.202100000-09] [Reference Citation Analysis]
203 Rispo A, Imperatore N, Testa A, Mainenti P, De Palma GD, Luglio G, Maurea S, Nardone OM, Caporaso N, Castiglione F. Bowel Damage in Crohnʼs Disease: Direct Comparison of Ultrasonography-based and Magnetic Resonance-based Lemann Index. Inflammatory Bowel Diseases 2017;23:143-51. [DOI: 10.1097/mib.0000000000000980] [Cited by in Crossref: 27] [Cited by in F6Publishing: 4] [Article Influence: 6.8] [Reference Citation Analysis]
204 Amezaga AJ, Van Assche G. Practical Approaches to "Top-Down" Therapies for Crohn's Disease. Curr Gastroenterol Rep 2016;18:35. [PMID: 27184044 DOI: 10.1007/s11894-016-0507-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
205 Uda A, Kuwabara H, Shimizu S, Iwakiri R, Fushimi K. Optimal use of biologics with endoscopic balloon dilatation for repeated intestinal strictures in Crohn's disease. JGH Open 2020;4:532-40. [PMID: 32514466 DOI: 10.1002/jgh3.12329] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
206 Lee KM, Lee JM. Crohn's disease in Korea: past, present, and future. Korean J Intern Med 2014;29:558-70. [PMID: 25228829 DOI: 10.3904/kjim.2014.29.5.558] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
207 Jürgens M, Brand S, Laubender RP, Seiderer J, Glas J, Wetzke M, Wagner J, Pfennig S, Tillack C, Beigel F. The presence of fistulas and NOD2 homozygosity strongly predict intestinal stenosis in Crohn’s disease independent of the IL23R genotype. J Gastroenterol. 2010;45:721-731. [PMID: 20428899 DOI: 10.1007/s00535-010-0231-7] [Cited by in Crossref: 35] [Cited by in F6Publishing: 23] [Article Influence: 3.2] [Reference Citation Analysis]
208 Laharie D, Salzmann M, Boubekeur H, Richy F, Amouretti M, Quinton A, Couzigou P, Lamouliatte H, Zerbib F. Predictors of response to infliximab in luminal Crohn's disease. Gastroenterol Clin Biol 2005;29:145-9. [PMID: 15795662 DOI: 10.1016/s0399-8320(05)80718-3] [Cited by in Crossref: 33] [Cited by in F6Publishing: 7] [Article Influence: 2.1] [Reference Citation Analysis]
209 Gardenbroek TJ, Eshuis EJ, van Acker GJ, Tanis PJ, Bemelman WA. Alternative specimen extraction techniques after laparoscopic emergency colectomy in inflammatory bowel disease. Surg Endosc. 2012;26:408-412. [PMID: 21909858 DOI: 10.1007/s00464-011-1888-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
210 Marcuzzi A, Bianco AM, Girardelli M, Tommasini A, Martelossi S, Monasta L, Crovella S. Genetic and functional profiling of Crohn's disease: autophagy mechanism and susceptibility to infectious diseases. Biomed Res Int 2013;2013:297501. [PMID: 23738324 DOI: 10.1155/2013/297501] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
211 Latella G, Caprilli R, Travis S. In favour of early surgery in Crohn's disease: a hypothesis to be tested. J Crohns Colitis. 2011;5:1-4. [PMID: 21272796 DOI: 10.1016/j.crohns.2010.11.003] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
212 Meier R, Lutz C, Cosín-roger J, Fagagnini S, Bollmann G, Hünerwadel A, Mamie C, Lang S, Tchouboukov A, Weber FE, Weber A, Rogler G, Hausmann M. Decreased Fibrogenesis After Treatment with Pirfenidone in a Newly Developed Mouse Model of Intestinal Fibrosis: . Inflammatory Bowel Diseases 2016;22:569-82. [DOI: 10.1097/mib.0000000000000716] [Cited by in Crossref: 27] [Cited by in F6Publishing: 14] [Article Influence: 5.4] [Reference Citation Analysis]
213 de Bruyn JR, Meijer SL, Wildenberg ME, Bemelman WA, van den Brink GR, D'Haens GR. Development of Fibrosis in Acute and Longstanding Ulcerative Colitis. J Crohns Colitis 2015;9:966-72. [PMID: 26245217 DOI: 10.1093/ecco-jcc/jjv133] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 6.0] [Reference Citation Analysis]
214 Axelrad JE, Lichtiger S, Sethi A. Treatment of Crohn’s Disease Anastomotic Stricture With a Lumen-apposing Metal Stent. Clinical Gastroenterology and Hepatology 2018;16:A25-6. [DOI: 10.1016/j.cgh.2017.05.016] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 4.7] [Reference Citation Analysis]
215 Kavanaugh AF, Mayer LF, Cush JJ, Hanauer SB. Shared experiences and best practices in the management of rheumatoid arthritis and Crohn's disease. Am J Med 2011;124:e1-18. [PMID: 21531240 DOI: 10.1016/j.amjmed.2011.01.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
216 Schnitzler F, Friedrich M, Wolf C, Stallhofer J, Angelberger M, Diegelmann J, Olszak T, Tillack C, Beigel F, Göke B, Glas J, Lohse P, Brand S. The NOD2 Single Nucleotide Polymorphism rs72796353 (IVS4+10 A>C) Is a Predictor for Perianal Fistulas in Patients with Crohn's Disease in the Absence of Other NOD2 Mutations. PLoS One 2015;10:e0116044. [PMID: 26147989 DOI: 10.1371/journal.pone.0116044] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
217 American Society for Gastrointestinal Endoscopy Standards of Practice Committee. , Shergill AK, Lightdale JR, Bruining DH, Acosta RD, Chandrasekhara V, Chathadi KV, Decker GA, Early DS, Evans JA, Fanelli RD, Fisher DA, Fonkalsrud L, Foley K, Hwang JH, Jue TL, Khashab MA, Muthusamy VR, Pasha SF, Saltzman JR, Sharaf R, Cash BD, DeWitt JM. The role of endoscopy in inflammatory bowel disease. Gastrointest Endosc 2015; 81: 1101-21. e1-13. [PMID: 25800660 DOI: 10.1016/j.gie.2014.10.030] [Cited by in Crossref: 172] [Cited by in F6Publishing: 137] [Article Influence: 28.7] [Reference Citation Analysis]
218 Condino G, Calabrese E, Zorzi F, Onali S, Lolli E, De Biasio F, Ascolani M, Pallone F, Biancone L. Anti-TNF-alpha treatments and obstructive symptoms in Crohn's disease: a prospective study. Dig Liver Dis 2013;45:258-62. [PMID: 23195667 DOI: 10.1016/j.dld.2012.10.009] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 3.3] [Reference Citation Analysis]
219 Li Y, Stocchi L, Shen B, Liu X, Remzi FH. Salvage surgery after failure of endoscopic balloon dilatation versus surgery first for ileocolonic anastomotic stricture due to recurrent Crohn's disease. Br J Surg 2015;102:1418-25; discussion 1425. [PMID: 26313750 DOI: 10.1002/bjs.9906] [Cited by in Crossref: 25] [Cited by in F6Publishing: 13] [Article Influence: 4.2] [Reference Citation Analysis]
220 Gomes TNF, de Azevedo FS, Argollo M, Miszputen SJ, Ambrogini O Jr. Clinical and Demographic Profile of Inflammatory Bowel Disease Patients in a Reference Center of São Paulo, Brazil. Clin Exp Gastroenterol 2021;14:91-102. [PMID: 33762838 DOI: 10.2147/CEG.S288688] [Reference Citation Analysis]
221 Chan W, Shim HH, Lim MS, Sawadjaan FLB, Isaac SP, Chuah SW, Leong R, Kong C. Symptoms of anxiety and depression are independently associated with inflammatory bowel disease-related disability. Digestive and Liver Disease 2017;49:1314-9. [DOI: 10.1016/j.dld.2017.08.020] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 5.8] [Reference Citation Analysis]
222 Zeitz J, Fournier N, Labenz C, Biedermann L, Frei P, Misselwitz B, Scharl S, Vavricka SR, Sulz MC, Fried M, Rogler G, Scharl M. Risk Factors for the Development of Fistulae and Stenoses in Crohn Disease Patients in the Swiss Inflammatory Bowel Disease Cohort. Inflamm Intest Dis. 2017;1:172-181. [PMID: 29922674 DOI: 10.1159/000458144] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
223 Yang D, Yang S, Song K, Hong M, Park SH, Lee H, Kim J, Lee HJ, Park S, Jung KW, Kim K, Ye BD, Byeon J, Myung S, Kim J, Shin US, Yu CS, Lee I. TNFSF15 is an independent predictor for the development of Crohn's disease-related complications in Koreans. Journal of Crohn's and Colitis 2014;8:1315-26. [DOI: 10.1016/j.crohns.2014.04.002] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
224 Pariente B, Mary JY, Danese S, Chowers Y, De Cruz P, D’Haens G, Loftus EV, Louis E, Panés J, Schölmerich J. Development of the Lémann index to assess digestive tract damage in patients with Crohn’s disease. Gastroenterology. 2015;148:52-63.e3. [PMID: 25241327 DOI: 10.1053/j.gastro.2014.09.015] [Cited by in Crossref: 183] [Cited by in F6Publishing: 148] [Article Influence: 26.1] [Reference Citation Analysis]
225 Pellino G, Selvaggi F, Ghezzi G, Corona D, Riegler G, Delaini GG. A think tank of the Italian society of colorectal surgery (SICCR) on the surgical treatment of inflammatory bowel disease using the Delphi method: Crohn's disease. Tech Coloproctol 2015;19:639-51. [PMID: 26403232 DOI: 10.1007/s10151-015-1368-4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
226 Brihier H, Nion-larmurier I, Afchain P, Tiret E, Beaugerie L, Gendre J, Cosnes J. Intestinal perforation in Crohn's disease. Gastroentérologie Clinique et Biologique 2005;29:1105-11. [DOI: 10.1016/s0399-8320(05)82174-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
227 Sheedy SP, Bruining DH, Dozois EJ, Faubion WA, Fletcher JG. MR Imaging of Perianal Crohn Disease. Radiology. 2017;282:628-645. [PMID: 28218881 DOI: 10.1148/radiol.2016151491] [Cited by in Crossref: 51] [Cited by in F6Publishing: 35] [Article Influence: 12.8] [Reference Citation Analysis]
228 Van Limbergen J, Russell RK, Drummond HE, Aldhous MC, Round NK, Nimmo ER, Smith L, Gillett PM, McGrogan P, Weaver LT, Bisset WM, Mahdi G, Arnott ID, Satsangi J, Wilson DC. Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease. Gastroenterology. 2008;135:1114-1122. [PMID: 18725221 DOI: 10.1053/j.gastro.2008.06.081] [Cited by in Crossref: 575] [Cited by in F6Publishing: 460] [Article Influence: 44.2] [Reference Citation Analysis]
229 Mahid SS, Minor KS, Stromberg AJ, Galandiuk S. Active and passive smoking in childhood is related to the development of inflammatory bowel disease. Inflamm Bowel Dis 2007;13:431-8. [PMID: 17206676 DOI: 10.1002/ibd.20070] [Cited by in Crossref: 58] [Cited by in F6Publishing: 51] [Article Influence: 4.1] [Reference Citation Analysis]
230 Kip KE, Swoger JM, Grandinetti LM, Barrie AM, Greer JB, Regueiro MD. Tumor necrosis factor α antagonist-associated psoriasis in inflammatory diseases: an analysis of the FDA adverse event reporting system. Inflamm Bowel Dis. 2013;19:1164-1172. [PMID: 23518804 DOI: 10.1097/MIB.0b013e31828075bd] [Cited by in Crossref: 22] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
231 Zobeiri M, Bashiri H, Askari L, Keshavars AA, Tavvafzadeh R, Fatahi K, Najafi F. Epidemiologic Characteristics of Patients with Inflammatory Bowel Disease in Kermanshah, Iran. Middle East J Dig Dis. 2017;9:164-169. [PMID: 28894519 DOI: 10.15171/mejdd.2017.68] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
232 Li Y, Stocchi L, Liu X, Rui Y, Liu G, Remzi FH, Shen B. Presence of Granulomas in Mesenteric Lymph Nodes Is Associated with Postoperative Recurrence in Crohn's Disease. Inflamm Bowel Dis. 2015;21:2613-2618. [PMID: 26218143 DOI: 10.1097/mib.0000000000000541] [Cited by in Crossref: 19] [Cited by in F6Publishing: 6] [Article Influence: 3.8] [Reference Citation Analysis]
233 Ingle SB, Loftus EV. The natural history of perianal Crohn’s disease. Dig Liver Dis. 2007;39:963-969. [PMID: 17720635 DOI: 10.1016/j.dld.2007.07.154] [Cited by in Crossref: 75] [Cited by in F6Publishing: 49] [Article Influence: 5.4] [Reference Citation Analysis]
234 Singh A, Agrawal N, Kurada S, Lopez R, Kessler H, Philpott J, Shen B, Lashner B, Rieder F. Efficacy, Safety, and Long-term Outcome of Serial Endoscopic Balloon Dilation for Upper Gastrointestinal Crohn's Disease-associated Strictures-A Cohort Study. J Crohns Colitis 2017;11:1044-51. [PMID: 28881875 DOI: 10.1093/ecco-jcc/jjx078] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
235 Feagan BG, Lémann M, Befrits R, Connell W, Dʼhaens G, Ghosh S, Michetti P, Ochsenkühn T, Panaccione R, Schreiber S, Silverberg M, Sorrentino D, van der Woude JC, Vermeire S, Rutgeerts P. Recommendations for the treatment of Crohnʼs disease with tumor necrosis factor antagonists: An expert consensus report: . Inflammatory Bowel Diseases 2012;18:152-60. [DOI: 10.1002/ibd.21870] [Cited by in Crossref: 51] [Cited by in F6Publishing: 43] [Article Influence: 5.7] [Reference Citation Analysis]
236 Hilmi I, Tan YM, Goh KL. Crohn's disease in adults: observations in a multiracial Asian population. World J Gastroenterol 2006;12:1435-8. [PMID: 16552816 DOI: 10.3748/wjg.v12.i9.1435] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 26] [Article Influence: 1.9] [Reference Citation Analysis]
237 Sands BE. The risks and benefits of early immunosuppression and biological therapy. Dig Dis. 2012;30 Suppl 3:100-106. [PMID: 23295699 DOI: 10.1159/000342731] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
238 Bruining DH, Sandborn WJ. Do not assume symptoms indicate failure of anti-tumor necrosis factor therapy in Crohn’s disease. Clin Gastroenterol Hepatol. 2011;9:395-399. [PMID: 21277392 DOI: 10.1016/j.cgh.2011.01.019] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
239 Gasparetto M, Guariso G, Pozza LV, Ross A, Heuschkel R, Zilbauer M. Clinical course and outcomes of diagnosing Inflammatory Bowel Disease in children 10 years and under: retrospective cohort study from two tertiary centres in the United Kingdom and in Italy. BMC Gastroenterol 2016;16:35. [PMID: 26976427 DOI: 10.1186/s12876-016-0455-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
240 Morar PS, Faiz O, Warusavitarne J, Brown S, Cohen R, Hind D, Abercrombie J, Ragunath K, Sanders DS, Arnott I, Wilson G, Bloom S, Arebi N; Crohn's Stricture Study (CroSS) Group. Systematic review with meta-analysis: endoscopic balloon dilatation for Crohn's disease strictures. Aliment Pharmacol Ther. 2015;42:1137-1148. [PMID: 26358739 DOI: 10.1111/apt.13388] [Cited by in Crossref: 59] [Cited by in F6Publishing: 45] [Article Influence: 9.8] [Reference Citation Analysis]
241 Panchal H, Wagner M, Chatterji M, Taouli B, McBride R, Patterson JR, Ungaro R, Dubinsky M, Cho J, Sachar DB. Earlier Anti-Tumor Necrosis Factor Therapy of Crohn's Disease Correlates with Slower Progression of Bowel Damage. Dig Dis Sci 2019;64:3274-83. [PMID: 30607690 DOI: 10.1007/s10620-018-5434-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
242 Shen B, Kochhar G, Navaneethan U, Liu X, Farraye FA, Gonzalez-Lama Y, Bruining D, Pardi DS, Lukas M, Bortlik M, Wu K, Sood A, Schwartz DA, Sandborn WJ;  Global Interventional Inflammatory Bowel Disease Group. Role of interventional inflammatory bowel disease in the era of biologic therapy: a position statement from the Global Interventional IBD Group. Gastrointest Endosc. 2019;89:215-237. [PMID: 30365985 DOI: 10.1016/j.gie.2018.09.045] [Cited by in Crossref: 31] [Cited by in F6Publishing: 20] [Article Influence: 10.3] [Reference Citation Analysis]
243 Chan WPW, Mourad F, Leong RW. Crohn's disease associated strictures. J Gastroenterol Hepatol. 2018;33:998-1008. [PMID: 29427364 DOI: 10.1111/jgh.14119] [Cited by in Crossref: 28] [Cited by in F6Publishing: 16] [Article Influence: 9.3] [Reference Citation Analysis]
244 Schoepfer AM, Safroneeva E, Bussmann C, Kuchen T, Portmann S, Simon H, Straumann A. Delay in Diagnosis of Eosinophilic Esophagitis Increases Risk for Stricture Formation in a Time-Dependent Manner. Gastroenterology 2013;145:1230-1236.e2. [DOI: 10.1053/j.gastro.2013.08.015] [Cited by in Crossref: 342] [Cited by in F6Publishing: 294] [Article Influence: 42.8] [Reference Citation Analysis]
245 Chatu S, Pilcher J, Saxena SK, Fry DH, Pollok RC. Diagnostic accuracy of small intestine ultrasonography using an oral contrast agent in Crohn’s disease: comparative study from the UK. Clin Radiol. 2012;67:553-559. [PMID: 22212635 DOI: 10.1016/j.crad.2011.11.005] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
246 Weder B, Schefer F, van Haaften WT, Patsenker E, Stickel F, Mueller S, Hutter S, Schuler C, Baebler K, Wang Y, Mamie C, Dijkstra G, de Vallière C, Imenez Silva PH, Wagner CA, Frey-Wagner I, Ruiz PA, Seuwen K, Rogler G, Hausmann M. New Therapeutic Approach for Intestinal Fibrosis Through Inhibition of pH-Sensing Receptor GPR4. Inflamm Bowel Dis 2021:izab140. [PMID: 34320209 DOI: 10.1093/ibd/izab140] [Reference Citation Analysis]
247 Onali S, Calabrese E, Pallone F. Measuring disease activity in Crohn’s disease. Abdom Imaging 2012;37:927-32. [DOI: 10.1007/s00261-012-9877-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
248 Selinger CP, Leong RW. Mortality from inflammatory bowel diseases. Inflamm Bowel Dis. 2012;18:1566-1572. [PMID: 22275300 DOI: 10.1002/ibd.22871] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 3.4] [Reference Citation Analysis]
249 Bettenworth D, Bokemeyer A, Kou L, Lopez R, Bena JF, El Ouali S, Mao R, Kurada S, Bhatt A, Beyna T, Halloran B, Reeson M, Hosomi S, Kishi M, Hirai F, Ohmiya N, Rieder F. Systematic review with meta-analysis: efficacy of balloon-assisted enteroscopy for dilation of small bowel Crohn's disease strictures.Aliment Pharmacol Ther. 2020;52:1104-1116. [PMID: 32813282 DOI: 10.1111/apt.16049] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
250 Verburgt CM, Ghiboub M, Benninga MA, de Jonge WJ, Van Limbergen JE. Nutritional Therapy Strategies in Pediatric Crohn's Disease. Nutrients 2021;13:212. [PMID: 33450982 DOI: 10.3390/nu13010212] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
251 Visschedijk MC, Spekhorst LM, Cheng SC, van Loo ES, Jansen BHD, Blokzijl T, Kil H, de Jong DJ, Pierik M, Maljaars JPWJ, van der Woude CJ, van Bodegraven AA, Oldenburg B, Löwenberg M, Nieuwenhuijs VB, Imhann F, van Sommeren S, Alberts R, Xavier RJ, Dijkstra G, Nico Faber K, Aldaz CM, Weersma RK, Festen EAM. Genomic and Expression Analyses Identify a Disease-Modifying Variant for Fibrostenotic Crohn's Disease. J Crohns Colitis 2018;12:582-8. [PMID: 29361163 DOI: 10.1093/ecco-jcc/jjy001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
252 Spiceland CM, Lodhia N. Endoscopy in inflammatory bowel disease: Role in diagnosis, management, and treatment. World J Gastroenterol 2018;24:4014-20. [PMID: 30254405 DOI: 10.3748/wjg.v24.i35.4014] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
253 Mak JWY, Ng SC. Epidemiology of fibrostenosing inflammatory bowel disease. J Dig Dis 2020;21:332-5. [PMID: 32105396 DOI: 10.1111/1751-2980.12853] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
254 Fiorino G, Allocca M, Chaparro M, Coenen S, Fidalgo C, Younge L, Gisbert JP. 'Quality of Care' Standards in Inflammatory Bowel Disease: A Systematic Review. J Crohns Colitis. 2019;13:127-137. [PMID: 30423033 DOI: 10.1093/ecco-jcc/jjy140] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 9.5] [Reference Citation Analysis]
255 Kaushal P, Somwaru AS, Charabaty A, Levy AD. MR Enterography of Inflammatory Bowel Disease with Endoscopic Correlation. RadioGraphics 2017;37:116-31. [DOI: 10.1148/rg.2017160064] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
256 Bouhnik Y, Carbonnel F, Laharie D, Stefanescu C, Hébuterne X, Abitbol V, Nachury M, Brixi H, Bourreille A, Picon L, Bourrier A, Allez M, Peyrin-Biroulet L, Moreau J, Savoye G, Fumery M, Nancey S, Roblin X, Altwegg R, Bouguen G, Bommelaer G, Danese S, Louis E, Zappa M, Mary JY; GETAID CREOLE Study Group. Efficacy of adalimumab in patients with Crohn's disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort (CREOLE) study. Gut 2018;67:53-60. [PMID: 28119352 DOI: 10.1136/gutjnl-2016-312581] [Cited by in Crossref: 102] [Cited by in F6Publishing: 78] [Article Influence: 25.5] [Reference Citation Analysis]
257 Ballester Ferré MP, Boscá-Watts MM, Mínguez Pérez M. Crohn's disease. Med Clin (Barc) 2018;151:26-33. [PMID: 29246562 DOI: 10.1016/j.medcli.2017.10.036] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
258 Włodarczyk M, Sobolewska-włodarczyk A, Stec-michalska K, Fichna J, Wiśniewska-jarosińska M. The influence of family pattern abnormalities in the early stages of life on the course of inflammatory bowel diseases. Pharmacological Reports 2016;68:852-8. [DOI: 10.1016/j.pharep.2016.04.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
259 Tozer PJ, Burling D, Gupta A, Phillips RKS, Hart AL. Review article: medical, surgical and radiological management of perianal Crohn’s fistulas: Review: multidisciplinary management of perianal Crohn’s fistulas. Alimentary Pharmacology & Therapeutics 2011;33:5-22. [DOI: 10.1111/j.1365-2036.2010.04486.x] [Cited by in Crossref: 59] [Cited by in F6Publishing: 41] [Article Influence: 5.4] [Reference Citation Analysis]
260 Serra I, Oller B, Mañosa M, Naves JE, Zabana Y, Cabré E, Domènech E. Systemic amyloidosis in inflammatory bowel disease: retrospective study on its prevalence, clinical presentation, and outcome. J Crohns Colitis. 2010;4:269-274. [PMID: 21122515 DOI: 10.1016/j.crohns.2009.11.009] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
261 Kaur M, Panikkath D, Yan X, Liu Z, Berel D, Li D, Vasiliauskas EA, Ippoliti A, Dubinsky M, Shih DQ, Melmed GY, Haritunians T, Fleshner P, Targan SR, McGovern DP. Perianal Crohn's Disease is Associated with Distal Colonic Disease, Stricturing Disease Behavior, IBD-Associated Serologies and Genetic Variation in the JAK-STAT Pathway. Inflamm Bowel Dis 2016;22:862-9. [PMID: 26937622 DOI: 10.1097/MIB.0000000000000705] [Cited by in Crossref: 20] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
262 Riis L, Munkholm P, Binder V, Skovgaard LT, Langholz E. Intra- and interobserver variation in the use of the Vienna classification of Crohn's disease. Inflamm Bowel Dis. 2005;11:657-661. [PMID: 15973120 DOI: 10.1097/01.MIB.0000165115.18310.e7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
263 Mathias H, Heisler C, Morrison J, Currie B, Phalen-Kelly K, Jones J. Examining the Association Between Referral Quality, Wait Time and Patient Outcomes for Patients Referred to an IBD Specialty Program. J Can Assoc Gastroenterol 2020;3:154-61. [PMID: 32671324 DOI: 10.1093/jcag/gwz002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
264 Siegmund B, Feakins RM, Barmias G, Ludvig JC, Teixeira FV, Rogler G, Scharl M. Results of the Fifth Scientific Workshop of the ECCO (II): Pathophysiology of Perianal Fistulizing Disease. J Crohns Colitis. 2016;10:377-386. [PMID: 26681764 DOI: 10.1093/ecco-jcc/jjv228] [Cited by in Crossref: 32] [Cited by in F6Publishing: 22] [Article Influence: 5.3] [Reference Citation Analysis]
265 Bello C, Belaiche J, Louis E, Reenaers C. Evolution and predictive factors of relapse in ulcerative colitis patients treated with mesalazine after a first course of corticosteroids. J Crohns Colitis. 2011;5:196-202. [PMID: 21575881 DOI: 10.1016/j.crohns.2010.12.011] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
266 Benevento G, Avellini C, Terrosu G, Geraci M, Lodolo I, Sorrentino D. Diagnosis and assessment of Crohn's disease: the present and the future. Expert Rev Gastroenterol Hepatol. 2010;4:757-766. [PMID: 21108595 DOI: 10.1586/egh.10.70] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 2.2] [Reference Citation Analysis]
267 Zorzi F, Calabrese E, Monteleone G. Pathogenic aspects and therapeutic avenues of intestinal fibrosis in Crohn's disease. Clin Sci (Lond) 2015;129:1107-13. [PMID: 26494636 DOI: 10.1042/CS20150472] [Cited by in Crossref: 16] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
268 Ng SC, Lied GA, Kamm MA, Sandhu F, Guenther T, Arebi N. Predictive value and clinical significance of myenteric plexitis in Crohn’s disease. Inflamm Bowel Dis. 2009;15:1499-1507. [PMID: 19338051 DOI: 10.1002/ibd.20932] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 2.3] [Reference Citation Analysis]
269 Cheifetz AS. Management of active Crohn disease. JAMA 2013;309:2150-8. [PMID: 23695484 DOI: 10.1001/jama.2013.4466] [Cited by in Crossref: 72] [Cited by in F6Publishing: 49] [Article Influence: 9.0] [Reference Citation Analysis]
270 Rutgeerts P, Vermeire S, Van Assche G. Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target? Gut. 2007;56:453-455. [PMID: 17369375 DOI: 10.1136/gut.2005. 088732] [Reference Citation Analysis]
271 Bhagya Rao B, Koutroubakis IE, Ramos Rivers C, Colombel JF, Regueiro M, Swoger J, Schwartz M, Baidoo L, Hashash J, Barrie A, Dunn MA, Binion DG. Delineation of Crohn’s Disease Trajectories Using Change in Lémann Index: A Natural History Study. Journal of Clinical Gastroenterology 2016;50:476-82. [DOI: 10.1097/mcg.0000000000000463] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 2.2] [Reference Citation Analysis]
272 Gutiérrez A, Holler E, Zapater P, Sempere L, Jover R, Pérez-Mateo M, Schoelmerich J, Such J, Wiest R, Francés R. Antimicrobial peptide response to blood translocation of bacterial DNA in Crohn's disease is affected by NOD2/CARD15 genotype. Inflamm Bowel Dis 2011;17:1641-50. [PMID: 21744420 DOI: 10.1002/ibd.21537] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 3.1] [Reference Citation Analysis]
273 Rieder F, Georgieva M, Schirbel A, Artinger M, Zügner A, Blank M, Brenmoehl J, Schölmerich J, Rogler G. Prostaglandin E2 inhibits migration of colonic lamina propria fibroblasts. Inflamm Bowel Dis 2010;16:1505-13. [PMID: 20803697 DOI: 10.1002/ibd.21255] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
274 Schreiber S, Reinisch W, Colombel JF, Sandborn WJ, Hommes DW, Robinson AM, Huang B, Lomax KG, Pollack PF. Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3 years for adalimumab-treated patients with early Crohn's disease. J Crohns Colitis. 2013;7:213-221. [PMID: 22704916 DOI: 10.1016/j.crohns.2012.05.015] [Cited by in Crossref: 97] [Cited by in F6Publishing: 81] [Article Influence: 10.8] [Reference Citation Analysis]
275 Wibmer AG, Kroesen AJ, Gröne J, Buhr HJ, Ritz JP. Comparison of strictureplasty and endoscopic balloon dilatation for stricturing Crohn’s disease--review of the literature. Int J Colorectal Dis. 2010;25:1149-1157. [PMID: 20628881 DOI: 10.1007/s00384-010-1010-x] [Cited by in Crossref: 62] [Cited by in F6Publishing: 48] [Article Influence: 5.6] [Reference Citation Analysis]
276 Attar A, Maunoury V, Vahedi K, Vernier-Massouille G, Vida S, Bulois P, Colombel JF, Bouhnik Y; GETAID. Safety and efficacy of extractible self-expandable metal stents in the treatment of Crohn's disease intestinal strictures: a prospective pilot study. Inflamm Bowel Dis. 2012;18:1849-1854. [PMID: 22161935 DOI: 10.1002/ibd.22844] [Cited by in Crossref: 55] [Cited by in F6Publishing: 44] [Article Influence: 5.5] [Reference Citation Analysis]
277 Zorzi F, Calabrese E, Di Fusco D, De Cristofaro E, Biancone L, Casella S, Palmieri G, Monteleone G. High Smad7 in the early post-operative recurrence of Crohn's disease. J Transl Med 2020;18:395. [PMID: 33076905 DOI: 10.1186/s12967-020-02558-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
278 Boirivant M, Cossu A. Inflammatory bowel disease. Oral Dis. 2012;18:1-15. [PMID: 21564424 DOI: 10.1111/j.1601-0825.2011.01811.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 3.2] [Reference Citation Analysis]
279 Rodrigues C, Oliveira A, Santos L, Pires E, Deus J. Biodegradable stent for the treatment of a colonic stricture in Crohn's disease. World J Gastrointest Endosc. 2013;5:265-269. [PMID: 23678382 DOI: 10.4253/wjge.v5.i5.265] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 12] [Article Influence: 2.9] [Reference Citation Analysis]
280 Park SK, Yang SK, Park SH, Park SH, Kim JW, Yang DH, Jung KW, Kim KJ, Ye BD, Byeon JS. Long-term prognosis of the jejunal involvement of Crohn’s disease. J Clin Gastroenterol. 2013;47:400-408. [PMID: 23269310 DOI: 10.1097/mcg.0b013e3182705f9e] [Cited by in Crossref: 32] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
281 Tomar SK, Kedia S, Singh N, Upadhyay AD, Kamat N, Bopanna S, Yadav DP, Goyal S, Jain S, Makharia G, Ahuja V. Higher education, professional occupation, and upper socioeconomic status are associated with lower adherence to medications in patients with inflammatory bowel disease. JGH Open 2019;3:302-9. [PMID: 31406923 DOI: 10.1002/jgh3.12160] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
282 Torres J, Colombel JF, Riddle MS. Evidence for Life Before Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2016;14:825-828. [PMID: 26968466 DOI: 10.1016/j.cgh.2016.03.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
283 Naismith GD, Smith LA, Barry SJ, Munro JI, Laird S, Rankin K, Morris AJ, Winter JW, Gaya DR. A prospective evaluation of the predictive value of faecal calprotectin in quiescent Crohn's disease. Journal of Crohn's and Colitis 2014;8:1022-9. [DOI: 10.1016/j.crohns.2014.01.029] [Cited by in Crossref: 30] [Cited by in F6Publishing: 22] [Article Influence: 4.3] [Reference Citation Analysis]
284 Ananthakrishnan AN. Personalizing therapy for inflammatory bowel diseases. Expert Rev Gastroenterol Hepatol 2013;7:549-58. [PMID: 23985004 DOI: 10.1586/17474124.2013.824693] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
285 Klag T, Wehkamp J, Goetz M. Endoscopic Balloon Dilation for Crohn's Disease-Associated Strictures. Clin Endosc 2017;50:429-36. [PMID: 29017297 DOI: 10.5946/ce.2017.147] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
286 Park JJ, Yang SK, Ye BD, Kim JW, Park DI, Yoon H, Im JP, Lee KM, Yoon SN, Lee H; IBD Study Group of the Korean Association for the Study of the Intestinal Diseases. [Second Korean Guidelines for the Management of Crohn's Disease]. Korean J Gastroenterol 2017;69:29-54. [PMID: 28135790 DOI: 10.4166/kjg.2017.69.1.29] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
287 Goodhand JR, Tshuma N, Rao A, Kotta S, Wahed M, Croft NM, Sanderson IR, Epstein J, Rampton DS. Do children with IBD really respond better than adults to thiopurines? J Pediatr Gastroenterol Nutr. 2011;52:702-707. [PMID: 21593643 DOI: 10.1097/mpg.0b013e31820ba46c] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
288 Bettenworth D, Nowacki TM, Cordes F, Buerke B, Lenze F. Assessment of stricturing Crohn's disease: Current clinical practice and future avenues. World J Gastroenterol. 2016;22:1008-1016. [PMID: 26811643 DOI: 10.3748/wjg.v22.i3.1008] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
289 Aratari A, Papi C, Leandro G, Viscido A, Capurso L, Caprilli R. Early versus late surgery for ileo-caecal Crohn’s disease. Aliment Pharmacol Ther. 2007;26:1303-1312. [PMID: 17848181 DOI: 10.1111/j.1365-2036.2007.03515.x] [Cited by in Crossref: 58] [Cited by in F6Publishing: 49] [Article Influence: 4.1] [Reference Citation Analysis]
290 Eidelwein AP, Thompson R, Fiorino K, Abadom V, Oliva-Hemker M. Disease presentation and clinical course in black and white children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007;44:555-60. [PMID: 17460486 DOI: 10.1097/MPG.0b013e3180335bb3] [Cited by in Crossref: 34] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
291 Latella G, Papi C. Crucial steps in the natural history of inflammatory bowel disease. World J Gastroenterol. 2012;18:3790-3799. [PMID: 22876029 DOI: 10.3748/wjg.v18.i29.3790] [Cited by in CrossRef: 70] [Cited by in F6Publishing: 57] [Article Influence: 8.8] [Reference Citation Analysis]
292 Ferro JM, Oliveira SN, Correia L. Neurologic manifestations of inflammatory bowel diseases. Handb Clin Neurol 2014;120:595-605. [PMID: 24365340 DOI: 10.1016/B978-0-7020-4087-0.00040-1] [Cited by in Crossref: 25] [Cited by in F6Publishing: 7] [Article Influence: 3.6] [Reference Citation Analysis]
293 Makanyanga JC, Taylor SA. Current and future role of MR enterography in the management of Crohn disease. AJR Am J Roentgenol. 2013;201:56-64. [PMID: 23789658 DOI: 10.2214/ajr.12.10406] [Cited by in Crossref: 29] [Cited by in F6Publishing: 9] [Article Influence: 3.6] [Reference Citation Analysis]
294 Rieder F, Latella G, Magro F, Yuksel ES, Higgins PDR, Di Sabatino A, de Bruyn JR, Rimola J, Brito J, Bettenworth D, van Assche G, Bemelman W, d’Hoore A, Pellino G, Dignass AU. European Crohn’s and Colitis Organisation Topical Review on Prediction, Diagnosis and Management of Fibrostenosing Crohn’s Disease. ECCOJC 2016;10:873-85. [DOI: 10.1093/ecco-jcc/jjw055] [Cited by in Crossref: 102] [Cited by in F6Publishing: 84] [Article Influence: 20.4] [Reference Citation Analysis]
295 Dubinsky MC, Lin YC, Dutridge D, Picornell Y, Landers CJ, Farrior S, Wrobel I, Quiros A, Vasiliauskas EA, Grill B. Serum immune responses predict rapid disease progression among children with Crohn’s disease: immune responses predict disease progression. Am J Gastroenterol. 2006;101:360-367. [PMID: 16454844 DOI: 10.1111/j.1572-0241.2006.00456.x] [Cited by in Crossref: 203] [Cited by in F6Publishing: 167] [Article Influence: 13.5] [Reference Citation Analysis]
296 Chaparro M, Ramas M, Benítez JM, López-García A, Juan A, Guardiola J, Mínguez M, Calvet X, Márquez L, Fernández Salazar LI, Bujanda L, García C, Zabana Y, Lorente R, Barrio J, Hinojosa E, Iborra M, Cajal MD, Van Domselaar M, García-Sepulcre MF, Gomollón F, Piqueras M, Alcaín G, García-Sánchez V, Panés J, Domènech E, García-Esquinas E, Rodríguez-Artalejo F, Gisbert JP. Extracolonic Cancer in Inflammatory Bowel Disease: Data from the GETECCU Eneida Registry. Am J Gastroenterol 2017;112:1135-43. [PMID: 28534520 DOI: 10.1038/ajg.2017.96] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 3.8] [Reference Citation Analysis]
297 Lawrance IC, Rogler G, Bamias G, Breynaert C, Florholmen J, Pellino G, Reif S, Speca S, Latella G. Cellular and Molecular Mediators of Intestinal Fibrosis. J Crohns Colitis. 2015; Nov 2; Epub ahead of print. [PMID: 25306501 DOI: 10.1016/j.crohns.2014.09.00] [Reference Citation Analysis]
298 Yu YR, Rodriguez JR. Clinical presentation of Crohn's, ulcerative colitis, and indeterminate colitis: Symptoms, extraintestinal manifestations, and disease phenotypes. Semin Pediatr Surg. 2017;26:349-355. [PMID: 29126502 DOI: 10.1053/j.sempedsurg.2017.10.003] [Cited by in Crossref: 69] [Cited by in F6Publishing: 43] [Article Influence: 17.3] [Reference Citation Analysis]
299 Ferrante M, Karmiris K, Newnham E, Siffledeen J, Zelinkova Z, van Assche G, Lakatos PL, Panés J, Sturm A, Travis S, van der Woude CJ, Reinisch W, Colombel J, Panaccione R. Physician perspectives on unresolved issues in the use of conventional therapy in Crohn's disease: Results from an international survey and discussion programme. Journal of Crohn's and Colitis 2012;6:116-31. [DOI: 10.1016/j.crohns.2011.09.009] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
300 Ferro JM, Oliveira Santos M. Neurology of inflammatory bowel disease. J Neurol Sci 2021;424:117426. [PMID: 33810878 DOI: 10.1016/j.jns.2021.117426] [Reference Citation Analysis]
301 Liu B, Yang MQ, Yu TY, Yin YY, Liu Y, Wang XD, He ZG, Yin L, Chen CQ, Li JY. Mast Cell Tryptase Promotes Inflammatory Bowel Disease-Induced Intestinal Fibrosis. Inflamm Bowel Dis 2021;27:242-55. [PMID: 32507895 DOI: 10.1093/ibd/izaa125] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
302 Jensen MD, Andersen RF, Christensen H, Nathan T, Kjeldsen J, Madsen JS. Circulating microRNAs as biomarkers of adult Crohn’s disease: . European Journal of Gastroenterology & Hepatology 2015;27:1038-44. [DOI: 10.1097/meg.0000000000000430] [Cited by in Crossref: 19] [Cited by in F6Publishing: 6] [Article Influence: 3.2] [Reference Citation Analysis]
303 Yanai H, Hanauer SB. Assessing response and loss of response to biological therapies in IBD. Am J Gastroenterol. 2011;106:685-698. [PMID: 21427713 DOI: 10.1038/ajg.2011.103] [Cited by in Crossref: 202] [Cited by in F6Publishing: 183] [Article Influence: 20.2] [Reference Citation Analysis]
304 Siegmund B. Medical Therapy of Fibrostenotic Crohn's Disease. Viszeralmedizin 2015;31:259-64. [PMID: 26557834 DOI: 10.1159/000435868] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
305 Thia KT, Loftus EV, Sandborn WJ, Yang SK. An update on the epidemiology of inflammatory bowel disease in Asia. Am J Gastroenterol. 2008;103:3167-3182. [PMID: 19086963 DOI: 10.1111/j.1572-0241.2008.02158.x] [Cited by in Crossref: 337] [Cited by in F6Publishing: 321] [Article Influence: 28.1] [Reference Citation Analysis]
306 Kwak MS, Kim KJ, Cheon JH, Kim WS, Lee JM, Hwang SW, Park SH, Yang DH, Ye BD, Byeon JS, Myung SJ, Yang SK. Comparison of Concomitant Mesalamine and Immunomodulator Therapy and Immunomodulator Monotherapy for Crohn's Disease. Gastroenterol Res Pract 2018;2018:4826973. [PMID: 29576767 DOI: 10.1155/2018/4826973] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
307 Dubinsky MC, Fleshner PP. Treatment of Crohn’s disease of inflammatory, stenotic, and fistulizing phenotypes. Curr Treat Options Gastro 2003;6:183-200. [DOI: 10.1007/s11938-003-0001-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
308 Goodhand JR, Kamperidis N, Joshi NM, Wahed M, Koodun Y, Cantor EJ, Croft NM, Langmead FL, Lindsay JO, Rampton DS. The phenotype and course of inflammatory bowel disease in UK patients of Bangladeshi descent. Aliment Pharmacol Ther. 2012;35:929-940. [PMID: 22404452 DOI: 10.1111/j.1365-2036.2012.05043.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
309 Ungaro RC, Aggarwal S, Topaloglu O, Lee WJ, Clark R, Colombel JF. Systematic review and meta-analysis: efficacy and safety of early biologic treatment in adult and paediatric patients with Crohn's disease. Aliment Pharmacol Ther 2020;51:831-42. [PMID: 32202328 DOI: 10.1111/apt.15685] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 14.0] [Reference Citation Analysis]
310 Gecse KB, Buskens CJ. Implication of Medical Treatment for Surgical Strategies in IBD. Curr Drug Targets 2019;20:1363-8. [PMID: 31113342 DOI: 10.2174/1389450120666190515095520] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
311 Lee H, Cleynen I. Molecular Profiling of IBD Subtypes and Therapy Responses. In: Hedin C, Rioux JD, D'amato M, editors. Molecular Genetics of Inflammatory Bowel Disease. Cham: Springer International Publishing; 2019. pp. 157-82. [DOI: 10.1007/978-3-030-28703-0_8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
312 Luján-Sanchis M, Sanchis-Artero L, Larrey-Ruiz L, Peño-Muñoz L, Núñez-Martínez P, Castillo-López G, González-González L, Clemente CB, Albert Antequera C, Durá-Ayet A, Sempere-Garcia-Argüelles J. Current role of capsule endoscopy in Crohn's disease. World J Gastrointest Endosc 2016;8:572-83. [PMID: 27668067 DOI: 10.4253/wjge.v8.i17.572] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
313 Simian D, Fluxá D, Flores L, Lubascher J, Ibáñez P, Figueroa C, Kronberg U, Acuña R, Moreno M, Quera R. Inflammatory bowel disease: A descriptive study of 716 local Chilean patients. World J Gastroenterol 2016;22:5267-75. [PMID: 27298570 DOI: 10.3748/wjg.v22.i22.5267] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 18] [Article Influence: 8.5] [Reference Citation Analysis]
314 Srinath A, Young E, Szigethy E. Pain management in patients with inflammatory bowel disease: translational approaches from bench to bedside. Inflamm Bowel Dis 2014;20:2433-49. [PMID: 25208108 DOI: 10.1097/MIB.0000000000000170] [Cited by in Crossref: 45] [Cited by in F6Publishing: 21] [Article Influence: 7.5] [Reference Citation Analysis]
315 Hendel J, Karstensen JG, Vilmann P. Serial intralesional injections of infliximab in small bowel Crohn's strictures are feasible and might lower inflammation. United European Gastroenterol J 2014;2:406-12. [PMID: 25360319 DOI: 10.1177/2050640614547805] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 4.1] [Reference Citation Analysis]
316 Seiderer J, Schnitzler F, Brand S, Staudinger T, Pfennig S, Herrmann K, Hofbauer K, Dambacher J, Tillack C, Sackmann M. Homozygosity for the CARD15 frameshift mutation 1007fs is predictive of early onset of Crohn’s disease with ileal stenosis, entero-enteral fistulas, and frequent need for surgical intervention with high risk of re-stenosis. Scand J Gastroenterol. 2006;41:1421-1432. [PMID: 17101573 DOI: 10.1080/00365520600703900] [Cited by in Crossref: 55] [Cited by in F6Publishing: 51] [Article Influence: 3.9] [Reference Citation Analysis]
317 Bueno de Mesquita M, Ferrante M, Henckaerts L, Joossens M, Janssens V, Hlavaty T, Pierik M, Joossens S, Van Schuerbeek N, Van Assche G. Clustering of (auto)immune diseases with early-onset and complicated inflammatory bowel disease. Eur J Pediatr. 2009;168:575-583. [PMID: 18670786 DOI: 10.1007/s00431-008-0798-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
318 Lan N, Shen B. Endoscopic Stricturotomy Versus Balloon Dilation in the Treatment of Anastomotic Strictures in Crohn’s Disease. Inflammatory Bowel Diseases 2018;24:897-907. [DOI: 10.1093/ibd/izx085] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 9.3] [Reference Citation Analysis]
319 Lichtenstein GR, Targan SR, Dubinsky MC, Rotter JI, Barken DM, Princen F, Carroll S, Brown M, Stachelski J, Chuang E, Landers CJ, Stempak JM, Singh S, Silverberg MS. Combination of genetic and quantitative serological immune markers are associated with complicated Crohn's disease behavior. Inflamm Bowel Dis 2011;17:2488-96. [PMID: 21391291 DOI: 10.1002/ibd.21661] [Cited by in Crossref: 57] [Cited by in F6Publishing: 48] [Article Influence: 5.7] [Reference Citation Analysis]
320 Navaneethan U. Stent placement through anastomotic strictures in Crohn’s disease: a new beginning. Gastrointestinal Endoscopy 2020;92:353-4. [DOI: 10.1016/j.gie.2020.03.3858] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
321 Moy MP, Sauk J, Gee MS. The Role of MR Enterography in Assessing Crohn's Disease Activity and Treatment Response. Gastroenterol Res Pract 2016;2016:8168695. [PMID: 26819611 DOI: 10.1155/2016/8168695] [Cited by in Crossref: 30] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
322 Danese S, Colombel JF, Reinisch W, Rutgeerts PJ. Review article: infliximab for Crohn's disease treatment--shifting therapeutic strategies after 10 years of clinical experience. Aliment Pharmacol Ther 2011;33:857-69. [PMID: 21320139 DOI: 10.1111/j.1365-2036.2011.04598.x] [Cited by in Crossref: 56] [Cited by in F6Publishing: 48] [Article Influence: 5.6] [Reference Citation Analysis]
323 Zabana Y, Garcia-planella E, Van Domselaar M, Mañosa M, Gordillo J, López San Román A, Cabré E, Domènech E. Does active smoking really influence the course of Crohn's disease? A retrospective observational study. Journal of Crohn's and Colitis 2013;7:280-5. [DOI: 10.1016/j.crohns.2012.03.020] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
324 Lightner AL, Ashburn JH, Brar MS, Carvello M, Chandrasinghe P, van Overstraeten ADB, Fleshner PR, Gallo G, Kotze PG, Holubar SD, Reza LM, Spinelli A, Strong SA, Tozer PJ, Truong A, Warusavitarne J, Yamamoto T, Zaghiyan K. Fistulizing Crohn's disease. Current Problems in Surgery 2020;57:100808. [DOI: 10.1016/j.cpsurg.2020.100808] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
325 Knobler R, Barr ML, Couriel DR, Ferrara JL, French LE, Jaksch P, Reinisch W, Rook AH, Schwarz T, Greinix H. Extracorporeal photopheresis: Past, present, and future. Journal of the American Academy of Dermatology 2009;61:652-65. [DOI: 10.1016/j.jaad.2009.02.039] [Cited by in Crossref: 84] [Cited by in F6Publishing: 60] [Article Influence: 7.0] [Reference Citation Analysis]
326 Fedorak RN. Is it time to re-classify Crohn's disease? Best Pract Res Clin Gastroenterol 2004;18 Suppl:99-106. [PMID: 15588801 DOI: 10.1016/j.bpg.2004.06.018] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
327 Arnott ID, Satsangi J. Crohn's disease or Crohn's diseases? Gut 2003;52:460-1. [PMID: 12631650 DOI: 10.1136/gut.52.4.460] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
328 Van Assche G, Vermeire S, Rutgeerts P. The potential for disease modification in Crohn's disease. Nat Rev Gastroenterol Hepatol. 2010;7:79-85. [PMID: 20134489 DOI: 10.1038/nrgastro.2009.220] [Cited by in Crossref: 58] [Cited by in F6Publishing: 57] [Article Influence: 5.3] [Reference Citation Analysis]
329 Smith BRK, Arnott IDR, Drummond HE, Nimmo ER, Satsangi J. Disease Location, Anti-Saccharomyces cerevisiae Antibody, and NOD2/CARD15 Genotype Influence the Progression of Disease Behavior in Crohn’s Disease: . Inflammatory Bowel Diseases 2004;10:521-8. [DOI: 10.1097/00054725-200409000-00005] [Cited by in Crossref: 71] [Cited by in F6Publishing: 67] [Article Influence: 4.2] [Reference Citation Analysis]
330 Chun J, Im JP, Kim JW, Lee KL, Choi CH, Kim H, Cheon JH, Ye BD, Kim YH, Kim YS, Jeen YT, Han DS, Kim WH, Kim JS. Association of Perianal Fistulas with Clinical Features and Prognosis of Crohn's Disease in Korea: Results from the CONNECT Study. Gut Liver 2018;12:544-54. [PMID: 30037171 DOI: 10.5009/gnl18157] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
331 Fraquelli M, Branchi F, Cribiù FM, Orlando S, Casazza G, Magarotto A, Massironi S, Botti F, Contessini-avesani E, Conte D, Basilisco G, Caprioli F. The Role of Ultrasound Elasticity Imaging in Predicting Ileal Fibrosis in Crohnʼs Disease Patients: . Inflammatory Bowel Diseases 2015;21:2605-12. [DOI: 10.1097/mib.0000000000000536] [Cited by in Crossref: 47] [Cited by in F6Publishing: 14] [Article Influence: 7.8] [Reference Citation Analysis]
332 Blackwell J, Saxena S, Jayasooriya N, Petersen I, Hotopf M, Creese H, Bottle A, Pollok RCG; POP-IBD Study Group. Stoma Formation in Crohn's Disease and the Likelihood of Antidepressant Use: A Population-Based Cohort Study. Clin Gastroenterol Hepatol 2020:S1542-3565(20)31722-5. [PMID: 33359727 DOI: 10.1016/j.cgh.2020.12.026] [Reference Citation Analysis]
333 Van Welden S, Selfridge AC, Hindryckx P. Intestinal hypoxia and hypoxia-induced signalling as therapeutic targets for IBD. Nat Rev Gastroenterol Hepatol 2017;14:596-611. [PMID: 28853446 DOI: 10.1038/nrgastro.2017.101] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 10.0] [Reference Citation Analysis]
334 Zhu M, Xu X, Feng Q, Cui Z, Wang T, Yan Y, Ran Z. Effectiveness of Infliximab on Deep Radiological Remission in Chinese Patients with Perianal Fistulizing Crohn's Disease. Dig Dis Sci. 2021;66:1658-1668. [PMID: 32524415 DOI: 10.1007/s10620-020-06398-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
335 Nunes T, Etchevers MJ, García-Sánchez V, Ginard D, Martí E, Barreiro-de Acosta M, Gomollón F, Arroyo M, Bastida G, Gonzalez B. Impact of Smoking Cessation on the Clinical Course of Crohn’s Disease Under Current Therapeutic Algorithms: A Multicenter Prospective Study. Am J Gastroenterol. 2016;111:411-419. [PMID: 26856753 DOI: 10.1038/ajg.2015.401] [Cited by in Crossref: 41] [Cited by in F6Publishing: 32] [Article Influence: 8.2] [Reference Citation Analysis]
336 Christensen B, Erlich J, Gibson PR, Turner JR, Hart J, Rubin DT. Histologic Healing Is More Strongly Associated with Clinical Outcomes in Ileal Crohn's Disease than Endoscopic Healing. Clin Gastroenterol Hepatol 2020; 18: 2518-2525. e1. [PMID: 31812654 DOI: 10.1016/j.cgh.2019.11.056] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 10.0] [Reference Citation Analysis]
337 Zhan S, Li N, Liu C, Mao R, Wu D, Li T, Chen M, Zhuang X, Zeng Z. Intestinal Fibrosis and Gut Microbiota: Clues From Other Organs. Front Microbiol 2021;12:694967. [PMID: 34335525 DOI: 10.3389/fmicb.2021.694967] [Reference Citation Analysis]
338 D’Haens GR, Fedorak R, Lémann M, Feagan BG, Kamm MA, Cosnes J, Rutgeerts PJ, Marteau P, Travis S, Schölmerich J. Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohn’s disease. Inflamm Bowel Dis. 2009;15:1599-1604. [PMID: 19653291 DOI: 10.1002/ibd.21034] [Cited by in Crossref: 75] [Cited by in F6Publishing: 67] [Article Influence: 6.3] [Reference Citation Analysis]
339 Koriche D, Gower-rousseau C, Chater C, Duhamel A, Salleron J, Tavernier N, Colombel J, Pariente B, Cortot A, Zerbib P. Post-operative recurrence of Crohn’s disease after definitive stoma: an underestimated risk. Int J Colorectal Dis 2017;32:453-8. [DOI: 10.1007/s00384-016-2707-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
340 Van Assche G, Vermeire S, Rutgeerts P. Infliximab therapy for patients with inflammatory bowel disease: 10 years on. Eur J Pharmacol 2009;623 Suppl 1:S17-25. [PMID: 19837056 DOI: 10.1016/j.ejphar.2009.10.025] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
341 Pernat Drobež C, Ferkolj I, Potočnik U, Repnik K. Crohn's Disease Candidate Gene Alleles Predict Time to Progression from Inflammatory B1 to Stricturing B2, or Penetrating B3 Phenotype. Genet Test Mol Biomarkers 2018;22:143-51. [PMID: 29446656 DOI: 10.1089/gtmb.2017.0210] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
342 Kamm MA, Ng SC, De Cruz P, Allen P, Hanauer SB. Practical application of anti-TNF therapy for luminal Crohn’s disease. Inflamm Bowel Dis. 2011;17:2366-2391. [PMID: 21337669 DOI: 10.1002/ibd.21655] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
343 He Z, Li P, Zhu J, Cui B, Xu L, Xiang J, Zhang T, Long C, Huang G, Ji G, Nie Y, Wu K, Fan D, Zhang F. Multiple fresh fecal microbiota transplants induces and maintains clinical remission in Crohn's disease complicated with inflammatory mass. Sci Rep. 2017;7:4753. [PMID: 28684845 DOI: 10.1038/s41598-017-04984-z] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 10.5] [Reference Citation Analysis]
344 Bloomfield LE, Riley TV. Epidemiology and Risk Factors for Community-Associated Clostridium difficile Infection: A Narrative Review. Infect Dis Ther 2016;5:231-51. [PMID: 27370914 DOI: 10.1007/s40121-016-0117-y] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 8.2] [Reference Citation Analysis]
345 Cosnes J, Nion-Larmurier I, Beaugerie L, Afchain P, Tiret E, Gendre JP. Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut. 2005;54:237-241. [PMID: 15647188 DOI: 10.1136/gut.2004.045294] [Cited by in Crossref: 466] [Cited by in F6Publishing: 403] [Article Influence: 29.1] [Reference Citation Analysis]
346 Ma C, Beilman CL, Huang VW, Fedorak DK, Kroeker KI, Dieleman LA, Halloran BP, Fedorak RN. Anti-TNF Therapy Within 2 Years of Crohn's Disease Diagnosis Improves Patient Outcomes: A Retrospective Cohort Study. Inflamm Bowel Dis 2016;22:870-9. [PMID: 26818419 DOI: 10.1097/MIB.0000000000000679] [Cited by in Crossref: 42] [Cited by in F6Publishing: 15] [Article Influence: 8.4] [Reference Citation Analysis]
347 Agrawal A, Durrani S, Leiper K, Ellis A, Morris AI, Rhodes JM. Effect of Systemic Corticosteroid Therapy on Risk for Intra-Abdominal or Pelvic Abscess in Non-operated Crohn’s Disease. Clinical Gastroenterology and Hepatology 2005;3:1215-20. [DOI: 10.1016/s1542-3565(05)00759-7] [Cited by in Crossref: 46] [Cited by in F6Publishing: 8] [Article Influence: 2.9] [Reference Citation Analysis]
348 Rieder F, Reinisch W. Thiopurines and the Natural Course of Crohn's Disease: Did We Finally Find the Right Therapeutic Target? American Journal of Gastroenterology 2014;109:1037-40. [DOI: 10.1038/ajg.2014.162] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
349 Bemelman WA, Allez M. The surgical intervention: earlier or never? Best Pract Res Clin Gastroenterol. 2014;28:497-503. [PMID: 24913388 DOI: 10.1016/j.bpg.2014.04.013] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 2.9] [Reference Citation Analysis]
350 Fiorino G, Bonifacio C, Malesci A, Balzarini L, Danese S. MRI in Crohn’s disease--current and future clinical applications. Nat Rev Gastroenterol Hepatol. 2012;9:23-31. [PMID: 22105109 DOI: 10.1038/nrgastro.2011.214] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 2.5] [Reference Citation Analysis]
351 Ditrich F, Blümel S, Biedermann L, Fournier N, Rossel JB, Ellinghaus D, Franke A, Stange EF, Rogler G, Scharl M; Swiss IBD Cohort Study Group. Genetic risk factors predict disease progression in Crohn's disease patients of the Swiss inflammatory bowel disease cohort. Therap Adv Gastroenterol 2020;13:1756284820959252. [PMID: 33281934 DOI: 10.1177/1756284820959252] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
352 Burisch J, Jess T, Martinato M, Lakatos PL; ECCO -EpiCom. The burden of inflammatory bowel disease in Europe. J Crohns Colitis. 2013;7:322-337. [PMID: 23395397 DOI: 10.1016/j.crohns.2013.01.010] [Cited by in Crossref: 541] [Cited by in F6Publishing: 437] [Article Influence: 67.6] [Reference Citation Analysis]
353 Arai R. Serologic markers: impact on early diagnosis and disease stratification in inflammatory bowel disease. Postgrad Med. 2010;122:177-185. [PMID: 20675980 DOI: 10.3810/pgm.2010.07.2184] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
354 Grillo AR, Scarpa M, D'Incà R, Brun P, Scarpa M, Porzionato A, De Caro R, Martines D, Buda A, Angriman I, Palù G, Sturniolo GC, Castagliuolo I. TAK1 is a key modulator of the profibrogenic phenotype of human ileal myofibroblasts in Crohn's disease. Am J Physiol Gastrointest Liver Physiol 2015;309:G443-54. [PMID: 26185333 DOI: 10.1152/ajpgi.00400.2014] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
355 Gaglani T, Davis CH, Bailey HR, Cusick MV. Trends and Outcomes for Minimally Invasive Surgery for Inflammatory Bowel Disease.J Surg Res. 2019;235:303-307. [PMID: 30691810 DOI: 10.1016/j.jss.2018.09.075] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
356 Lin L, Zhou G, Chen P, Wang Y, Han J, Chen M, He Y, Zhang S. Which long noncoding RNAs and circular RNAs contribute to inflammatory bowel disease? Cell Death Dis 2020;11:456. [PMID: 32541691 DOI: 10.1038/s41419-020-2657-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 7.0] [Reference Citation Analysis]
357 Newnham E, Hawkes E, Surender A, James SL, Gearry R, Gibson PR. Quantifying exposure to diagnostic medical radiation in patients with inflammatory bowel disease: are we contributing to malignancy? Aliment Pharmacol Ther. 2007;26:1019-1024. [PMID: 17877508 DOI: 10.1111/j.1365-2036.2007.03449.x] [Cited by in Crossref: 46] [Cited by in F6Publishing: 35] [Article Influence: 3.5] [Reference Citation Analysis]
358 Pallotta N, Barberani F, Hassan NA, Guagnozzi D, Vincoli G, Corazziari E. Effect of infliximab on small bowel stenoses in patients with Crohn's disease. World J Gastroenterol 2008;14:1885-90. [PMID: 18350627 DOI: 10.3748/wjg.14.1885] [Cited by in CrossRef: 48] [Cited by in F6Publishing: 39] [Article Influence: 3.7] [Reference Citation Analysis]
359 Franzè E, Dinallo V, Laudisi F, Di Grazia A, Di Fusco D, Colantoni A, Ortenzi A, Giuffrida P, Di Carlo S, Sica GS, Di Sabatino A, Monteleone G. Interleukin-34 Stimulates Gut Fibroblasts to Produce Collagen Synthesis. J Crohns Colitis 2020;14:1436-45. [PMID: 32271873 DOI: 10.1093/ecco-jcc/jjaa073] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
360 Tarabar D, Hirsch A, Rubin DT. Vedolizumab in the treatment of Crohn’s disease. Expert Review of Gastroenterology & Hepatology 2015;10:283-90. [DOI: 10.1586/17474124.2016.1135051] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.6] [Reference Citation Analysis]
361 Battat R, Dulai PS, Jairath V, Vande Casteele N. A product review of vedolizumab in inflammatory bowel disease. Hum Vaccin Immunother 2019;15:2482-90. [PMID: 30897022 DOI: 10.1080/21645515.2019.1591139] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
362 Takeda T, Kishi M, Takatsu N, Takada Y, Beppu T, Miyaoka M, Hisabe T, Ueki T, Arima H, Hirai F, Yao K. Long-term outcomes of endoscopic balloon dilation for intestinal strictures in patients with Crohn's disease during maintenance treatment with anti-tumor necrosis factor alpha antibodies. Dig Endosc 2021. [PMID: 34185921 DOI: 10.1111/den.14073] [Reference Citation Analysis]
363 Ripollés T, Martínez-Pérez MJ, Paredes JM, Vizuete J, García-Martínez E, Jiménez-Restrepo DH. Contrast-enhanced ultrasound in the differentiation between phlegmon and abscess in Crohn's disease and other abdominal conditions. Eur J Radiol 2013;82:e525-31. [PMID: 23838329 DOI: 10.1016/j.ejrad.2013.05.043] [Cited by in Crossref: 57] [Cited by in F6Publishing: 37] [Article Influence: 7.1] [Reference Citation Analysis]
364 Louis E, Belaiche J, Reenaers C. Are we giving biologics too much time? When should we stop treatment? WJG 2008;14:5528. [DOI: 10.3748/wjg.14.5528] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
365 Wehkamp J, Stange EF. An Update Review on the Paneth Cell as Key to Ileal Crohn's Disease. Front Immunol 2020;11:646. [PMID: 32351509 DOI: 10.3389/fimmu.2020.00646] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 16.0] [Reference Citation Analysis]
366 Vester-Andersen MK, Prosberg MV, Jess T, Andersson M, Bengtsson BG, Blixt T, Munkholm P, Bendtsen F, Vind I. Disease course and surgery rates in inflammatory bowel disease: a population-based, 7-year follow-up study in the era of immunomodulating therapy. Am J Gastroenterol. 2014;109:705-714. [PMID: 24642581 DOI: 10.1038/ajg.2014.45] [Cited by in Crossref: 111] [Cited by in F6Publishing: 97] [Article Influence: 15.9] [Reference Citation Analysis]
367 Gasche C, Grundtner P. Genotypes and phenotypes in Crohn's disease: do they help in clinical management? Gut 2005;54:162-7. [PMID: 15591523 DOI: 10.1136/gut.2003.035600] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 2.6] [Reference Citation Analysis]
368 Spinelli A, Fiorino G, Bazzi P, Sacchi M, Bonifacio C, De Bastiani S, Malesci A, Balzarini L, Peyrin-biroulet L, Montorsi M, Danese S. Preoperative Magnetic Resonance Enterography in Predicting Findings and Optimizing Surgical Approach in Crohn's Disease. J Gastrointest Surg 2014;18:83-91. [DOI: 10.1007/s11605-013-2404-1] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
369 Santiago M, Magro F, Correia L, Portela F, Ministro P, Lago P, Dias CC. What forecasting the prevalence of inflammatory bowel disease may tell us about its evolution on a national scale. Therap Adv Gastroenterol 2019;12:1756284819860044. [PMID: 31467592 DOI: 10.1177/1756284819860044] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
370 Marques CC, Castelo-Branco MT, Pacheco RG, Buongusto F, do Rosário A Jr, Schanaider A, Coutinho-Silva R, de Souza HS. Prophylactic systemic P2X7 receptor blockade prevents experimental colitis. Biochim Biophys Acta 2014;1842:65-78. [PMID: 24184714 DOI: 10.1016/j.bbadis.2013.10.012] [Cited by in Crossref: 43] [Cited by in F6Publishing: 36] [Article Influence: 5.4] [Reference Citation Analysis]
371 Swaminath A, Lichtiger S. Dilation of colonic strictures by intralesional injection of infliximab in patients with Crohn's colitis. Inflamm Bowel Dis. 2008;14:213-216. [PMID: 18022870 DOI: 10.1002/ibd.20318] [Cited by in Crossref: 71] [Cited by in F6Publishing: 54] [Article Influence: 5.5] [Reference Citation Analysis]
372 Vuyyuru SK, Desai D, Kedia S, Dhoble P, Sahu P, Kante B, Agarwal S, Bopanna S, Dhingra R, Venigalla PM, Sharma R, Gupta SD, Makharia G, Sahni P, Ahuja V. Long-term outcomes of anti-tumor necrosis factor therapy and surgery in nonperianal fistulizing Crohn's disease. JGH Open 2021;5:420-7. [PMID: 33860091 DOI: 10.1002/jgh3.12370] [Reference Citation Analysis]
373 Hanauer SB, Panes J, Colombel JF, Bloomfield R, Schreiber S, Sandborn WJ. Clinical trial: impact of prior infliximab therapy on the clinical response to certolizumab pegol maintenance therapy for Crohn's disease. Aliment Pharmacol Ther. 2010;32:384-393. [PMID: 20491747 DOI: 10.1111/j.1365-2036.2010.04360.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 3.2] [Reference Citation Analysis]
374 Coelho J, Soyer P, Pautrat K, Boudiaf M, Vahedi K, Reignier S, Valleur P, Marteau P. [Management of ileal stenosis in patients with Crohn’s disease]. Gastroenterol Clin Biol. 2009;33:F75-F81. [PMID: 19733458 DOI: 10.1016/j.gcb.2009.07.024] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
375 Ricart E, García-Bosch O, Ordás I, Panés J. Are we giving biologics too late? The case for early versus late use. World J Gastroenterol 2008;14:5523-7. [PMID: 18810770 DOI: 10.3748/wjg.14.5523] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
376 Zhao JF, Ling FM, Li JR, Chen YD, Huang L, Zhu LR. Role of non-inflammatory factors in intestinal fibrosis. J Dig Dis 2020;21:315-8. [PMID: 32406603 DOI: 10.1111/1751-2980.12883] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
377 Henderson P, van Limbergen JE, Wilson DC, Satsangi J, Russell RK. Genetics of childhood-onset inflammatory bowel disease. Inflamm Bowel Dis. 2011;17:346-361. [PMID: 20839313 DOI: 10.1002/ibd.21283] [Cited by in Crossref: 49] [Cited by in F6Publishing: 44] [Article Influence: 4.9] [Reference Citation Analysis]
378 Miheller P, Kiss LS, Lorinczy K, Lakatos PL. Anti-TNF trough levels and detection of antibodies to anti-TNF in inflammatory bowel disease: are they ready for everyday clinical use? Expert Opinion on Biological Therapy 2012;12:179-92. [DOI: 10.1517/14712598.2012.644271] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 2.2] [Reference Citation Analysis]
379 Yamamoto T, Watanabe T. Surgery for luminal Crohn's disease. World J Gastroenterol. 2014;20:78-90. [PMID: 24415860 DOI: 10.3748/wjg.v20.i1.78] [Cited by in CrossRef: 48] [Cited by in F6Publishing: 31] [Article Influence: 6.9] [Reference Citation Analysis]
380 Magro F, Rodrigues-Pinto E, Coelho R, Andrade P, Santos-Antunes J, Lopes S, Camila-Dias C, Macedo G. Is it possible to change phenotype progression in Crohn's disease in the era of immunomodulators? Predictive factors of phenotype progression. Am J Gastroenterol. 2014;109:1026-1036. [PMID: 24796767 DOI: 10.1038/ajg.2014.97] [Cited by in Crossref: 61] [Cited by in F6Publishing: 49] [Article Influence: 8.7] [Reference Citation Analysis]
381 Samimi R, Flasar MH, Kavic S, Tracy K, Cross RK. Outcome of medical treatment of stricturing and penetrating Crohn’s disease: a retrospective study. Inflamm Bowel Dis. 2010;16:1187-1194. [PMID: 19902541 DOI: 10.1002/ibd.21160] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 3.4] [Reference Citation Analysis]
382 Brenmoehl J, Falk W, Göke M, Schölmerich J, Rogler G. Inflammation modulates fibronectin isoform expression in colonic lamina propria fibroblasts (CLPF). Int J Colorectal Dis. 2008;23:947-955. [PMID: 18633626 DOI: 10.1007/s00384-008-0523-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
383 Nunes T, Etchevers MJ, Merino O, Gallego S, García-Sánchez V, Marín-Jiménez I, Menchén L, Barreiro-de Acosta M, Bastida G, García S, Gento E, Ginard D, Gomollón F, Arroyo M, Monfort D, García-Planella E, Gonzalez B, Loras C, Agustí C, Figueroa C, Sans M; TABACROHN Study Group of GETECCU, Spanish Working Group in Crohn's Disease and Ulcerative Colitis. Does smoking influence Crohn's disease in the biologic era? The TABACROHN study. Inflamm Bowel Dis 2013;19:23-9. [PMID: 22467185 DOI: 10.1002/ibd.22959] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 4.0] [Reference Citation Analysis]
384 Löfberg R, Louis EV, Reinisch W, Robinson AM, Kron M, Camez A, Pollack PF. Adalimumab produces clinical remission and reduces extraintestinal manifestations in Crohn’s disease: results from CARE. Inflamm Bowel Dis. 2012;18:1-9. [PMID: 21351211 DOI: 10.1002/ibd.21663] [Cited by in Crossref: 75] [Cited by in F6Publishing: 63] [Article Influence: 7.5] [Reference Citation Analysis]
385 Prideaux L, De Cruz P, Ng SC, Kamm MA. Serological antibodies in inflammatory bowel disease: a systematic review. Inflamm Bowel Dis. 2012;18:1340-1355. [PMID: 22069240 DOI: 10.1002/ibd.21903] [Cited by in Crossref: 111] [Cited by in F6Publishing: 83] [Article Influence: 11.1] [Reference Citation Analysis]
386 Tandon P, Malhi G, Abdali D, Pogue E, Marshall JK, de Buck van Overstraeten A, Riddell R, Narula N. Active Margins, Plexitis, and Granulomas Increase Postoperative Crohn's Recurrence: Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2021;19:451-62. [PMID: 32801016 DOI: 10.1016/j.cgh.2020.08.014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
387 Rinawi F, Assa A, Hartman C, Mozer Glassberg Y, Nachmias Friedler V, Rosenbach Y, Silbermintz A, Zevit N, Shamir R. Evolution of disease phenotype in pediatric-onset Crohn’s disease after more than 10 years follow up—Cohort study. Digestive and Liver Disease 2016;48:1444-50. [DOI: 10.1016/j.dld.2016.08.118] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.2] [Reference Citation Analysis]
388 Stoddard PB, Ghazi LJ, Wong-You-Cheong J, Cross RK, Vandermeer FQ. Magnetic resonance enterography: State of the art. Inflamm Bowel Dis. 2015;21:229-239. [PMID: 25222657 DOI: 10.1097/mib.0000000000000186] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 1.2] [Reference Citation Analysis]
389 Lee YM, Kang B, Lee Y, Kim MJ, Choe YH. Infliximab “Top-Down” Strategy is Superior to “Step-Up” in Maintaining Long-Term Remission in the Treatment of Pediatric Crohn Disease. Journal of Pediatric Gastroenterology & Nutrition 2015;60:737-43. [DOI: 10.1097/mpg.0000000000000711] [Cited by in Crossref: 34] [Cited by in F6Publishing: 12] [Article Influence: 5.7] [Reference Citation Analysis]
390 Bruining DH, Zimmermann EM, Loftus EV Jr, Sandborn WJ, Sauer CG, Strong SA; Society of Abdominal Radiology Crohn’s Disease-Focused Panel. Consensus Recommendations for Evaluation, Interpretation, and Utilization of Computed Tomography and Magnetic Resonance Enterography in Patients With Small Bowel Crohn's Disease. Gastroenterology 2018;154:1172-94. [PMID: 29329905 DOI: 10.1053/j.gastro.2017.11.274] [Cited by in Crossref: 79] [Cited by in F6Publishing: 56] [Article Influence: 26.3] [Reference Citation Analysis]
391 Florin TH, Paterson EW, Fowler EV, Radford-Smith GL. Clinically active Crohn's disease in the presence of a low C-reactive protein. Scand J Gastroenterol 2006;41:306-11. [PMID: 16497618 DOI: 10.1080/00365520500217118] [Cited by in Crossref: 79] [Cited by in F6Publishing: 66] [Article Influence: 5.3] [Reference Citation Analysis]
392 Brand S, Staudinger T, Schnitzler F, Pfennig S, Hofbauer K, Dambacher J, Seiderer J, Tillack C, Konrad A, Crispin A, Göke B, Lohse P, Ochsenkühn T. The role of Toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms and CARD15/NOD2 mutations in the susceptibility and phenotype of Crohn's disease. Inflamm Bowel Dis 2005;11:645-52. [PMID: 15973118 DOI: 10.1097/01.mib.0000168372.94907.d2] [Cited by in Crossref: 117] [Cited by in F6Publishing: 42] [Article Influence: 7.3] [Reference Citation Analysis]
393 Kayar Y, Baran B, Ormeci AC, Akyuz F, Demir K, Besisik F, Kaymakoglu S. Risk factors associated with progression to intestinal complications of Crohn disease. Chin Med J (Engl) 2019;132:2423-9. [PMID: 31651515 DOI: 10.1097/CM9.0000000000000489] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
394 Xavier S, Cúrdia Gonçalves T, Dias de Castro F, Magalhães J, Rosa B, Moreira MJ, Cotter J. Perianal Crohn’s disease – association with significant inflammatory activity in proximal small bowel segments. Scandinavian Journal of Gastroenterology 2018;53:426-9. [DOI: 10.1080/00365521.2018.1437928] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
395 Vaughn BP, Moss AC. Prevention of post-operative recurrence of Crohn’s disease. World J Gastroenterol. 2014;20:1147-1154. [PMID: 24574791 DOI: 10.3748/wjg.v20.i5.1147] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 24] [Article Influence: 4.6] [Reference Citation Analysis]
396 Hirai F, Andoh A, Ueno F, Watanabe K, Ohmiya N, Nakase H, Kato S, Esaki M, Endo Y, Yamamoto H, Matsui T, Iida M, Hibi T, Watanabe M, Suzuki Y, Matsumoto T. Efficacy of Endoscopic Balloon Dilation for Small Bowel Strictures in Patients With Crohn's Disease: A Nationwide, Multi-centre, Open-label, Prospective Cohort Study. J Crohns Colitis. 2018;12:394-401. [PMID: 29194463 DOI: 10.1093/ecco-jcc/jjx159] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 8.3] [Reference Citation Analysis]
397 Lunney PC, Kariyawasam VC, Wang RR, Middleton KL, Huang T, Selinger CP, Andrews JM, Katelaris PH, Leong RW. Smoking prevalence and its influence on disease course and surgery in Crohn's disease and ulcerative colitis. Aliment Pharmacol Ther 2015;42:61-70. [PMID: 25968332 DOI: 10.1111/apt.13239] [Cited by in Crossref: 58] [Cited by in F6Publishing: 47] [Article Influence: 9.7] [Reference Citation Analysis]
398 Golovics PA, Mandel MD, Lovasz BD, Lakatos PL. Inflammatory bowel disease course in Crohn’s disease: is the natural history changing? World J Gastroenterol. 2014;20:3198-3207. [PMID: 24696605 DOI: 10.3748/wjg.v20.i12.3198] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
399 Yang SB, Du SW, Wang JH. Correlation between age of onset and gastrointestinal stenosis in hospitalized patients with Crohn's disease. World J Clin Cases 2020;8:2769-77. [PMID: 32742987 DOI: 10.12998/wjcc.v8.i13.2769] [Reference Citation Analysis]
400 Allocca M, Bonifacio C, Fiorino G, Spinelli A, Furfaro F, Balzarini L, Bonovas S, Danese S. Efficacy of tumour necrosis factor antagonists in stricturing Crohn’s disease: A tertiary center real-life experience. Digestive and Liver Disease 2017;49:872-7. [DOI: 10.1016/j.dld.2017.03.012] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
401 Savoye G, Salleron J, Gower-rousseau C, Dupas J, Vernier-massouille G, Fumery M, Merle V, Lerebours E, Cortot A, Turck D, Salomez J, Lemann M, Colombel J, Duhamel A. Clinical predictors at diagnosis of disabling pediatric Crohnʼs disease: . Inflammatory Bowel Diseases 2012;18:2072-8. [DOI: 10.1002/ibd.22898] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
402 Aggarwal D, Limdi JK. Anti-TNF therapy is associated with a reduction in radiation exposure in patients with Crohn's disease. Eur J Gastroenterol Hepatol 2015;27:13-9. [PMID: 25341058 DOI: 10.1097/MEG.0000000000000222] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
403 Cucchiara S, D'Arcangelo G, Isoldi S, Aloi M, Stronati L. Mucosal healing in Crohn's disease: new insights. Expert Rev Gastroenterol Hepatol. 2020;14:335-345. [PMID: 32315209 DOI: 10.1080/17474124.2020.1759416] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
404 Bossuyt P, Debeuckelaere C, Ferrante M, de Buck van Overstraeten A, Vanbeckevoort D, Billiet T, Wolthuis A, Cleynen I, Van Assche G, D’hoore A, Vermeire S. Risk Stratification for Surgery in Stricturing Ileal Crohn’s Disease: The BACARDI Risk Model. Journal of Crohn's and Colitis 2018;12:32-8. [DOI: 10.1093/ecco-jcc/jjx110] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 4.5] [Reference Citation Analysis]
405 Ooi CJ, Makharia GK, Hilmi I, Gibson PR, Fock KM, Ahuja V, Ling KL, Lim WC, Thia KT, Wei SC, Leung WK, Koh PK, Gearry RB, Goh KL, Ouyang Q, Sollano J, Manatsathit S, de Silva HJ, Rerknimitr R, Pisespongsa P, Abu Hassan MR, Sung J, Hibi T, Boey CC, Moran N, Leong RW; Asia Pacific Association of Gastroenterology (APAGE) Working Group on Inflammatory Bowel Disease. Asia-Pacific consensus statements on Crohn's disease. Part 2: Management. J Gastroenterol Hepatol. 2016;31:56-68. [PMID: 25819311 DOI: 10.1111/jgh.12958] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 5.4] [Reference Citation Analysis]
406 Evans AT, Lee SD. A review and expert opinion of the use of certolizumab for Crohn's disease. Expert Opin Biol Ther 2012;12:363-70. [PMID: 22339409 DOI: 10.1517/14712598.2012.658770] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
407 Hagel AF, Hahn A, Dauth W, Matzel K, Konturek PC, Neurath MF, Raithel M. Outcome and complications of endoscopic balloon dilatations in various types of ileocaecal and colonic stenosis in patients with Crohn's disease. Surg Endosc. 2014;28:2966-2972. [PMID: 24853850 DOI: 10.1007/s00464-014-3559-x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
408 Iskandar HN, Ciorba MA. Biomarkers in inflammatory bowel disease: current practices and recent advances. Transl Res. 2012;159:313-325. [PMID: 22424434 DOI: 10.1016/j.trsl.2012.01.001] [Cited by in Crossref: 116] [Cited by in F6Publishing: 97] [Article Influence: 12.9] [Reference Citation Analysis]
409 Caparrós E, Wiest R, Scharl M, Rogler G, Gutiérrez Casbas A, Yilmaz B, Wawrzyniak M, Francés R. Dysbiotic microbiota interactions in Crohn's disease. Gut Microbes 2021;13:1949096. [PMID: 34313550 DOI: 10.1080/19490976.2021.1949096] [Reference Citation Analysis]
410 Louis E, Belaiche J, Reenaers C. Do clinical factors help to predict disease course in inflammatory bowel disease? World J Gastroenterol. 2010;16:2600-2603. [PMID: 20518080 DOI: 10.3748/wjg.v16.i21.2600] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
411 Nahon S, Lahmek P, Paupard T, Lesgourgues B, Chaussade S, Peyrin-Biroulet L, Abitbol V. Diagnostic Delay Is Associated with a Greater Risk of Early Surgery in a French Cohort of Crohn's Disease Patients. Dig Dis Sci. 2016;61:3278-3284. [PMID: 27207180 DOI: 10.1007/s10620-016-4189-z] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 5.2] [Reference Citation Analysis]
412 González-Lama Y, Suárez C, González-Partida I, Calvo M, Matallana V, de la Revilla J, Magaz M, Bernardo C, Agudo B, Ibarrola P, Relea L, Arévalo J, Vera MI, Abreu L. Timing of Thiopurine or Anti-TNF Initiation Is Associated with the Risk of Major Abdominal Surgery in Crohn's Disease: A Retrospective Cohort Study. J Crohns Colitis 2016;10:55-60. [PMID: 26520164 DOI: 10.1093/ecco-jcc/jjv187] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
413 Ruel J, Ruane D, Mehandru S, Gower-Rousseau C, Colombel JF. IBD across the age spectrum: is it the same disease? Nat Rev Gastroenterol Hepatol. 2014;11:88-98. [PMID: 24345891 DOI: 10.1038/nrgastro.2013.240] [Cited by in Crossref: 118] [Cited by in F6Publishing: 105] [Article Influence: 14.8] [Reference Citation Analysis]
414 Kondo J, Iijima H, Abe T, Komori M, Hiyama S, Ito T, Nakama A, Tominaga K, Kubo M, Suzuki K, Iwanaga Y, Ebara R, Takeda A, Tsuji S, Nishida T, Tsutsui S, Tsujii M, Hayashi N. Roles of double-balloon endoscopy in the diagnosis and treatment of Crohn's disease: a multicenter experience. J Gastroenterol. 2010;45:713-720. [PMID: 20174832 DOI: 10.1007/s00535-010-0216-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
415 Kang B, Choe YH. Early Biologic Treatment in Pediatric Crohn's Disease: Catching the Therapeutic Window of Opportunity in Early Disease by Treat-to-Target. Pediatr Gastroenterol Hepatol Nutr 2018;21:1-11. [PMID: 29383299 DOI: 10.5223/pghn.2018.21.1.1] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 8.0] [Reference Citation Analysis]
416 Pallotta N, Vincoli G, Pezzotti P, Giovannone M, Gigliozzi A, Badiali D, Vernia P, Corazziari ES. A risk score system to timely manage treatment in Crohn's disease: a cohort study. BMC Gastroenterol 2018;18:164. [PMID: 30400823 DOI: 10.1186/s12876-018-0889-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
417 Gasparetto M, Guariso G. Highlights in IBD Epidemiology and Its Natural History in the Paediatric Age. Gastroenterol Res Pract. 2013;2013:829040. [PMID: 24454343 DOI: 10.1155/2013/829040] [Cited by in Crossref: 56] [Cited by in F6Publishing: 49] [Article Influence: 7.0] [Reference Citation Analysis]
418 da Silva Moraes AC, de Freitas Moraes G, de Araújo ALE, Luiz RR, Elia C, Carneiro AJ, de Souza HSP. Abdominal ultrasonography with color Doppler analysis in the assessment of ileal Crohn's disease: comparison with magnetic resonance enterography. Intest Res 2019;17:227-36. [PMID: 30962408 DOI: 10.5217/ir.2018.00124] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
419 Koelewijn CL, Schwartz MP, Samsom M, Oldenburg B. C-reactive protein levels during a relapse of Crohn's disease are associated with the clinical course of the disease. World J Gastroenterol. 2008;14:85-89. [PMID: 18176967 DOI: 10.3748/wjg.14.85] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 30] [Article Influence: 2.8] [Reference Citation Analysis]
420 Rutgeerts P, Vermeire S, Van Assche G. Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target? Gut. 2007;56:453-455. [PMID: 17369375 DOI: 10.1136/gut.2005.088732.] [Reference Citation Analysis]
421 Elriz K, Palascak-Juif V, Joly F, Seguy D, Beau P, Chambrier C, Boncompain M, Fontaine E, Laharie D, Savoye G, Lerebours E. Crohn's disease patients with chronic intestinal failure receiving long-term parenteral nutrition: a cross-national adult study. Aliment Pharmacol Ther 2011;34:931-40. [PMID: 21848855 DOI: 10.1111/j.1365-2036.2011.04806.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
422 Kassam Z, Belga S, Roifman I, Hirota S, Jijon H, Kaplan GG, Ghosh S, Beck PL. Inflammatory bowel disease cause-specific mortality: a primer for clinicians. Inflamm Bowel Dis 2014;20:2483-92. [PMID: 25185685 DOI: 10.1097/MIB.0000000000000173] [Cited by in Crossref: 28] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
423 Johnson LA, Sauder KL, Rodansky ES, Simpson RU, Higgins PD. CARD-024, a vitamin D analog, attenuates the pro-fibrotic response to substrate stiffness in colonic myofibroblasts. Exp Mol Pathol 2012;93:91-8. [PMID: 22542712 DOI: 10.1016/j.yexmp.2012.04.014] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
424 Kruis W, Katalinic A, Klugmann T, Franke GR, Weismüller J, Leifeld L, Ceplis-Kastner S, Reimers B, Bokemeyer B. Predictive factors for an uncomplicated long-term course of Crohn's disease: a retrospective analysis. J Crohns Colitis 2013;7:e263-70. [PMID: 23182164 DOI: 10.1016/j.crohns.2012.10.012] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
425 Colombel JF, Rutgeerts PJ, Sandborn WJ, Yang M, Camez A, Pollack PF, Thakkar RB, Robinson AM, Chen N, Mulani PM, Chao J. Adalimumab induces deep remission in patients with Crohn's disease. Clin Gastroenterol Hepatol 2014; 12: 414-22. e5. [PMID: 23856361 DOI: 10.1016/j.cgh.2013.06.019] [Cited by in Crossref: 149] [Cited by in F6Publishing: 125] [Article Influence: 18.6] [Reference Citation Analysis]
426 Daperno M, Castiglione F, de Ridder L, Dotan I, Färkkilä M, Florholmen J, Fraser G, Fries W, Hebuterne X, Lakatos PL. Results of the 2nd part Scientific Workshop of the ECCO. II: Measures and markers of prediction to achieve, detect, and monitor intestinal healing in inflammatory bowel disease. J Crohns Colitis. 2011;5:484-498. [PMID: 21939926 DOI: 10.1016/j.crohns.2011.07.003] [Cited by in Crossref: 72] [Cited by in F6Publishing: 64] [Article Influence: 7.2] [Reference Citation Analysis]
427 Zéphir H, Gower-rousseau C, Salleron J, Simon O, Debouverie M, Le Page E, Bouhnik Y, Lebrun-frenay C, Papeix C, Vigneron B, Allez M, Prin L, Cosnes J, Vermersch P, Colombel J; for the CFSEP, GETAID and EPIMAD Groups. Milder multiple sclerosis course in patients with concomitant inflammatory bowel disease. Mult Scler 2014;20:1135-9. [DOI: 10.1177/1352458513515081] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
428 Fowler KJ, Dassopoulos T, Raptis C. Magnetic Resonance Enterography in the Evaluation of Crohnʼs Disease: A Primer for the Gastroenterologist. Inflammatory Bowel Diseases 2014;20:2179-88. [DOI: 10.1097/mib.0000000000000132] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
429 Halfvarson J, Jess T, Bodin L, Järnerot G, Munkholm P, Binder V, Tysk C. Longitudinal concordance for clinical characteristics in a Swedish-Danish twin population with inflammatory bowel disease. Inflamm Bowel Dis 2007;13:1536-44. [PMID: 17828780 DOI: 10.1002/ibd.20242] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 2.2] [Reference Citation Analysis]
430 Rivière P, D'Haens G, Peyrin-Biroulet L, Baert F, Lambrecht G, Pariente B, Bossuyt P, Buisson A, Oldenburg B, Vermeire S, Laharie D. Location but Not Severity of Endoscopic Lesions Influences Endoscopic Remission Rates in Crohn's Disease: A Post Hoc Analysis of TAILORIX. Am J Gastroenterol 2021;116:134-41. [PMID: 33177349 DOI: 10.14309/ajg.0000000000000834] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
431 Vermeire S, Van Assche G, Rutgeerts P. Classification of inflammatory bowel disease: the old and the new. Curr Opin Gastroenterol. 2012;28:321-326. [PMID: 22647554 DOI: 10.1097/mog.0b013e328354be1e] [Cited by in Crossref: 40] [Cited by in F6Publishing: 16] [Article Influence: 4.4] [Reference Citation Analysis]
432 Cotter J, Dias de Castro F, Moreira MJ, Rosa B. Tailoring Crohn's disease treatment: the impact of small bowel capsule endoscopy. J Crohns Colitis. 2014;8:1610-1615. [PMID: 24631311 DOI: 10.1016/j.crohns.2014.02.018] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 5.9] [Reference Citation Analysis]
433 Nass BYS, Dibbets P, Markus CR. Impact of the COVID-19 pandemic on inflammatory bowel disease: The role of emotional stress and social isolation. Stress Health 2021. [PMID: 34273129 DOI: 10.1002/smi.3080] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
434 Wolters FL, Joling C, Russel MG, Sijbrandij J, De Bruin M, Odes S, Riis L, Munkholm P, Bodini P, Ryan B. Treatment inferred disease severity in Crohn's disease: evidence for a European gradient of disease course. Scand J Gastroenterol. 2007;42:333-344. [PMID: 17354113 DOI: 10.1080/00365520600930750] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
435 Casas Deza D, García López S, Lafuente Blasco M, Vicente Lidón R, Nerín de la Puerta J, Peña Gonzalez E, Ber Nieto Y, Charro Calvillo M, Alcalá Escriche MJ, Gomollón García F, Arroyo Villarino M. Efficacy and safety of ustekinumab in real clinical practice. Retrospective multicentre study. ARAINF cohort. Gastroenterol Hepatol 2020;43:126-32. [PMID: 31866167 DOI: 10.1016/j.gastrohep.2019.09.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
436 Hansel SL, McCurdy JD, Barlow JM, Fidler J, Fletcher JG, Becker B, Prabhu NC, Faubion WA, Hanson KA, Kane SV, Kisiel JB, Loftus EV, Papadakis KA, Pardi DS, Raffals LE, Schoenoff S, Tremaine WJ, Bruining DH. Clinical Benefit of Capsule Endoscopy in Crohn's Disease: Impact on Patient Management and Prevalence of Proximal Small Bowel Involvement. Inflamm Bowel Dis. 2018;24:1582-1588. [PMID: 29788055 DOI: 10.1093/ibd/izy050] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 7.5] [Reference Citation Analysis]
437 Kumar S, Hakim A, Alexakis C, Chhaya V, Tzias D, Pilcher J, Vlahos J, Pollok R. Small intestinal contrast ultrasonography for the detection of small bowel complications in Crohn's disease: correlation with intraoperative findings and magnetic resonance enterography. J Gastroenterol Hepatol. 2015;30:86-91. [PMID: 25168482 DOI: 10.1111/jgh.12724] [Cited by in Crossref: 31] [Cited by in F6Publishing: 20] [Article Influence: 5.2] [Reference Citation Analysis]
438 Doherty GA, Miksad RA, Cheifetz AS, Moss AC. Comparative cost-effectiveness of strategies to prevent postoperative clinical recurrence of Crohn’s disease. Inflamm Bowel Dis. 2012;18:1608-1616. [PMID: 21905173 DOI: 10.1002/ibd.21904] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
439 Fagagnini S, Heinrich H, Rossel JB, Biedermann L, Frei P, Zeitz J, Spalinger M, Battegay E, Zimmerli L, Vavricka SR, Rogler G, Scharl M, Misselwitz B. Risk factors for gallstones and kidney stones in a cohort of patients with inflammatory bowel diseases. PLoS One 2017;12:e0185193. [PMID: 29023532 DOI: 10.1371/journal.pone.0185193] [Cited by in Crossref: 28] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
440 Velayos FS, Sandborn WJ. Editorial: Use of Azathioprine and 6MP in Postoperative Crohn's: Changing Natural History or Just Along for the Ride? Am J Gastroenterol 2009;104:2097-9. [DOI: 10.1038/ajg.2009.306] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
441 Goffin L, Fagagnini S, Vicari A, Mamie C, Melhem H, Weder B, Lutz C, Lang S, Scharl M, Rogler G, Chvatchko Y, Hausmann M. Anti-MMP-9 Antibody: A Promising Therapeutic Strategy for Treatment of Inflammatory Bowel Disease Complications with Fibrosis. Inflammatory Bowel Diseases 2016;22:2041-57. [DOI: 10.1097/mib.0000000000000863] [Cited by in Crossref: 35] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
442 Goldstein NS. Isolated Ileal Erosions in Patients With Mildly Altered Bowel Habits: A Follow-up Study of 28 Patients. Am J Clin Pathol 2006;125:838-46. [DOI: 10.1309/4pk0g68m2g1l6x47] [Cited by in Crossref: 21] [Article Influence: 1.4] [Reference Citation Analysis]
443 Rimola J, Capozzi N. Differentiation of fibrotic and inflammatory component of Crohn's disease-associated strictures. Intest Res 2020;18:144-50. [PMID: 32326668 DOI: 10.5217/ir.2020.00015] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
444 Jensen MD, Brodersen JB, Kjeldsen J. Capsule endoscopy for the diagnosis and follow up of Crohn's disease: a comprehensive review of current status. Ann Gastroenterol. 2017;30:168-178. [PMID: 28243037 DOI: 10.20524/aog.2016.0119] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
445 Felley C, Vader JP, Juillerat P, Pittet V, O'Morain C, Panis Y, Vucelic B, Gonvers JJ, Mottet C, Froehlich F. Appropriate therapy for fistulizing and fibrostenotic Crohn's disease: Results of a multidisciplinary expert panel - EPACT II. J Crohns Colitis. 2009;3:250-256. [PMID: 21172283 DOI: 10.1016/j.crohns.2009.06.001] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
446 Kedia S, Sharma R, Makharia GK, Ahuja V, Desai D, Kandasamy D, Eapen A, Ganesan K, Ghoshal UC, Kalra N, Karthikeyan D, Madhusudhan KS, Philip M, Puri AS, Puri S, Sinha SK, Banerjee R, Bhatia S, Bhat N, Dadhich S, Dhali GK, Goswami BD, Issar SK, Jayanthi V, Misra SP, Nijhawan S, Puri P, Sarkar A, Singh SP, Srivastava A, Abraham P, Ramakrishna BS; for Indian Society of Gastroenterology Task Force on Inflammatory Bowel Disease. Imaging of the small intestine in Crohn's disease: Joint position statement of the Indian Society of Gastroenterology and Indian Radiological and Imaging Association. Indian J Gastroenterol. 2017;36:487-508. [PMID: 29307029 DOI: 10.1007/s12664-017-0804-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
447 Stallmach A, Bokemeyer B, Helwig U, Lügering A, Teich N, Fischer I, Rath S, Lang D, Schmidt C; EPIC Study Group. Predictive parameters for the clinical course of Crohn's disease: development of a simple and reliable risk model. Int J Colorectal Dis 2019;34:1653-60. [PMID: 31446480 DOI: 10.1007/s00384-019-03369-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
448 Regueiro MD, Greer JB, Hanauer SB. Established Management Paradigms in IBD: Treatment Targets and Therapeutic Tools. Am J Gastroenterol Suppl 2016;3:8-16. [DOI: 10.1038/ajgsup.2016.16] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
449 Bharadwaj S, Tandon P, Kulkarni G, Rivas J, Charles R. The role of endoscopy in inflammatory bowel disease. J Dig Dis. 2015;16:689-698. [PMID: 26595156 DOI: 10.1111/1751-2980.12301] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
450 Narula N, Wong ECL, Aruljothy A, Dulai PS, Colombel JF, Marshall JK, Ferrante M, Reinisch W. Ileal and Rectal Ulcer Size Affects the Ability to Achieve Endoscopic Remission: A Post hoc Analysis of the SONIC Trial. Am J Gastroenterol 2020;115:1236-45. [PMID: 32759621 DOI: 10.14309/ajg.0000000000000617] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
451 Endo K, Takahashi S, Shiga H, Kakuta Y, Kinouchi Y, Shimosegawa T. Short and long-term outcomes of endoscopic balloon dilatation for Crohn's disease strictures. World J Gastroenterol 2013;19:86-91. [PMID: 23326167 DOI: 10.3748/wjg.v19.i1.86] [Cited by in CrossRef: 44] [Cited by in F6Publishing: 34] [Article Influence: 5.5] [Reference Citation Analysis]
452 Dillman JR, Stidham RW, Higgins PD, Moons DS, Johnson LA, Rubin JM. US elastography-derived shear wave velocity helps distinguish acutely inflamed from fibrotic bowel in a Crohn disease animal model. Radiology. 2013;267:757-766. [PMID: 23401585 DOI: 10.1148/radiol.13121775] [Cited by in Crossref: 66] [Cited by in F6Publishing: 55] [Article Influence: 8.3] [Reference Citation Analysis]
453 de’Angelis N, Carra MC, Borrelli O, Bizzarri B, Vincenzi F, Fornaroli F, De Caro G, de’Angelis GL. Short- and long-term efficacy of endoscopic balloon dilation in Crohn’s disease strictures. World J Gastroenterol. 2013;19:2660-2667. [PMID: 23674873 DOI: 10.3748/wjg.v19.i17.2660] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 26] [Article Influence: 4.3] [Reference Citation Analysis]
454 Rispo A, Imperatore N, Testa A, Bucci L, Luglio G, De Palma GD, Rea M, Nardone OM, Caporaso N, Castiglione F. Combined Endoscopic/Sonographic-based Risk Matrix Model for Predicting One-year Risk of Surgery: A Prospective Observational Study of a Tertiary Centre Severe/Refractory Crohn's Disease Cohort. J Crohns Colitis. 2018;12:784-793. [PMID: 29528382 DOI: 10.1093/ecco-jcc/jjy032] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 6.7] [Reference Citation Analysis]
455 Ryan JD, Silverberg MS, Xu W, Graff LA, Targownik LE, Walker JR, Carr R, Clara I, Miller N, Rogala L, Bernstein CN. Predicting complicated Crohn's disease and surgery: phenotypes, genetics, serology and psychological characteristics of a population-based cohort. Aliment Pharmacol Ther 2013;38:274-83. [PMID: 23725363 DOI: 10.1111/apt.12368] [Cited by in Crossref: 52] [Cited by in F6Publishing: 41] [Article Influence: 6.5] [Reference Citation Analysis]
456 Afzal NA, Davies S, Paintin M, Arnaud-Battandier F, Walker-Smith JA, Murch S, Heuschkel R, Fell J. Colonic Crohn's disease in children does not respond well to treatment with enteral nutrition if the ileum is not involved. Dig Dis Sci 2005;50:1471-5. [PMID: 16110838 DOI: 10.1007/s10620-005-2864-6] [Cited by in Crossref: 90] [Cited by in F6Publishing: 67] [Article Influence: 5.6] [Reference Citation Analysis]
457 Coelho R, Ribeiro H, Maconi G. Bowel Thickening in Crohn's Disease: Fibrosis or Inflammation? Inflamm Bowel Dis. 2017;23:23-34. [PMID: 28002125 DOI: 10.1097/mib.0000000000000997] [Cited by in Crossref: 23] [Cited by in F6Publishing: 6] [Article Influence: 7.7] [Reference Citation Analysis]
458 Kurowski JA, Achkar JP, Gupta R, Barbur I, Bonfield TL, Worley S, Remer EM, Fiocchi C, Viswanath SE, Kay MH. Adipokine Resistin Levels at Time of Pediatric Crohn Disease Diagnosis Predict Escalation to Biologic Therapy. Inflamm Bowel Dis 2021;27:1088-95. [PMID: 32978938 DOI: 10.1093/ibd/izaa250] [Reference Citation Analysis]
459 Shah SC, Colombel JF, Sands BE, Narula N. Systematic review with meta-analysis: mucosal healing is associated with improved long-term outcomes in Crohn's disease. Aliment Pharmacol Ther. 2016;43:317-333. [PMID: 26607562 DOI: 10.1111/apt.13475] [Cited by in Crossref: 154] [Cited by in F6Publishing: 122] [Article Influence: 25.7] [Reference Citation Analysis]
460 Ferretti F, Cannatelli R, Ardizzone S, Maier JA, Maconi G. Ultrasonographic Evaluation of Intestinal Fibrosis and Inflammation in Crohn's Disease. The State of the Art. Front Pharmacol 2021;12:679924. [PMID: 33981246 DOI: 10.3389/fphar.2021.679924] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
461 Aldhous MC, Drummond HE, Anderson N, Smith LA, Arnott ID, Satsangi J. Does cigarette smoking influence the phenotype of Crohn's disease? Analysis using the Montreal classification. Am J Gastroenterol 2007;102:577-88. [PMID: 17338736 DOI: 10.1111/j.1572-0241.2007.01064.x] [Cited by in Crossref: 69] [Cited by in F6Publishing: 76] [Article Influence: 4.9] [Reference Citation Analysis]
462 Matsumoto T, Yanai S, Toya Y, Ueno M, Nakamura S. Internet-orientated Assessment of QOL and Actual Treatment Status in Japanese Patients with Inflammatory Bowel Disease: The 3I survey. J Crohns Colitis 2015;9:477-82. [PMID: 25814388 DOI: 10.1093/ecco-jcc/jjv052] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
463 Fowler SA, Ananthakrishnan AN, Gardet A, Stevens CR, Korzenik JR, Sands BE, Daly MJ, Xavier RJ, Yajnik V. SMAD3 gene variant is a risk factor for recurrent surgery in patients with Crohn's disease. J Crohns Colitis 2014;8:845-51. [PMID: 24461721 DOI: 10.1016/j.crohns.2014.01.003] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 5.4] [Reference Citation Analysis]
464 De Cruz P, Kamm MA, Hamilton AL, Ritchie KJ, Krejany EO, Gorelik A, Liew D, Prideaux L, Lawrance IC, Andrews JM, Bampton PA, Jakobovits S, Florin TH, Gibson PR, Debinski H, Gearry RB, Macrae FA, Leong RW, Kronborg I, Radford-Smith G, Selby W, Johnston MJ, Woods R, Elliott PR, Bell SJ, Brown SJ, Connell WR, Desmond PV. Efficacy of thiopurines and adalimumab in preventing Crohn's disease recurrence in high-risk patients - a POCER study analysis. Aliment Pharmacol Ther. 2015;42:867-879. [PMID: 26314275 DOI: 10.1111/apt.13353] [Cited by in Crossref: 65] [Cited by in F6Publishing: 46] [Article Influence: 10.8] [Reference Citation Analysis]
465 Vermeire S, van Assche G, Rutgeerts P. Review article: Altering the natural history of Crohn’s disease--evidence for and against current therapies. Aliment Pharmacol Ther. 2007;25:3-12. [PMID: 17229216 DOI: 10.1111/j.1365-2036.2006.03134.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 34] [Article Influence: 0.7] [Reference Citation Analysis]
466 Crespi M, Dulbecco P, De Ceglie A, Conio M. Strictures in Crohn's Disease: From Pathophysiology to Treatment. Dig Dis Sci 2020;65:1904-16. [PMID: 32279173 DOI: 10.1007/s10620-020-06227-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 7.0] [Reference Citation Analysis]
467 Charpentier C, Salleron J, Savoye G, Fumery M, Merle V, Laberenne JE, Vasseur F, Dupas JL, Cortot A, Dauchet L, Peyrin-Biroulet L, Lerebours E, Colombel JF, Gower-Rousseau C. Natural history of elderly-onset inflammatory bowel disease: a population-based cohort study. Gut. 2014;63:423-432. [PMID: 23408350 DOI: 10.1136/gutjnl-2012-303864] [Cited by in Crossref: 188] [Cited by in F6Publishing: 159] [Article Influence: 23.5] [Reference Citation Analysis]
468 Moran GW, Dubeau MF, Kaplan GG, Yang H, Seow CH, Fedorak RN, Dieleman LA, Barkema HW, Ghosh S, Panaccione R. Phenotypic features of Crohn’s disease associated with failure of medical treatment. Clin Gastroenterol Hepatol. 2014;12:434-42.e1. [PMID: 23978351 DOI: 10.1016/j.cgh.2013.08.026] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 5.3] [Reference Citation Analysis]
469 Feldman PA, Wolfson D, Barkin JS. Medical management of Crohn's disease. Clin Colon Rectal Surg 2007;20:269-81. [PMID: 20011423 DOI: 10.1055/s-2007-991026] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
470 Govani SM, Stidham RW, Higgins PD. How early to take arms against a sea of troubles? The case for aggressive early therapy in Crohn's disease to prevent fibrotic intestinal strictures. J Crohns Colitis 2013;7:923-7. [PMID: 23880128 DOI: 10.1016/j.crohns.2013.06.011] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
471 De Greef E, Hoffman I, Smets F, Van Biervliet S, Bontems P, Hauser B, Paquot I, Alliet P, Arts W, Dewit O, De Vos M, Baert F, Bossuyt P, Rahier JF, Franchimont D, Vermeire S, Fontaine F, Louis E, Coche JC, Veereman G; IBD working group of BESPGHAN, BIRD. Paediatric Crohn Disease: Disease Activity and Growth in the BELCRO Cohort After 3 Years Follow-up. J Pediatr Gastroenterol Nutr 2016;63:253-8. [PMID: 26835906 DOI: 10.1097/MPG.0000000000001132] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
472 Malmborg P, Hildebrand H. The emerging global epidemic of paediatric inflammatory bowel disease--causes and consequences. J Intern Med. 2016;279:241-258. [PMID: 26355194 DOI: 10.1111/joim.12413] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 4.3] [Reference Citation Analysis]
473 Lei X, Wang Y. Predicting Microbe-Disease Association by Learning Graph Representations and Rule-Based Inference on the Heterogeneous Network. Front Microbiol 2020;11:579. [PMID: 32351464 DOI: 10.3389/fmicb.2020.00579] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
474 Hirai F. Current status of endoscopic balloon dilation for Crohn's disease. Intest Res. 2017;15:166-173. [PMID: 28522945 DOI: 10.5217/ir.2017.15.2.166] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
475 Feagan BG, Schwartz D, Danese S, Rubin DT, Lissoos TW, Xu J, Lasch K. Efficacy of Vedolizumab in Fistulising Crohn's Disease: Exploratory Analyses of Data from GEMINI 2. J Crohns Colitis. 2018;12:621-626. [PMID: 29471381 DOI: 10.1093/ecco-jcc/jjy019] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 12.0] [Reference Citation Analysis]
476 Qiu Y, Chen BL, Mao R, Zhang SH, He Y, Zeng ZR, Chen MH. Early Thiopurines Versus Conventional Step-Care Therapy for Modifying the Disease Course of Early Crohn's Disease: A Tertiary Referral Center Cohort Study. Medicine (Baltimore) 2015;94:e1148. [PMID: 26252273 DOI: 10.1097/MD.0000000000001148] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
477 De Cruz P, Kamm MA, Prideaux L, Allen PB, Moore G. Mucosal Healing in Crohnʼs Disease: A Systematic Review. Inflammatory Bowel Diseases 2013;19:429-44. [DOI: 10.1002/ibd.22977] [Cited by in Crossref: 101] [Cited by in F6Publishing: 84] [Article Influence: 12.6] [Reference Citation Analysis]
478 Cho A, Jantschitsch C, Knobler R. Extracorporeal Photopheresis-An Overview. Front Med (Lausanne). 2018;5:236. [PMID: 30211164 DOI: 10.3389/fmed.2018.00236] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 9.7] [Reference Citation Analysis]
479 Fiocchi C, Lund PK. Themes in fibrosis and gastrointestinal inflammation. Am J Physiol Gastrointest Liver Physiol. 2011;300:G677-G683. [PMID: 21415411 DOI: 10.1152/ajpgi.00104.2011] [Cited by in Crossref: 63] [Cited by in F6Publishing: 58] [Article Influence: 6.3] [Reference Citation Analysis]
480 Patil SA, Rustgi A, Quezada SM, Flasar MH, Vandermeer F, Cross RK. Anti-TNF Therapy Is Associated with Decreased Imaging and Radiation Exposure in Patients with Crohnʼs Disease: . Inflammatory Bowel Diseases 2013;19:92-8. [DOI: 10.1002/ibd.22982] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
481 Aloi M, Viola F, D'Arcangelo G, Di Nardo G, Civitelli F, Casciani E, Oliva S, Nuti F, Dilillo A, Cucchiara S. Disease course and efficacy of medical therapy in stricturing paediatric Crohn's disease. Dig Liver Dis 2013;45:464-8. [PMID: 23465684 DOI: 10.1016/j.dld.2013.01.020] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
482 de Buck van Overstraeten A, Eshuis EJ, Vermeire S, Van Assche G, Ferrante M, D'Haens GR, Ponsioen CY, Belmans A, Buskens CJ, Wolthuis AM, Bemelman WA, D'Hoore A. Short- and medium-term outcomes following primary ileocaecal resection for Crohn's disease in two specialist centres. Br J Surg. 2017;104:1713-1722. [PMID: 28745410 DOI: 10.1002/bjs.10595] [Cited by in Crossref: 55] [Cited by in F6Publishing: 34] [Article Influence: 13.8] [Reference Citation Analysis]
483 Wu CQ, Lin QR, Ying SJ, Luo JK, Hong WJ, Lin ZJ, Jiang Y. Association of Crohn's Disease with Aryl Hydrocarbon Receptor Gene Polymorphisms in Patients from Southeast China. Immunol Invest 2019;48:809-21. [PMID: 31405308 DOI: 10.1080/08820139.2019.1569677] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
484 Principi M, Labarile N, Bianchi FP, Contaldo A, Tafuri S, Ierardi E, Di Leo A. The Cost of Inflammatory Bowel Disease Management Matches with Clinical Course: A Single Outpatient Centre Analysis. Int J Environ Res Public Health 2020;17:E4549. [PMID: 32599816 DOI: 10.3390/ijerph17124549] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
485 Niewiadomski O, Studd C, Hair C, Wilson J, McNeill J, Knight R, Prewett E, Dabkowski P, Dowling D, Alexander S, Allen B, Tacey M, Connell W, Desmond P, Bell S. Health Care Cost Analysis in a Population-based Inception Cohort of Inflammatory Bowel Disease Patients in the First Year of Diagnosis. J Crohns Colitis. 2015;9:988-996. [PMID: 26129692 DOI: 10.1093/ecco-jcc/jjv117] [Cited by in Crossref: 33] [Cited by in F6Publishing: 24] [Article Influence: 5.5] [Reference Citation Analysis]
486 Solberg IC, Vatn MH, Høie O, Stray N, Sauar J, Jahnsen J, Moum B, Lygren I. Clinical course in Crohn’s disease: results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol. 2007;5:1430-1438. [PMID: 18054751 DOI: 10.1016/j.cgh.2007.09.002] [Cited by in Crossref: 441] [Cited by in F6Publishing: 374] [Article Influence: 33.9] [Reference Citation Analysis]
487 Atreja A, Aggarwal A, Dwivedi S, Rieder F, Lopez R, Lashner BA, Brzezinski A, Vargo JJ, Shen B. Safety and efficacy of endoscopic dilation for primary and anastomotic Crohn's disease strictures. J Crohns Colitis 2014;8:392-400. [PMID: 24189349 DOI: 10.1016/j.crohns.2013.10.001] [Cited by in Crossref: 63] [Cited by in F6Publishing: 45] [Article Influence: 7.9] [Reference Citation Analysis]
488 Dubinsky MC, Kugathasan S, Kwon S, Haritunians T, Wrobel I, Wahbeh G, Quiros A, Bahar R, Silber G, Farrior S, Stephens M, Teleten N, Panikkath D, Ippoliti A, Vasiliauskas E, Fleshner P, Williams C, Landers C, Rotter JI, Targan SR, Taylor KD, McGovern DP. Multidimensional prognostic risk assessment identifies association between IL12B variation and surgery in Crohn's disease. Inflamm Bowel Dis 2013;19:1662-70. [PMID: 23665963 DOI: 10.1097/MIB.0b013e318281f275] [Cited by in Crossref: 31] [Cited by in F6Publishing: 12] [Article Influence: 4.4] [Reference Citation Analysis]
489 Lee HS, Chiorean MV, Boden E, Lord J, Irani S, Kozarek R, Larsen M, Ross A. Usefulness of Fluoroscopy for Endoscopic Balloon Dilation of Crohn's Disease-Related Strictures. Dig Dis Sci 2021. [PMID: 33740171 DOI: 10.1007/s10620-021-06935-1] [Reference Citation Analysis]
490 Icht O, Yanai H, Ron Y, Rosner G, Yaron A, Waizbard A, Ziv-Baran T, Fishman S, Dotan I. Comparative Study of Two Cohorts of Newly Diagnosed Crohn's Disease Demonstrates Change in Therapeutic Strategies. Digestion 2017;96:135-41. [PMID: 28848118 DOI: 10.1159/000477438] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
491 Schnitzler F, Fidder H, Ferrante M, Noman M, Arijs I, Van Assche G, Hoffman I, Van Steen K, Vermeire S, Rutgeerts P. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. Inflamm Bowel Dis 2009;15:1295-301. [PMID: 19340881 DOI: 10.1002/ibd.20927] [Cited by in Crossref: 468] [Cited by in F6Publishing: 399] [Article Influence: 39.0] [Reference Citation Analysis]
492 Hünerwadel A, Fagagnini S, Rogler G, Lutz C, Jaeger SU, Mamie C, Weder B, Ruiz PA, Hausmann M. Severity of local inflammation does not impact development of fibrosis in mouse models of intestinal fibrosis. Sci Rep 2018;8:15182. [PMID: 30315190 DOI: 10.1038/s41598-018-33452-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
493 Mannon PJ. Immunological Diseases of the Gastrointestinal Tract. Clinical Immunology. Elsevier; 2019. pp. 1005-1019.e1. [DOI: 10.1016/b978-0-7020-6896-6.00075-2] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
494 Park Y, Cheon JH, Park YL, Ye BD, Kim YS, Han DS, Kim JS, Hong SN, Kim YH, Jeon SR, Kim WH; IBD Study Group of the Korean Association for the Study of Intestinal Diseases (KASID). Development of a Novel Predictive Model for the Clinical Course of Crohn's Disease: Results from the CONNECT Study. Inflamm Bowel Dis. 2017;23:1071-1079. [PMID: 28410345 DOI: 10.1097/mib.0000000000001106] [Cited by in Crossref: 17] [Cited by in F6Publishing: 7] [Article Influence: 5.7] [Reference Citation Analysis]
495 Dubinsky MC, Taylor K, Targan SR, Rotter JI. Immunogenetic phenotypes in inflammatory bowel disease. World J Gastroenterol. 2006;12:3645-3650. [PMID: 16773679 DOI: 10.3748/wjg.v12.i23.3645] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
496 Sachar DB. Recurrence rates in Crohn's disease: predicting the future and predicting the past. Gut 2006;55:1069-70. [PMID: 16849342 DOI: 10.1136/gut.2005.088658] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
497 Vogelaar L, Spijker AV, van der Woude CJ. The impact of biologics on health-related quality of life in patients with inflammatory bowel disease. Clin Exp Gastroenterol. 2009;2:101-109. [PMID: 21694833 DOI: 10.2147/ceg.s4512] [Cited by in Crossref: 43] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
498 Zorzi F, Calabrese E, Monteleone I, Fantini M, Onali S, Biancone L, Pallone F, Monteleone G. A phase 1 open-label trial shows that smad7 antisense oligonucleotide (GED0301) does not increase the risk of small bowel strictures in Crohn’s disease. Aliment Pharmacol Ther 2012;36:850-7. [PMID: 22971085 DOI: 10.1111/apt.12051] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 5.4] [Reference Citation Analysis]
499 Hanauer SB, Kornbluth AA, Messick J, Rubin DT, Sandborn WJ, Sands BE. Clinical scenarios in IBD: optimizing the use of conventional and biologic agents. Inflamm Bowel Dis. 2010;16 Suppl 1:S1-S11. [PMID: 21104734 DOI: 10.1002/ibd.21529] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
500 Anyane-Yeboa A, Yamada A, Haider H, Wang Y, Komaki Y, Komaki F, Pekow J, Dalal S, Cohen RD, Cannon L, Umanskiy K, Smith R, Hurst R, Hyman N, Rubin DT, Sakuraba A. A comparison of the risk of postoperative recurrence between African-American and Caucasian patients with Crohn's disease. Aliment Pharmacol Ther 2018;48:933-40. [PMID: 30126019 DOI: 10.1111/apt.14951] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
501 Chaudhry NA, Riverso M, Grajo JR, Moser PP, Zou F, Homsi M, Punglia DR, Zimmermann EM. A Fixed Stricture on Routine Cross-sectional Imaging Predicts Disease-Related Complications and Adverse Outcomes in Patients with Crohnʼs Disease: . Inflammatory Bowel Diseases 2017;23:641-9. [DOI: 10.1097/mib.0000000000001054] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
502 Das R, Singh R, Din S, Lund J, Krishnamoorthy R, Hearing S, Norton B, Williams J, Fraser C, Goddard A, Cole A. Therapeutic resolution of focal, predominantly anastomotic Crohn’s disease strictures using removable stents: outcomes from a single-center case series in the United Kingdom. Gastrointestinal Endoscopy 2020;92:344-52. [DOI: 10.1016/j.gie.2020.01.053] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
503 Mazor Y, Maza I, Kaufman E, Ben-Horin S, Karban A, Chowers Y, Eliakim R. Prediction of disease complication occurrence in Crohn's disease using phenotype and genotype parameters at diagnosis. J Crohns Colitis. 2011;5:592-597. [PMID: 22115380 DOI: 10.1016/j.crohns.2011.06.002] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
504 Serra C, Rizzello F, Pratico' C, Felicani C, Fiorini E, Brugnera R, Mazzotta E, Giunchi F, Fiorentino M, D'Errico A, Morselli-Labate AM, Mastroroberto M, Campieri M, Poggioli G, Gionchetti P. Real-time elastography for the detection of fibrotic and inflammatory tissue in patients with stricturing Crohn's disease. J Ultrasound 2017;20:273-84. [PMID: 29204231 DOI: 10.1007/s40477-017-0265-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
505 Bern EM, Bousvaros A. Loss of response to biologics versus increased risk of lymphoma in children with inflammatory bowel disease: the clinician’s conundrum. Expert Review of Clinical Immunology 2014;9:117-27. [DOI: 10.1586/eci.12.97] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
506 Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 2007;369:1641-1657. [PMID: 17499606 DOI: 10.1016/s0140-6736(07)60751-x] [Cited by in Crossref: 1121] [Cited by in F6Publishing: 445] [Article Influence: 80.1] [Reference Citation Analysis]
507 Li Y, Ge Y, Gong J, Zhu W, Cao L, Guo Z, Gu L, Li J. Mesenteric Lymphatic Vessel Density Is Associated with Disease Behavior and Postoperative Recurrence in Crohn's Disease. J Gastrointest Surg 2018;22:2125-32. [PMID: 30043133 DOI: 10.1007/s11605-018-3884-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
508 Cullen G, Keegan D, Mulcahy HE, O'donoghue DP. A 5-Year Prospective Observational Study of the Outcomes of International Treatment Guidelines for Crohn's Disease. Clinical Gastroenterology and Hepatology 2009;7:323-8. [DOI: 10.1016/j.cgh.2008.10.018] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
509 Ma C, Jairath V, Click B, Hirota SA, Lu C, Parker CE, Rieder F; Stenosis Therapy and Anti-Fibrotic Research (STAR) Consortium. Targeting anti-fibrotic pathways in Crohn's disease - The final frontier? Best Pract Res Clin Gastroenterol 2019;38-39:101603. [PMID: 31327400 DOI: 10.1016/j.bpg.2019.02.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
510 Seifarth C, Kreis ME, Gröne J. Indications and Specific Surgical Techniques in Crohn’s Disease. Viszeralmedizin. 2015;31:273-279. [PMID: 26557836 DOI: 10.1159/000438955] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
511 Kalaria R, Desai D, Abraham P, Joshi A, Gupta T, Shah S. Temporal Change in Phenotypic Behaviour in Patients with Crohn's Disease: Do Indian Patients Behave Differently from Western and Other Asian Patients? J Crohns Colitis. 2016;10:255-261. [PMID: 26519461 DOI: 10.1093/ecco-jcc/jjv202] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
512 Lawal TA, Frischer JS, Falcone RA, Chatoorgoon K, Denson LA, Levitt MA. The transanal approach with laparoscopy or laparotomy for the treatment of rectal strictures in Crohn's disease. J Laparoendosc Adv Surg Tech A 2010;20:791-5. [PMID: 20874230 DOI: 10.1089/lap.2009.0470] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
513 Siegel CA, Bernstein CN. Identifying Patients With Inflammatory Bowel Diseases at High vs Low Risk of Complications. Clinical Gastroenterology and Hepatology 2020;18:1261-7. [DOI: 10.1016/j.cgh.2019.11.034] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 9.0] [Reference Citation Analysis]
514 Wenger S, Nikolaus S, Howaldt S, Bokemeyer B, Sturm A, Preiss JC, Schoepfer AM, Stallmach A, Schmidt C. Predictors for subsequent need for immunosuppressive therapy in early Crohn's disease. Journal of Crohn's and Colitis 2012;6:21-8. [DOI: 10.1016/j.crohns.2011.06.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
515 Fernandes SR, Rodrigues RV, Bernardo S, Cortez-pinto J, Rosa I, da Silva JP, Gonçalves AR, Valente A, Baldaia C, Santos PM, Correia L, Venâncio J, Campos P, Pereira AD, Velosa J. Transmural Healing Is Associated with Improved Long-term Outcomes of Patients with Crohnʼs Disease: . Inflammatory Bowel Diseases 2017;23:1403-9. [DOI: 10.1097/mib.0000000000001143] [Cited by in Crossref: 73] [Cited by in F6Publishing: 15] [Article Influence: 18.3] [Reference Citation Analysis]
516 Reenaers C, Louis E, Belaiche J. Current directions of biologic therapies in inflammatory bowel disease. Therap Adv Gastroenterol. 2010;3:99-106. [PMID: 21180594 DOI: 10.1177/1756283x09356872] [Cited by in Crossref: 19] [Cited by in F6Publishing: 7] [Article Influence: 1.9] [Reference Citation Analysis]
517 Amitai MM, Zarchin M, Lahat A, Yablecovitch D, Neuman S, Levhar N, Klang E, Avidan B, Ben-Horin S, Eliakim R, Kopylov U; Israeli IBD research Nucleus (IIRN). Structural bowel damage in quiescent Crohn's disease. Dig Liver Dis. 2017;49:490-494. [PMID: 28233685 DOI: 10.1016/j.dld.2017.02.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
518 Arieira C, Cúrdia Gonçaves T, Dias de Castro F, João Moreira M, Cotter J. Clinical course in Crohn’s disease: factors associated with behaviour change and surgery. Scandinavian Journal of Gastroenterology 2018;53:1222-7. [DOI: 10.1080/00365521.2018.1503709] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
519 Schnitzler F, Brand S, Staudinger T, Pfennig S, Hofbauer K, Seiderer J, Tillack C, Göke B, Ochsenkühn T, Lohse P. Eight novel CARD15 variants detected by DNA sequence analysis of the CARD15 gene in 111 patients with inflammatory bowel disease. Immunogenetics 2006;58:99-106. [PMID: 16485124 DOI: 10.1007/s00251-005-0073-2] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 2.6] [Reference Citation Analysis]
520 Johnson LA, Luke A, Sauder K, Moons DS, Horowitz JC, Higgins PD. Intestinal fibrosis is reduced by early elimination of inflammation in a mouse model of IBD: impact of a “Top-Down” approach to intestinal fibrosis in mice. Inflamm Bowel Dis. 2012;18:460-471. [PMID: 21761511 DOI: 10.1002/ibd.21812] [Cited by in Crossref: 67] [Cited by in F6Publishing: 61] [Article Influence: 6.7] [Reference Citation Analysis]
521 Bessissow T, Reinglas J, Aruljothy A, Lakatos PL, Van Assche G. Endoscopic management of Crohn's strictures. World J Gastroenterol. 2018;24:1859-1867. [PMID: 29740201 DOI: 10.3748/wjg.v24.i17.1859] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
522 Fang ZN, Li XH, Lin JJ, Huang SY, Cao QH, Chen ZH, Sun CH, Zhang ZW, Rieder F, Rimola J, Chen MH, Li ZP, Mao R, Feng ST. Magnetisation transfer imaging adds information to conventional MRIs to differentiate inflammatory from fibrotic components of small intestinal strictures in Crohn's disease. Eur Radiol 2020;30:1938-47. [PMID: 31900705 DOI: 10.1007/s00330-019-06594-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
523 Adler J, Rangwalla SC, Dwamena BA, Higgins PD. The prognostic power of the NOD2 genotype for complicated Crohn’s disease: a meta-analysis. Am J Gastroenterol. 2011;106:699-712. [PMID: 21343918 DOI: 10.1038/ajg.2011.19] [Cited by in Crossref: 119] [Cited by in F6Publishing: 97] [Article Influence: 11.9] [Reference Citation Analysis]
524 Scharl M, Huber N, Lang S, Fürst A, Jehle E, Rogler G. Hallmarks of epithelial to mesenchymal transition are detectable in Crohn's disease associated intestinal fibrosis. Clin Transl Med 2015;4:1. [PMID: 25852817 DOI: 10.1186/s40169-015-0046-5] [Cited by in Crossref: 61] [Cited by in F6Publishing: 58] [Article Influence: 10.2] [Reference Citation Analysis]
525 Niewiadomski O, Studd C, Hair C, Wilson J, Ding NS, Heerasing N, Ting A, McNeill J, Knight R, Santamaria J. Prospective population-based cohort of inflammatory bowel disease in the biologics era: Disease course and predictors of severity. J Gastroenterol Hepatol. 2015;30:1346-1353. [PMID: 25867770 DOI: 10.1111/jgh.12967] [Cited by in Crossref: 50] [Cited by in F6Publishing: 41] [Article Influence: 10.0] [Reference Citation Analysis]
526 Lorinczy K, Miheller P, Kiss SL, Lakatos PL. [Epidemiology, predictors and clinical aspects of loss of response to biological therapy]. Orv Hetil 2012;153:163-73. [PMID: 22275731 DOI: 10.1556/OH.2012.29294] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
527 Jeuring SFG, van den Heuvel TRA, Liu LYL, Zeegers MP, Hameeteman WH, Romberg-camps MJL, Oostenbrug LE, Masclee AAM, Jonkers DMAE, Pierik MJ. Improvements in the Long-Term Outcome of Crohn’s Disease Over the Past Two Decades and the Relation to Changes in Medical Management: Results from the Population-Based IBDSL Cohort. American Journal of Gastroenterology 2017;112:325-36. [DOI: 10.1038/ajg.2016.524] [Cited by in Crossref: 69] [Cited by in F6Publishing: 56] [Article Influence: 17.3] [Reference Citation Analysis]
528 Leung WK, Ng SC, Chow DK, Lao WC, Leung VK, Li MK, Hui YT, Ng SS, Hui AJ, Lai ST. Use of biologics for inflammatory bowel disease in Hong Kong: consensus statement. Hong Kong Med J. 2013;19:61-68. [PMID: 23378357 DOI: 10.1007/s00535-012-0673-1] [Cited by in Crossref: 74] [Cited by in F6Publishing: 61] [Article Influence: 9.3] [Reference Citation Analysis]
529 Loras C, Mañosa M, Andújar X, Sánchiz V, Martí-Gallostra M, Zabana Y, Gutiérrez A, Barreiro-de Acosta M; en representación de GETECCU. Position Statement. Recommendations of the Spanish Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the treatment of strictures in Crohn's disease. Gastroenterol Hepatol 2021:S0210-5705(21)00219-3. [PMID: 34274357 DOI: 10.1016/j.gastrohep.2021.07.001] [Reference Citation Analysis]
530 Mensink PB, Aktas H, Zelinkova Z, West RL, Kuipers EJ, van der Woude CJ. Impact of double-balloon enteroscopy findings on the management of Crohn’s disease. Scand J Gastroenterol. 2010;45:483-489. [PMID: 20059403 DOI: 10.3109/00365520903563774] [Cited by in Crossref: 33] [Cited by in F6Publishing: 25] [Article Influence: 3.0] [Reference Citation Analysis]
531 Schwartz DA, Wang A, Ozbay B, Skup M, Eichner SF, Lin J, Chao J. Comparison of Health Care Utilization and Costs Between Patients with Perianal Fistulizing Crohn's Disease Treated with Biologics with or Without Previous Seton Placement. Inflamm Bowel Dis 2017;23:1860-6. [PMID: 28858069 DOI: 10.1097/MIB.0000000000001243] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 2.7] [Reference Citation Analysis]
532 Rieder F, Zimmermann EM, Remzi FH, Sandborn WJ. Crohn's disease complicated by strictures: a systematic review. Gut. 2013;62:1072-1084. [PMID: 23626373 DOI: 10.1136/gutjnl-2012-304353] [Cited by in Crossref: 243] [Cited by in F6Publishing: 191] [Article Influence: 30.4] [Reference Citation Analysis]
533 Gower-Rousseau C, Vasseur F, Fumery M, Savoye G, Salleron J, Dauchet L, Turck D, Cortot A, Peyrin-Biroulet L, Colombel JF. Epidemiology of inflammatory bowel diseases: new insights from a French population-based registry (EPIMAD). Dig Liver Dis. 2013;45:89-94. [PMID: 23107487 DOI: 10.1016/j.dld.2012.09.005] [Cited by in Crossref: 106] [Cited by in F6Publishing: 94] [Article Influence: 11.8] [Reference Citation Analysis]
534 Kanaan Z, Ahmad S, Bilchuk N, Vahrenhold C, Pan J, Galandiuk S. Perianal Crohn's disease: predictive factors and genotype-phenotype correlations. Dig Surg 2012;29:107-14. [PMID: 22440928 DOI: 10.1159/000335745] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
535 Bernstein CN. The Natural History of Inflammatory Bowel Disease. In: Baumgart DC, editor. Crohn's Disease and Ulcerative Colitis. Boston: Springer US; 2012. pp. 343-63. [DOI: 10.1007/978-1-4614-0998-4_26] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
536 Achkar JP, Dassopoulos T, Silverberg MS, Tuvlin JA, Duerr RH, Brant SR, Siminovitch K, Reddy D, Datta LW, Bayless TM, Zhang L, Barmada MM, Rioux JD, Steinhart AH, McLeod RS, Griffiths AM, Cohen Z, Yang H, Bromfield GP, Schumm P, Hanauer SB, Cho JH, Nicolae DL. Phenotype-stratified genetic linkage study demonstrates that IBD2 is an extensive ulcerative colitis locus. Am J Gastroenterol 2006;101:572-80. [PMID: 16542294 DOI: 10.1111/j.1572-0241.2006.00451.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.3] [Reference Citation Analysis]
537 Oh EH, Oh K, Han M, Seo H, Chang K, Lee SH, Kim GU, Song EM, Seo M, Lee HS, Hwang SW, Park SH, Yang DH, Kim KJ, Byeon JS, Myung SJ, Yang SK, Ye BD. Early anti-TNF/immunomodulator therapy is associated with better long-term clinical outcomes in Asian patients with Crohn's disease with poor prognostic factors. PLoS One 2017;12:e0177479. [PMID: 28542298 DOI: 10.1371/journal.pone.0177479] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 5.5] [Reference Citation Analysis]
538 Johnson LA, Rodansky ES, Sauder KL, Horowitz JC, Mih JD, Tschumperlin DJ, Higgins PD. Matrix stiffness corresponding to strictured bowel induces a fibrogenic response in human colonic fibroblasts.Inflamm Bowel Dis. 2013;19:891-903. [PMID: 23502354 DOI: 10.1097/MIB.0b013e3182813297] [Cited by in Crossref: 88] [Cited by in F6Publishing: 47] [Article Influence: 11.0] [Reference Citation Analysis]
539 Tanaka H, Kamata N, Yamada A, Endo K, Fujii T, Yoshino T, Sugaya T, Yokoyama Y, Bamba S, Umeno J, Yanai Y, Ishii M, Kawaguchi T, Shinzaki S, Toya Y, Kobayashi T, Nojima M, Hibi T; ADJUST study group. Long-term retention of adalimumab treatment and associated prognostic factors for 1189 patients with Crohn's disease. J Gastroenterol Hepatol 2018;33:1031-8. [PMID: 29087616 DOI: 10.1111/jgh.14034] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
540 Lakatos PL, Kiss LS. Current status of thiopurine analogues in the treatment in Crohn’s disease. World J Gastroenterol. 2011;17:4372-4381. [PMID: 22110262 DOI: 10.3748/wjg.v17.i39.4372] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
541 Nos P, Garrigues V, Bastida G, Maroto N, Ponce M, Ponce J. Outcome of patients with nonstenotic, nonfistulizing Crohn’s disease. Dig Dis Sci. 2004;49:1771-1776. [PMID: 15628701 DOI: 10.1007/s10620-004-9568-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
542 Torkzad MR, Ullberg U, Nyström N, Blomqvist L, Hellström P, Fagerberg UL. Manifestations of small bowel disease in pediatric Crohn's disease on magnetic resonance enterography. Inflamm Bowel Dis 2012;18:520-8. [PMID: 21538711 DOI: 10.1002/ibd.21725] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
543 Vidigal FM, de Souza GS, Chebli LA, da Rocha Ribeiro TC, Furtado MC, Castro AC, Pinto AL, do Valle Pinheiro B, de Lima Pace FH, Machado de Oliveira J, de Oliveira Zanini KA, Gaburri PD, Zanini A, Ribeiro LC, Chebli JM. Azathioprine is more effective than mesalazine at preventing recurrent bowel obstruction in patients with ileocecal Crohn's disease. Med Sci Monit 2014;20:2165-70. [PMID: 25370731 DOI: 10.12659/MSM.890975] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
544 Gionchetti P, Calabrese C, Tambasco R, Brugnera R, Straforini G, Liguori G, Fornarini GS, Riso D, Campieri M, Rizzello F. Role of conventional therapies in the era of biological treatment in Crohn's disease. World J Gastroenterol. 2011;17:1797-1806. [PMID: 21528051 DOI: 10.3748/wjg.v17.i14.1797] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
545 Gajendran M, Loganathan P, Catinella AP, Hashash JG. A comprehensive review and update on Crohn's disease. Dis Mon. 2018;64:20-57. [PMID: 28826742 DOI: 10.1016/j.disamonth.2017.07.001] [Cited by in Crossref: 108] [Cited by in F6Publishing: 76] [Article Influence: 27.0] [Reference Citation Analysis]
546 Helper DJ. Medical management of Crohn's disease: A guide for radiologists. European Journal of Radiology 2009;69:371-4. [DOI: 10.1016/j.ejrad.2008.11.028] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
547 Scharl M, Bruckner RS, Rogler G. The two sides of the coin: Similarities and differences in the pathomechanisms of fistulas and stricture formations in irritable bowel disease. United European Gastroenterol J 2016;4:506-14. [PMID: 27536360 DOI: 10.1177/2050640616635957] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
548 Pasha SF, Leighton JA. Enteroscopy in the diagnosis and management of Crohn disease. Gastrointest Endosc Clin N Am 2009;19:427-44. [PMID: 19647650 DOI: 10.1016/j.giec.2009.04.004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
549 Kim YJ, Kim JW, Lee CK, Park HJ, Shim JJ, Jang JY, Dong SH, Kim HJ, Kim BH, Chang YW. [Clinical outcome of treatment with infliximab in Crohn's disease: a single-center experience]. Korean J Gastroenterol 2013;61:270-8. [PMID: 23756669 DOI: 10.4166/kjg.2013.61.5.270] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
550 Plevris N, Fulforth J, Lyons M, Siakavellas SI, Jenkinson PW, Chuah CS, Lucaciu L, Pattenden RJ, Arnott ID, Jones G, Lees CW. Normalization of Fecal Calprotectin Within 12 Months of Diagnosis Is Associated With Reduced Risk of Disease Progression in Patients With Crohn’s Disease. Clinical Gastroenterology and Hepatology 2021;19:1835-1844.e6. [DOI: 10.1016/j.cgh.2020.08.022] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
551 Yap LM, Ahmad T, Jewell DP. The contribution of HLA genes to IBD susceptibility and phenotype. Best Pract Res Clin Gastroenterol. 2004;18:577-596. [PMID: 15157829 DOI: 10.1016/j.bpg.2004.01.003] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 2.4] [Reference Citation Analysis]
552 Magro F, Portela F, Lago P, Ramos de Deus J, Vieira A, Peixe P, Cremers I, Cotter J, Cravo M, Tavares L, Reis J, Gonçalves R, Lopes H, Caldeira P, Ministro P, Carvalho L, Azevedo L, da Costa-Pereira A; GEDII. Crohn's disease in a southern European country: Montreal classification and clinical activity. Inflamm Bowel Dis 2009;15:1343-50. [PMID: 19235885 DOI: 10.1002/ibd.20901] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
553 Chatu S, Subramanian V, Saxena S, Pollok RC. The role of thiopurines in reducing the need for surgical resection in Crohn’s disease: a systematic review and meta-analysis. Am J Gastroenterol. 2014;109:23-34; quiz 35. [PMID: 24322839 DOI: 10.1038/ajg.2013.402] [Cited by in Crossref: 68] [Cited by in F6Publishing: 53] [Article Influence: 8.5] [Reference Citation Analysis]
554 Sivasailam B, Manski S, Wentz A, Cross RK. Presence of Obstructive Symptoms and Absence of Perianal Crohn Disease Is Predictive of Surgery After Endoscopic Balloon Dilation. Inflamm Bowel Dis 2021;27:1230-6. [PMID: 33165536 DOI: 10.1093/ibd/izaa276] [Reference Citation Analysis]
555 Lichtenstein GR, Olson A, Travers S, Diamond RH, Chen DM, Pritchard ML, Feagan BG, Cohen RD, Salzberg BA, Hanauer SB. Factors associated with the development of intestinal strictures or obstructions in patients with Crohn’s disease. Am J Gastroenterol. 2006;101:1030-1038. [PMID: 16606351 DOI: 10.1111/j.1572-0241.2006.00463.x] [Cited by in Crossref: 139] [Cited by in F6Publishing: 120] [Article Influence: 9.3] [Reference Citation Analysis]
556 Mocci G, Migaleddu V, Cabras F, Sirigu D, Scanu D, Virgilio G, Marzo M. SICUS and CEUS imaging in Crohn's disease: an update. J Ultrasound 2017;20:1-9. [PMID: 28298939 DOI: 10.1007/s40477-016-0230-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
557 Weizman AV, Silverberg MS. Have genomic discoveries in inflammatory bowel disease translated into clinical progress? Curr Gastroenterol Rep. 2012;14:139-145. [PMID: 22302508 DOI: 10.1007/s11894-012-0248-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
558 Rankala R, Kosonen J, Mattila K, Tuominen R, Voutilainen M, Mustonen A. Direct costs of inflammatory bowel diseases in a Finnish tertiary-level clinic. Frontline Gastroenterol 2021;12:385-9. [DOI: 10.1136/flgastro-2020-101466] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
559 Moon CM, Jung SA, Kim SE, Song HJ, Jung Y, Ye BD, Cheon JH, Kim YS, Kim YH, Kim JS, Han DS; CONNECT study group. Clinical Factors and Disease Course Related to Diagnostic Delay in Korean Crohn's Disease Patients: Results from the CONNECT Study. PLoS One. 2015;10:e0144390. [PMID: 26647084 DOI: 10.1371/journal.pone.0144390] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
560 Cui B, Feng Q, Wang H, Wang M, Peng Z, Li P, Huang G, Liu Z, Wu P, Fan Z, Ji G, Wang X, Wu K, Fan D, Zhang F. Fecal microbiota transplantation through mid-gut for refractory Crohn's disease: safety, feasibility, and efficacy trial results. J Gastroenterol Hepatol. 2015;30:51-58. [PMID: 25168749 DOI: 10.1111/jgh.12727] [Cited by in Crossref: 176] [Cited by in F6Publishing: 151] [Article Influence: 29.3] [Reference Citation Analysis]
561 Novak KL, Wilson SR. The Role of Ultrasound in the Evaluation of Inflammatory Bowel Disease. Seminars in Roentgenology 2013;48:224-33. [DOI: 10.1053/j.ro.2013.03.003] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
562 Klebl FH, Bataille F, Huy C, Hofst??dter F, Sch??lmerich J, Rogler G. Association of antibodies to exocrine pancreas with subtypes of Crohn's disease: . European Journal of Gastroenterology & Hepatology 2005;17:73-7. [DOI: 10.1097/00042737-200501000-00015] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 1.9] [Reference Citation Analysis]
563 Li X, Song P, Li J, Tao Y, Li G, Li X, Yu Z. The Disease Burden and Clinical Characteristics of Inflammatory Bowel Disease in the Chinese Population: A Systematic Review and Meta-Analysis. Int J Environ Res Public Health. 2017;14. [PMID: 28264519 DOI: 10.3390/ijerph14030238] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 6.8] [Reference Citation Analysis]
564 Picco MF, Zubiaurre I, Adluni M, Cangemi JR, Shelton D. Immunomodulators are associated with a lower risk of first surgery among patients with non-penetrating non-stricturing Crohn’s disease. Am J Gastroenterol. 2009;104:2754-2759. [PMID: 19584832 DOI: 10.1038/ajg.2009.387] [Cited by in Crossref: 49] [Cited by in F6Publishing: 41] [Article Influence: 4.1] [Reference Citation Analysis]
565 Vuyyuru SK, Kante B, Kumar P, Sahu P, Kedia S, Ranjan MK, Sharma R, Panwar R, Makharia G, Ahuja V. Real world analysis on the efficacy and safety of anti-tumor necrosis factor therapy in patients with stricturing Crohn's disease. Sci Rep 2021;11:11704. [PMID: 34083575 DOI: 10.1038/s41598-021-90660-2] [Reference Citation Analysis]
566 Motomura Y, Khan WI, El-Sharkawy RT, Verma-Gandhu M, Verdu EF, Gauldie J, Collins SM. Induction of a fibrogenic response in mouse colon by overexpression of monocyte chemoattractant protein 1. Gut. 2006;55:662-670. [PMID: 16299040 DOI: 10.1136/gut.2005.068429] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 2.4] [Reference Citation Analysis]
567 Mahid SS, Minor KS, Soto RE, Hornung CA, Galandiuk S. Smoking and inflammatory bowel disease: a meta-analysis. Mayo Clin Proc. 2006;81:1462-1471. [PMID: 17120402 DOI: 10.4065/81.11.1462] [Cited by in Crossref: 410] [Cited by in F6Publishing: 348] [Article Influence: 27.3] [Reference Citation Analysis]
568 Langholz E. Current trends in inflammatory bowel disease: the natural history. Therap Adv Gastroenterol. 2010;3:77-86. [PMID: 21180592 DOI: 10.1177/1756283x10361304] [Cited by in Crossref: 52] [Cited by in F6Publishing: 21] [Article Influence: 5.2] [Reference Citation Analysis]
569 Shaoul R, Karban A, Reif S, Weiss B, Shamir R, Tamir A, Davidovich O, Halevi J, Silver EL, Levine A. Disease behavior in children with Crohn’s disease: the effect of disease duration, ethnicity, genotype, and phenotype. Dig Dis Sci. 2009;54:142-150. [PMID: 18594982 DOI: 10.1007/s10620-008-0326-7] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 2.1] [Reference Citation Analysis]
570 Targownik LE, Leung S, Lix LM, Singh H, Bernstein CN. Persistence With Immunomodulator Monotherapy Use And Incidence of Therapeutic Ineffectiveness Among Users of Immunomodulator Monotherapy in IBD. Am J Gastroenterol 2018;113:1206-16. [PMID: 29925912 DOI: 10.1038/s41395-018-0108-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
571 Benjamin JL, Hedin CR, Koutsoumpas A, Ng SC, McCarthy NE, Prescott NJ, Pessoa-Lopes P, Mathew CG, Sanderson J, Hart AL. Smokers with active Crohn’s disease have a clinically relevant dysbiosis of the gastrointestinal microbiota. Inflamm Bowel Dis. 2012;18:1092-1100. [PMID: 22102318 DOI: 10.1002/ibd.21864] [Cited by in Crossref: 118] [Cited by in F6Publishing: 109] [Article Influence: 11.8] [Reference Citation Analysis]
572 Gaya DR, Russell RK, Nimmo ER, Satsangi J. New genes in inflammatory bowel disease: lessons for complex diseases? Lancet 2006;367:1271-84. [PMID: 16631883 DOI: 10.1016/S0140-6736(06)68345-1] [Cited by in Crossref: 166] [Cited by in F6Publishing: 52] [Article Influence: 11.1] [Reference Citation Analysis]
573 Moulton CD, Pavlidis P, Norton C, Norton S, Pariante C, Hayee B, Powell N. Depressive symptoms in inflammatory bowel disease: an extraintestinal manifestation of inflammation? Clin Exp Immunol 2019;197:308-18. [PMID: 30762873 DOI: 10.1111/cei.13276] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 13.5] [Reference Citation Analysis]
574 Solberg IC, Cvancarova M, Vatn MH, Moum B; IBSEN Study Group. Risk matrix for prediction of advanced disease in a population-based study of patients with Crohn's Disease (the IBSEN Study). Inflamm Bowel Dis. 2014;20:60-68. [PMID: 24280875 DOI: 10.1097/01.mib.0000436956.78220.67] [Cited by in Crossref: 36] [Cited by in F6Publishing: 14] [Article Influence: 5.1] [Reference Citation Analysis]
575 Louis E. Epidemiology of the transition from early to late Crohn’s disease. Dig Dis. 2012;30:376-379. [PMID: 22796799 DOI: 10.1159/000338129] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
576 Weder B, Mamie C, Rogler G, Clarke S, McRae B, Ruiz PA, Hausmann M. BCL2 Regulates Differentiation of Intestinal Fibroblasts. Inflamm Bowel Dis 2018;24:1953-66. [PMID: 29796658 DOI: 10.1093/ibd/izy147] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 8.0] [Reference Citation Analysis]
577 Arulanandan A, Dulai PS, Singh S, Sandborn WJ, Kalmaz D. Systematic review: Safety of balloon assisted enteroscopy in Crohn's disease. World J Gastroenterol. 2016;22:8999-9011. [PMID: 27833391 DOI: 10.3748/wjg.v22.i40.8999] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
578 Zaharie R, Tantau A, Zaharie F, Tantau M, Gheorghe L, Gheorghe C, Gologan S, Cijevschi C, Trifan A, Dobru D, Goldis A, Constantinescu G, Iacob R, Diculescu M; IBDPROSPECT Study Group. Diagnostic Delay in Romanian Patients with Inflammatory Bowel Disease: Risk Factors and Impact on the Disease Course and Need for Surgery. J Crohns Colitis. 2016;10:306-314. [PMID: 26589956 DOI: 10.1093/ecco-jcc/jjv215] [Cited by in Crossref: 36] [Cited by in F6Publishing: 23] [Article Influence: 6.0] [Reference Citation Analysis]
579 Mensink PB, Groenen MJ, van Buuren HR, Kuipers EJ, van der Woude CJ. Double-balloon enteroscopy in Crohn's disease patients suspected of small bowel activity: findings and clinical impact. J Gastroenterol. 2009;44:271-276. [PMID: 19271117 DOI: 10.1007/s00535-009-0011-4] [Cited by in Crossref: 42] [Cited by in F6Publishing: 26] [Article Influence: 3.5] [Reference Citation Analysis]
580 Goodhand JR, Alazawi W, Rampton DS. Systematic review: Clostridium difficile and inflammatory bowel disease. Aliment Pharmacol Ther. 2011;33:428-441. [PMID: 21198703 DOI: 10.1111/j.1365-2036.2010.04548.x] [Cited by in Crossref: 71] [Cited by in F6Publishing: 63] [Article Influence: 6.5] [Reference Citation Analysis]
581 Levine A, Griffiths A, Markowitz J, Wilson DC, Turner D, Russell RK, Fell J, Ruemmele FM, Walters T, Sherlock M, Dubinsky M, Hyams JS. Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification. Inflamm Bowel Dis. 2011;17:1314-1321. [PMID: 21560194 DOI: 10.1002/ibd.21493] [Cited by in Crossref: 789] [Cited by in F6Publishing: 637] [Article Influence: 71.7] [Reference Citation Analysis]
582 Gupta N, Bostrom AG, Kirschner BS, Ferry GD, Gold BD, Cohen SA, Winter HS, Baldassano RN, Abramson O, Smith T. Incidence of stricturing and penetrating complications of Crohn’s disease diagnosed in pediatric patients. Inflamm Bowel Dis. 2010;16:638-644. [PMID: 19760783 DOI: 10.1002/ibd.21099] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 4.2] [Reference Citation Analysis]
583 Seiderer J, Brand S, Herrmann KA, Schnitzler F, Hatz R, Crispin A, Pfennig S, Schoenberg SO, Göke B, Lohse P, Ochsenkühn T. Predictive value of the CARD15 variant 1007fs for the diagnosis of intestinal stenoses and the need for surgery in Crohnʼs disease in clinical practice: Results of a Prospective Study: . Inflammatory Bowel Diseases 2006;12:1114-21. [DOI: 10.1097/01.mib.0000235836.32176.5e] [Cited by in Crossref: 70] [Cited by in F6Publishing: 62] [Article Influence: 4.7] [Reference Citation Analysis]
584 Lewis RT, Bleier JI. Surgical treatment of anorectal crohn disease. Clin Colon Rectal Surg. 2013;26:90-99. [PMID: 24436656 DOI: 10.1055/s-0033-1348047] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
585 Fiorino G, Bonifacio C, Allocca M, Repici A, Balzarini L, Malesci A, Peyrin-Biroulet L, Danese S. Bowel Damage as Assessed by the Lémann Index is Reversible on Anti-TNF Therapy for Crohn's Disease. J Crohns Colitis 2015;9:633-9. [PMID: 25958059 DOI: 10.1093/ecco-jcc/jjv080] [Cited by in Crossref: 52] [Cited by in F6Publishing: 44] [Article Influence: 8.7] [Reference Citation Analysis]
586 Pelletier AL, Stefanescu C, Vincent C, Etienney I, Mentré F, Soulé JC. Is the length of postoperative recurrence on the neo ileum terminal ileum predictable in Crohn's disease? J Crohns Colitis 2011;5:24-7. [PMID: 21272800 DOI: 10.1016/j.crohns.2010.08.010] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
587 Fiorino G, Bonifacio C, Peyrin-Biroulet L, Danese S. Preventing Collateral Damage in Crohn's Disease: The Lémann Index. J Crohns Colitis 2016;10:495-500. [PMID: 26744441 DOI: 10.1093/ecco-jcc/jjv240] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
588 Oliva S, Thomson M, de Ridder L, Martín-de-Carpi J, Van Biervliet S, Braegger C, Dias JA, Kolacek S, Miele E, Buderus S, Bronsky J, Winter H, Navas-López VM, Assa A, Chong SKF, Afzal NA, Smets F, Shaoul R, Hussey S, Turner D, Cucchiara S. Endoscopy in Pediatric Inflammatory Bowel Disease: A Position Paper on Behalf of the Porto IBD Group of the European Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2018;67:414-30. [PMID: 30130311 DOI: 10.1097/MPG.0000000000002092] [Cited by in Crossref: 31] [Cited by in F6Publishing: 7] [Article Influence: 15.5] [Reference Citation Analysis]
589 Shen B. Is it a prime time for small-bowel colon video capsule endoscopy to cover both sides of the ileocecal valve in Crohn’s disease? Gastrointestinal Endoscopy 2017;85:206-9. [DOI: 10.1016/j.gie.2016.09.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
590 Gustavsson A, Magnuson A, Blomberg B, Andersson M, Halfvarson J, Tysk C. Endoscopic dilation is an efficacious and safe treatment of intestinal strictures in Crohn's disease. Aliment Pharmacol Ther. 2012;36:151-158. [PMID: 22612326 DOI: 10.1111/j.1365-2036.2012.05146.x] [Cited by in Crossref: 86] [Cited by in F6Publishing: 66] [Article Influence: 9.6] [Reference Citation Analysis]
591 Levesque BG, Loftus EV. Initiating azathioprine for Crohn’s disease. Clin Gastroenterol Hepatol. 2012;10:460-465. [PMID: 22330233 DOI: 10.1016/j.cgh.2012.01.018] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
592 Battat R, Ma C, Jairath V, Khanna R, Feagan BG. Benefit–Risk Assessment of Vedolizumab in the Treatment of Crohn’s Disease and Ulcerative Colitis. Drug Saf 2019;42:617-32. [DOI: 10.1007/s40264-018-00783-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
593 Yang SK. How Does the Epidemiology of Inflammatory Bowel Disease Differ between East and West? A Korean Perspective. Inflamm Intest Dis. 2017;2:95-101. [PMID: 30018960 DOI: 10.1159/000454712] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
594 Amiot A, Setakhr V, Seksik P, Allez M, Treton X, De Vos M, Laharie D, Colombel JF, Abitbol V, Reimund JM, Moreau J, Veyrac M, Flourié B, Cosnes J, Lemann M, Bouhnik Y. Long-term outcome of enterocutaneous fistula in patients with Crohn's disease treated with anti-TNF therapy: a cohort study from the GETAID. Am J Gastroenterol 2014;109:1443-9. [PMID: 25091063 DOI: 10.1038/ajg.2014.183] [Cited by in Crossref: 48] [Cited by in F6Publishing: 34] [Article Influence: 6.9] [Reference Citation Analysis]
595 Latella G, Cocco A, Angelucci E, Viscido A, Bacci S, Necozione S, Caprilli R. Clinical course of Crohn’s disease first diagnosed at surgery for acute abdomen. Dig Liver Dis. 2009;41:269-276. [PMID: 18955023 DOI: 10.1016/j.dld.2008.09.010] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 2.5] [Reference Citation Analysis]
596 Kurowski JA, Milinovich A, Ji X, Bauman J, Sugano D, Kattan MW, Achkar JP. Differences in Biologic Utilization and Surgery Rates in Pediatric and Adult Crohn's Disease: Results From a Large Electronic Medical Record-derived Cohort. Inflamm Bowel Dis 2021;27:1035-44. [PMID: 32914165 DOI: 10.1093/ibd/izaa239] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
597 Freeman HJ. Natural history and clinical behavior of Crohn’s disease extending beyond two decades. J Clin Gastroenterol. 2003;37:216-219. [PMID: 12960719 DOI: 10.1097/00004836-200309000-00005] [Cited by in Crossref: 72] [Cited by in F6Publishing: 64] [Article Influence: 4.0] [Reference Citation Analysis]
598 Lawrance IC. Modifying T-cell trafficking to the intestinal as a potential management for inflammatory bowel disease. Expert Opin Investig Drugs. 2012;21:975-984. [PMID: 22612537 DOI: 10.1517/13543784.2012.690030] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
599 Etchevers MJ, Aceituno M, Sans M. Are we giving azathioprine too late? The case for early immunomodulation in inflammatory bowel disease. World J Gastroenterol. 2008;14:5512-5518. [PMID: 18810768 DOI: 10.3748/wjg.14.5512] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 26] [Article Influence: 2.4] [Reference Citation Analysis]
600 Thalmaier D, Dambacher J, Seiderer J, Konrad A, Schachinger V, Pfennig S, Otte JM, Crispin A, Göke B, Ochsenkühn T, Lohse P, Brand S. The +1059G/C polymorphism in the C-reactive protein (CRP) gene is associated with involvement of the terminal ileum and decreased serum CRP levels in patients with Crohn's disease. Aliment Pharmacol Ther 2006;24:1105-15. [PMID: 16984505 DOI: 10.1111/j.1365-2036.2006.03093.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 1.9] [Reference Citation Analysis]
601 Yoon JY, Cheon JH, Park SJ, Kim TI, Kim WH. Effects of Perianal Involvement on Clinical Outcomes in Crohn's Disease over 10 Years. Gut Liver 2018;12:297-305. [PMID: 29108399 DOI: 10.5009/gnl17275] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
602 Collyer R, Clancy A, Agrawal G, Borody TJ. Crohn's strictures open with anti-mycobacterial antibiotic therapy: A retrospective review. World J Gastrointest Endosc 2020;12:542-54. [PMID: 33362907 DOI: 10.4253/wjge.v12.i12.542] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
603 Wang X, Shen B. Advances in Perianal Disease Associated with Crohn's Disease-Evolving Approaches. Gastrointest Endosc Clin N Am. 2019;29:515-530. [PMID: 31078250 DOI: 10.1016/j.giec.2019.02.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
604 Berg DR, Colombel JF, Ungaro R. The Role of Early Biologic Therapy in Inflammatory Bowel Disease. Inflamm Bowel Dis 2019;25:1896-905. [PMID: 30934053 DOI: 10.1093/ibd/izz059] [Cited by in Crossref: 31] [Cited by in F6Publishing: 21] [Article Influence: 31.0] [Reference Citation Analysis]
605 Bettenworth D, Rieder F. Medical therapy of stricturing Crohn’s disease: what the gut can learn from other organs - a systematic review. Fibrogenesis Tissue Repair. 2014;7:5. [PMID: 24678903 DOI: 10.1186/1755-1536-7-5] [Cited by in Crossref: 49] [Cited by in F6Publishing: 44] [Article Influence: 7.0] [Reference Citation Analysis]
606 Fernández A, Hernández V, Martínez-Ares D, Sanromán L, de Castro ML, Pineda JR, Carmona A, González-Portela C, Salgado C, Martínez-Cadilla J, Pereira S, García-Burriel JI, Vázquez S, Rodríguez-Prada I; EpiCom Group. Incidence and phenotype at diagnosis of inflammatory bowel disease. Results in Spain of the EpiCom study. Gastroenterol Hepatol 2015;38:534-40. [PMID: 25890448 DOI: 10.1016/j.gastrohep.2015.03.001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
607 Peyrin-Biroulet L, Loftus EV Jr, Colombel JF, Sandborn WJ. The natural history of adult Crohn's disease in population-based cohorts. Am J Gastroenterol. 2010;105:289-297. [PMID: 19861953 DOI: 10.1038/ajg.2009.579] [Cited by in Crossref: 566] [Cited by in F6Publishing: 474] [Article Influence: 47.2] [Reference Citation Analysis]
608 Lawrance IC. Early investigational TNF receptor antagonists for the treatment of ulcerative colitis. Expert Opin Investig Drugs 2015;24:761-8. [PMID: 25719407 DOI: 10.1517/13543784.2015.1020371] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
609 Reenaers C, Pirard C, Vankemseke C, Latour P, Belaiche J, Louis E. Long-term evolution and predictive factors of mild inflammatory bowel disease. Scand J Gastroenterol 2016;51:712-9. [PMID: 26815198 DOI: 10.3109/00365521.2015.1128965] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
610 Gearry RB, Kamm MA, Hart AL, Bassett P, Gabe SM, Nightingale JM. Predictors for developing intestinal failure in patients with Crohn’s disease. J Gastroenterol Hepatol. 2013;28:801-807. [PMID: 23301990 DOI: 10.1111/jgh.12115] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
611 Fiorino G, Morin M, Bonovas S, Bonifacio C, Spinelli A, Germain A, Laurent V, Zallot C, Peyrin-Biroulet L, Danese S. Prevalence of Bowel Damage Assessed by Cross-Sectional Imaging in Early Crohn's Disease and its Impact on Disease Outcome. J Crohns Colitis. 2017;11:274-280. [PMID: 27799269 DOI: 10.1093/ecco-jcc/jjw185] [Cited by in Crossref: 5] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
612 Everett SM, Hamlin PJ. Evidence-based use of anti-TNFα therapy in Crohn's disease; where are we in 2011? Frontline Gastroenterol 2011;2:144-50. [PMID: 28839599 DOI: 10.1136/fg.2010.003566] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
613 O’Sullivan S, Gilmer JF, Medina C. Matrix metalloproteinases in inflammatory bowel disease: an update. Mediators Inflamm. 2015;2015:964131. [PMID: 25948887 DOI: 10.1155/2015/964131] [Cited by in Crossref: 63] [Cited by in F6Publishing: 53] [Article Influence: 10.5] [Reference Citation Analysis]
614 D’amico F, Pugliese N, Peyrin-biroulet L, Danese S. Efficacy of anti-TNFα drugs in patients with stricturing Crohn’s disease. Expert Review of Gastroenterology & Hepatology 2020;14:347-53. [DOI: 10.1080/17474124.2020.1759417] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
615 Devlin SM, Panaccione R. Evolving inflammatory bowel disease treatment paradigms: top-down versus step-up. Med Clin North Am. 2010;94:1-18. [PMID: 19944795 DOI: 10.1016/j.mcna.2009.08.017] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.0] [Reference Citation Analysis]
616 Tamboli CP, Doman DB, Patel A. Current and future role of biomarkers in Crohn’s disease risk assessment and treatment. Clin Exp Gastroenterol. 2011;4:127-140. [PMID: 21753895 DOI: 10.2147/ceg.s18187] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
617 Lawrance IC, Rogler G, Bamias G, Breynaert C, Florholmen J, Pellino G, Reif S, Speca S, Latella G. Cellular and Molecular Mediators of Intestinal Fibrosis. J Crohns Colitis 2017;11:1491-503. [PMID: 25306501 DOI: 10.1016/j.crohns.2014.09.008] [Cited by in Crossref: 29] [Cited by in F6Publishing: 46] [Article Influence: 9.7] [Reference Citation Analysis]
618 Targownik LE, Kaplan GG, Witt J, Bernstein CN, Singh H, Tennakoon A, Aviña Zubieta A, Coward SB, Jones J, Kuenzig ME, Murthy SK, Nguyen GC, Peña-Sánchez JN, Benchimol EI. Longitudinal Trends in the Direct Costs and Health Care Utilization Ascribable to Inflammatory Bowel Disease in the Biologic Era: Results From a Canadian Population-Based Analysis. Am J Gastroenterol 2020;115:128-37. [PMID: 31895723 DOI: 10.14309/ajg.0000000000000503] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 15.0] [Reference Citation Analysis]
619 Lönnkvist MH, Befrits R, Lundberg JO, Lundahl J, Fagerberg UL, Hjortswang H, van Hage M, Hellström PM. Infliximab in clinical routine: experience with Crohnʼs disease and biomarkers of inflammation over 5 years: . European Journal of Gastroenterology & Hepatology 2009;21:1168-76. [DOI: 10.1097/meg.0b013e32832b125c] [Cited by in Crossref: 13] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
620 Wu J, Lubman DM, Kugathasan S, Denson LA, Hyams JS, Dubinsky MC, Griffiths AM, Baldassano RN, Noe JD, Rabizadeh S, Gulati AS, Rosh JR, Crandall WV, Higgins PDR, Stidham RW. Serum Protein Biomarkers of Fibrosis Aid in Risk Stratification of Future Stricturing Complications in Pediatric Crohn's Disease. Am J Gastroenterol 2019;114:777-85. [PMID: 31058681 DOI: 10.14309/ajg.0000000000000237] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 8.0] [Reference Citation Analysis]
621 Lan N, Stocchi L, Delaney CP, Hull TL, Shen B. Endoscopic stricturotomy versus ileocolonic resection in the treatment of ileocolonic anastomotic strictures in Crohn’s disease. Gastrointestinal Endoscopy 2019;90:259-68. [DOI: 10.1016/j.gie.2019.01.021] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 9.0] [Reference Citation Analysis]
622 Bodini G, Giannini EG, De Maria C, Dulbecco P, Furnari M, Marabotto E, Savarino V, Savarino E. Anti-TNF therapy is able to stabilize bowel damage progression in patients with Crohn's disease. A study performed using the Lémann Index. Dig Liver Dis 2017;49:175-80. [PMID: 27864028 DOI: 10.1016/j.dld.2016.10.014] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
623 Zbar AP, Horesh N, Bucholtz V, Zmora O, Beer-gabel M, Carter D. Are there specific endosonographic features in Crohn's patients with perianal fistulae? Journal of Crohn's and Colitis 2013;7:490-6. [DOI: 10.1016/j.crohns.2012.07.024] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
624 Nahon S, Lahmek P, Lesgourgues B, Poupardin C, Chaussade S, Peyrin-Biroulet L, Abitbol V. Diagnostic delay in a French cohort of Crohn's disease patients. J Crohns Colitis. 2014;8:964-969. [PMID: 24529604 DOI: 10.1016/j.crohns.2014.01.023] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 5.4] [Reference Citation Analysis]
625 Peyrin-biroulet L, Danese S, Cummings F, Atreya R, Greveson K, Pieper B, Kang T. Anti-TNF biosimilars in Crohn’s Disease: a patient-centric interdisciplinary approach. Expert Review of Gastroenterology & Hepatology 2019;13:731-8. [DOI: 10.1080/17474124.2019.1645595] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
626 Tarrant KM, Barclay ML, Frampton CM, Gearry RB. Perianal disease predicts changes in Crohn’s disease phenotype-results of a population-based study of inflammatory bowel disease phenotype. Am J Gastroenterol. 2008;103:3082-3093. [PMID: 19086959 DOI: 10.1111/j.1572-0241.2008.02212.x] [Cited by in Crossref: 153] [Cited by in F6Publishing: 137] [Article Influence: 12.8] [Reference Citation Analysis]
627 Sordo-Mejia R, Gaertner WB. Multidisciplinary and evidence-based management of fistulizing perianal Crohn's disease. World J Gastrointest Pathophysiol 2014;5:239-51. [PMID: 25133026 DOI: 10.4291/wjgp.v5.i3.239] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
628 Branchi F, Caprioli F, Orlando S, Conte D, Fraquelli M. Non-invasive evaluation of intestinal disorders: The role of elastographic techniques. World J Gastroenterol 2017;23:2832-40. [PMID: 28522902 DOI: 10.3748/wjg.v23.i16.2832] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
629 Allocca M, Fiorino G, Bonifacio C, Peyrin-biroulet L, Danese S. Noninvasive Multimodal Methods to Differentiate Inflamed vs Fibrotic Strictures in Patients With Crohn's Disease. Clinical Gastroenterology and Hepatology 2019;17:2397-415. [DOI: 10.1016/j.cgh.2019.04.025] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 8.5] [Reference Citation Analysis]
630 Lin MV, Blonski W, Lichtenstein GR. What is the optimal therapy for Crohn‘s disease: step-up or top-down? Expert Rev Gastroenterol Hepatol. 2010;4:167-180. [PMID: 20350264 DOI: 10.1586/egh.10.4] [Cited by in Crossref: 31] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
631 Lan N, Stocchi L, Ashburn JH, Hull TL, Steele SR, Delaney CP, Shen B. Outcomes of Endoscopic Balloon Dilation vs Surgical Resection for Primary Ileocolic Strictures in Patients With Crohn's Disease. Clin Gastroenterol Hepatol 2018;16:1260-7. [PMID: 29505909 DOI: 10.1016/j.cgh.2018.02.035] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
632 Fumery M, Yzet C, Chatelain D, Yzet T, Brazier F, LeMouel JP, Laharie D, Sabbagh C. Colonic strictures in inflammatory bowel disease: epidemiology, complications, and management. J Crohns Colitis 2021:jjab068. [PMID: 33844013 DOI: 10.1093/ecco-jcc/jjab068] [Reference Citation Analysis]
633 Siegel CA, Whitman CB, Spiegel BMR, Feagan B, Sands B, Loftus EV Jr, Panaccione R, D'Haens G, Bernstein CN, Gearry R, Ng SC, Mantzaris GJ, Sartor B, Silverberg MS, Riddell R, Koutroubakis IE, O'Morain C, Lakatos PL, McGovern DPB, Halfvarson J, Reinisch W, Rogler G, Kruis W, Tysk C, Schreiber S, Danese S, Sandborn W, Griffiths A, Moum B, Gasche C, Pallone F, Travis S, Panes J, Colombel JF, Hanauer S, Peyrin-Biroulet L. Development of an index to define overall disease severity in IBD. Gut. 2018;67:244-254. [PMID: 27780886 DOI: 10.1136/gutjnl-2016-312648] [Cited by in Crossref: 64] [Cited by in F6Publishing: 55] [Article Influence: 12.8] [Reference Citation Analysis]
634 Greener T, Klang E, Yablecovitch D, Lahat A, Neuman S, Levhar N, Avidan B, Yanai H, Dotan I, Chowers Y, Weiss B, Saibil F, Amitai MM, Ben-Horin S, Kopylov U, Eliakim R; Israeli IBD Research Nucleus (IIRN). The Impact of Magnetic Resonance Enterography and Capsule Endoscopy on the Re-classification of Disease in Patients with Known Crohn's Disease: A Prospective Israeli IBD Research Nucleus (IIRN) Study. J Crohns Colitis. 2016;10:525-531. [PMID: 26748404 DOI: 10.1093/ecco-jcc/jjw006] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 8.0] [Reference Citation Analysis]
635 Bergeron F, Bouin M, D'Aoust L, Lemoyne M, Presse N. Food avoidance in patients with inflammatory bowel disease: What, when and who? Clin Nutr 2018;37:884-9. [PMID: 28359542 DOI: 10.1016/j.clnu.2017.03.010] [Cited by in Crossref: 21] [Cited by in F6Publishing: 10] [Article Influence: 5.3] [Reference Citation Analysis]
636 Shivaji UN, Evans M, Critchlow T, Gui X, Smith SCL, Pinkney T, Iacucci M, Cooney R, Ghosh S, Skordilis K. Chronic inflammation and other changes are significant components of clinically fibrotic strictures in Crohn's disease: a histological study of resected strictures clinically characterized as noninflamed. Eur J Gastroenterol Hepatol 2020;32:1432-9. [PMID: 32639416 DOI: 10.1097/MEG.0000000000001796] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
637 Franzè E, Monteleone I, Laudisi F, Rizzo A, Dinallo V, Di Fusco D, Colantoni A, Ortenzi A, Giuffrida P, Di Carlo S, Sica GS, Di Sabatino A, Monteleone G. Cadherin-11 Is a Regulator of Intestinal Fibrosis. J Crohns Colitis 2020;14:406-17. [PMID: 31504344 DOI: 10.1093/ecco-jcc/jjz147] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
638 Stenke E, Bourke B, Knaus U. Crohn's Strictures-Moving Away from the Knife.Front Pediatr. 2017;5:141. [PMID: 28670577 DOI: 10.3389/fped.2017.00141] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
639 Modha K, Navaneethan U. Advanced therapeutic endoscopist and inflammatory bowel disease: dawn of a new role. World J Gastroenterol. 2014;20:3485-3494. [PMID: 24707131 DOI: 10.3748/wjg.v20.i13.3485] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
640 Torres J, Burisch J, Riddle M, Dubinsky M, Colombel J. Preclinical disease and preventive strategies in IBD: perspectives, challenges and opportunities. Gut 2016;65:1061-9. [DOI: 10.1136/gutjnl-2016-311785] [Cited by in Crossref: 38] [Cited by in F6Publishing: 30] [Article Influence: 7.6] [Reference Citation Analysis]
641 Ohara N, Mizushima T, Iijima H, Takahashi H, Hiyama S, Haraguchi N, Inoue T, Nishimura J, Shinzaki S, Hata T, Matsuda C, Yamamoto H, Doki Y, Mori M. Adherence to an elemental diet for preventing postoperative recurrence of Crohn’s disease. Surg Today 2017;47:1519-25. [DOI: 10.1007/s00595-017-1543-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
642 Lan N, Hull TL, Shen B. Endoscopic stricturotomy and ileo-colonic resection in patients with primary Crohn's disease-related distal ileum strictures. Gastroenterol Rep (Oxf) 2020;8:312-8. [PMID: 32843979 DOI: 10.1093/gastro/goz071] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
643 Allen PB, Kamm MA, Peyrin-Biroulet L, Studd C, McDowell C, Allen BC, Connell WR, De Cruz PP, Bell SJ, Elliot RP. Development and validation of a patient-reported disability measurement tool for patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2013;37:438-444. [PMID: 23278192 DOI: 10.1111/apt.12187] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 3.8] [Reference Citation Analysis]
644 Hirai F, Takeda T, Takada Y, Kishi M, Beppu T, Takatsu N, Miyaoka M, Hisabe T, Yao K, Ueki T. Efficacy of enteral nutrition in patients with Crohn's disease on maintenance anti-TNF-alpha antibody therapy: a meta-analysis. J Gastroenterol 2020;55:133-41. [PMID: 31641874 DOI: 10.1007/s00535-019-01634-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
645 Gauci J, Sammut L, Sciberras M, Piscopo N, Micallef K, Cortis K, Ellul P. Small bowel imaging in Crohn's disease patients. Ann Gastroenterol 2018;31:395-405. [PMID: 29991884 DOI: 10.20524/aog.2018.0268] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
646 Cosnes J, Bourrier A, Nion-Larmurier I, Sokol H, Beaugerie L, Seksik P. Factors affecting outcomes in Crohn's disease over 15 years. Gut. 2012;61:1140-1145. [PMID: 22387526 DOI: 10.1136/gutjnl-2011-301971] [Cited by in Crossref: 71] [Cited by in F6Publishing: 53] [Article Influence: 7.9] [Reference Citation Analysis]
647 Eglinton TW, Roberts R, Pearson J, Barclay M, Merriman TR, Frizelle FA, Gearry RB. Clinical and genetic risk factors for perianal Crohn’s disease in a population-based cohort. Am J Gastroenterol. 2012;107:589-596. [PMID: 22158027 DOI: 10.1038/ajg.2011.437] [Cited by in Crossref: 46] [Cited by in F6Publishing: 37] [Article Influence: 4.6] [Reference Citation Analysis]
648 Funayama Y, Takahashi K, Sasaki I. Surgical management in intestinal Crohn’s disease. Clin J Gastroenterol 2010;3:1-5. [DOI: 10.1007/s12328-009-0129-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
649 Banerjee R, Pal P, Girish BG, Reddy DN. Risk factors for diagnostic delay in Crohn's disease and their impact on long-term complications: how do they differ in a tuberculosis endemic region? Aliment Pharmacol Ther 2018;47:1367-74. [DOI: 10.1111/apt.14617] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
650 Mao R, Tang RH, Qiu Y, Chen BL, Guo J, Zhang SH, Li XH, Feng R, He Y, Li ZP, Zeng ZR, Eliakim R, Ben-Horin S, Chen MH. Different clinical outcomes in Crohn's disease patients with esophagogastroduodenal, jejunal, and proximal ileal disease involvement: is L4 truly a single phenotype? Therap Adv Gastroenterol. 2018;11:1756284818777938. [PMID: 29899757 DOI: 10.1177/1756284818777938] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
651 Deepak P, Fletcher JG, Fidler JL, Barlow JM, Sheedy SP, Kolbe AB, Harmsen WS, Loftus EV, Hansel SL, Becker BD, Bruining DH. Radiological Response Is Associated With Better Long-Term Outcomes and Is a Potential Treatment Target in Patients With Small Bowel Crohn's Disease. Am J Gastroenterol. 2016;111:997-1006. [PMID: 27166131 DOI: 10.1038/ajg.2016.177] [Cited by in Crossref: 75] [Cited by in F6Publishing: 56] [Article Influence: 15.0] [Reference Citation Analysis]
652 Ye L, Cheng W, Chen BQ, Lan X, Wang SD, Wu XC, Huang W, Wang FY. Levels of Faecal Calprotectin and Magnetic Resonance Enterocolonography Correlate with Severity of Small Bowel Crohn's Disease: A Retrospective Cohort Study. Sci Rep 2017;7:1970. [PMID: 28512287 DOI: 10.1038/s41598-017-02111-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
653 Chatu S, Saxena S, Subramanian V, Curcin V, Yadegarfar G, Gunn L, Majeed A, Pollok RC. The impact of timing and duration of thiopurine treatment on first intestinal resection in Crohn's disease: national UK population-based study 1989-2010. Am J Gastroenterol 2014;109:409-16. [PMID: 24469612 DOI: 10.1038/ajg.2013.462] [Cited by in Crossref: 49] [Cited by in F6Publishing: 41] [Article Influence: 7.0] [Reference Citation Analysis]
654 Hart AL, Ng SC. Crohn’s disease. Medicine 2011;39:229-36. [DOI: 10.1016/j.mpmed.2011.01.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
655 Louis E, Van Kemseke C, Reenaers C. Necessity of phenotypic classification of inflammatory bowel disease. Best Pract Res Clin Gastroenterol 2011;25 Suppl 1:S2-7. [PMID: 21640927 DOI: 10.1016/S1521-6918(11)70003-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
656 Farias E Silva K, Nanini HF, Cascabulho CM, Rosas SLB, Santana PT, Carneiro AJV, Anaissie E, Nucci M, de Souza HSP. Serum 1,3-beta-D-glucan as a noninvasive test to predict histologic activity in patients with inflammatory bowel disease. World J Gastroenterol 2021;27:866-85. [PMID: 33727775 DOI: 10.3748/wjg.v27.i9.866] [Reference Citation Analysis]
657 Leighton JA, Pasha SF. Inflammatory Disorders of the Small Bowel. Gastrointest Endosc Clin N Am. 2017;27:63-77. [PMID: 27908519 DOI: 10.1016/j.giec.2016.08.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
658 Chatzicostas C, Roussomoustakaki M, Potamianos S, Paspatis G, Mouzas I, Romanos J, Mavrogeni H, Kouroumalis E. Factors associated with disease evolution in Greek patients with inflammatory bowel disease. BMC Gastroenterol 2006;6:21. [PMID: 16869971 DOI: 10.1186/1471-230X-6-21] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
659 Bufman H, Eliakim R, Tau N, Amitai MM. Magnetic resonance enterography in Crohn's disease patients: current state of the art and future perspectives. Expert Rev Med Devices 2021;18:657-67. [PMID: 34109891 DOI: 10.1080/17434440.2021.1939682] [Reference Citation Analysis]
660 Hoffmann P, Krisam J, Wehling C, Kloeters-Plachky P, Leopold Y, Belling N, Gauss A. Ustekinumab: "Real-world" outcomes and potential predictors of nonresponse in treatment-refractory Crohn's disease. World J Gastroenterol 2019;25:4481-92. [PMID: 31496626 DOI: 10.3748/wjg.v25.i31.4481] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 11] [Article Influence: 17.0] [Reference Citation Analysis]
661 Laube R, Liu K, Schifter M, Yang JL, Suen MK, Leong RW. Oral and upper gastrointestinal Crohn's disease. J Gastroenterol Hepatol. 2018;33:355-364. [PMID: 28708248 DOI: 10.1111/jgh.13866] [Cited by in Crossref: 26] [Cited by in F6Publishing: 9] [Article Influence: 8.7] [Reference Citation Analysis]
662 Kang B, Kim JE, Jung JH, Choe JY, Kim MJ, Choe YH, Kim S, Koh H, Lee YM, Lee JH, Lee Y, Lee JH, Lee HJ, Jang HJ, Choi Y, Choi SY, Kim JY, Choe BH. Korean Ch